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ABSTRACT 
The targeted reversely attenuated probe (TRAP) is an aptamer-based biosensor 
in which the aptamer activity can be regulated by a specific nucleic acid sequence such 
as an mRNA. The TRAP has the potential of being developed for imaging gene 
expression in vivo. The central portion of the TRAP, between the aptamer and the 
attenuator, is complementary to a target nucleic acid, such as an mRNA, which is 
referred to as a regulatory nucleic acid (regDNA) because it regulates activity of the 
aptamer in the TRAP by hybridization with the central (intervening) sequence. 
I developed 8att-cmRas20 and 9att-cmRas15 ATP DNA TRAPs with regDNA-
dependent aptamer activity. The results suggested that, as well as inhibiting the 
aptamer, the attenuator also acted as a structural guide, much like a chaperone, to 
promote proper folding of the TRAP such that it can be fully activated by the regDNA. 
We also showed that activation of the aptamer in the TRAP at physiological 
temperatures by a regDNA complementary to the intervening sequence was sensitive 
to single base mismatches. 
I then utilized a tiled microarray to identify the regions on the mRNA that can be 
easily targeted by antisense oligonucleotides and the results showed that the 
microarray approach provided a better match with the in vivo antisense than 
computational analysis. 
Selected from a microarray study, the 20nt antisense oligonucleotide that targets 
positions 741-760 of Lcn2 mRNA was chosen for the malachite green (MG) RNA 
TRAP. To develop the probe, the structure of the 38nt MG RNA aptamer was first 
destabilized by introducing truncations and mutations. The KDs for MG of several 
truncated and mutated MG RNA aptamers were estimated and the results showed that 
the KDS of 34nt and 32nt MG RNA aptamers were within a 2-fold range of the 38nt MG 
Kd. By rational design and after screening different MG RNA TRAPs, the aptamer 
activity of a TRAP that consists of a 32nt modified MG RNA aptamer and 9nt attenuator 
sequence was shown to be increased about 20-fold in the presence of a 20nt regDNA. 
A yeast selection system has been designed to test the function in vivo of the 
selected TRAP. In this assay, URA3 translation is inhibited by a MG aptamer sequence 
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inserted in the 5'UTR of the URA3 mRNA, which results in growth arrest in the 
presence of tetramethylrosamine (TMR)that can be detected by the yeast spot assay. 
A hammerhead (HH) ribozyme - aptamer/TRAP - hepatitis Delta Virus (HDV) ribozyme 
cassette was constructed to produce aptamers or TRAPs with defined and 
homogeneous 5' and 3' ends. An in vitro cleavage assay showed that the HH-MG 
aptamer-HDV expression cassette produced MG aptamers with homogeneous ends. 
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CHAPTER 1. GENERAL INTRODUCTION 
DISSERTATION ORGANIZATION 
Chapter 1 of this dissertation starts with a brief summary of the organization. In the 
following background section, the research fields closely related to the development of 
an aptamer based nucleic acid probes for imaging specific RNA molecules are 
reviewed briefly. In the research aims and significance section, the Targeted 
Reversibly Attenuated Prob (TRAP) is introduced for developing an aptamer based 
probe for non-i nvasive in vivo imaging of specific RNA molecules. Questions regarding 
the theoretical basis and practical design of TRAPs are briefly discussed. Chapter 2 
contains a literature review covering topics related to the TRAP. The TRAP design 
utilizes aptamers that have been selected by SELEX. A brief review of SELEX and 
aptamers are given in chapter 2. Chapter 2 also discusses some fundamental issues 
related to the TRAP. Functioning as an allosteic aptamer, the TRAP is indeed a 
targeted nucleic acid molecule-dependent aptamer. A brief review of artificial and 
natural allosteric nucleotide acid molecules is included. After a review of selected in 
vivo and applications of aptamer, the development of methods for detection and 
imaging of RNA molecules in vitro and in living cells is briefly discussed. At the end of 
chapter 2, a brief review of RNA secondary structure prediction is given. In chapter 3, 
the results of the ATP DNA TRAPs with their aptamer activities regulated by a 
regulatory nucleic acid molecule (regDNA) are presented. The design and function of 
the TRAPs and oligonucleotides in the study are shown in figure 1. The activation of 
the TRAP by sequence specific regDNA is presented in figure 2. In figure 3, the dose-
dependent activation of the TRAP by regDNA and the reversibility of activation are 
shown. The impact of attenuator and intervening sequences on TRAP function is 
presented in figures 4 and 5. In figures 6 and 7, the results from isothermal titration 
calorimetry (ITC) and polyacrylamide gel electrophoresis (PAGE) are used to illustrate 
the role of the attenuator as a structural guide for regDNA hybridization with the TRAP. 
The TRAP'S ability to distinguish a single base mismatch is shown in figure 8. In 
chapter 4, the results of using of microarray to identify the region(s) on the mRNA that 
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can be easily targeted by antisense oligonucleotides are presented. In chapter 5, 
results from the development of a malachite green (MG) RNA TRAP targeting 
uterocalin/Lcn2 mRNA are reported. The sequence information can be found in tables 
1 through 7. In figure 1 is the X-ray crystal structure of MG RNA aptamer with 
tetramethylrosamine (TMR), a structure analog of MG, solved by Baugh et al.(1). In 
figure 2 are the predicted folding and KD estimation of selected truncated and mutated 
MG aptamers. In figure 3 are the results of using short oligo to find out the region on 
the MG RNA aptamer that can be used as the target of the attenuator. In figure 4, the 
rational design and screening results of 15 different MG TRAPs are presented. Figures 
5 and 6 show the design of yeast in vivo selection system and spot assay results to test 
the practicability of yeast in vivo selection system. Figures 7 and 8 show the design of 
hammerhead (HH) ribozyme-aptamer/TRAP-hepatitis delta virus (HDV) ribozyme 
expression cassette and the results of in vitro cleavage reaction. In figure 9 are the 
structural information, chemical reaction scheme and thin layer chromatography (TLC) 
results related to the synthesis of biotinylated MG. Figure 10 contains a summary of 
the results of fluorescence measurements from TRAP SELEX. In figure 11 some of my 
thoughts about the thermodynamics related in TRAP design is presented. In chapter 
6, general conclusions are drawn based on the data presented above. Chapter 7 is a 
list of references cited in chapters 1,2 and 6. Those cited in chapters 3, 4 and 5 are 
listed at the end of the respective chapter. The people who have contributed to my 
studies are thanked in the acknowledgments. 
BACKGROUND 
Compared to proteins, which are made of 20 different amino acid residues, RNAs 
contain only four kinds of nucleosides: adenosine (A), guanosine (G), cytidine (C) and 
uridine (U). But this simple composition does not limit the biological activities of RNAs 
which include the messenger RNAs that convey and the ribosome RNAs and tRNAs 
that interpret the genetic information stored in DNA. Many RNAs provide essential 
catalytic activity as well as structural support for molecular machinery complex. More 
recently, small RNAs have been found to be very active and critical in the regulation of 
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gene expression and gene silencing. The expression levels and stabilities as well as 
the temporal and spatially distributions of specific RNAs in the cell are directly related 
to their functions. Knowing the dynamics and localization of RNA molecules is critical 
for fully understanding the biological mechanisms of RNA molecules in fulfilling their 
functions in the living cell. 
Although fluorescent labeled linear antisense oligonucleotides have been used to 
imaging mRNA in living cells (2-4), they suffer from drawbacks such as high 
background and low specificity and the inability to distinguish single nucleotide 
mutations (5). The molecular beacon is a nucleic acid probe with a stem-loop structure 
(6, 7). The fluorescent labeled molecular beacon enables the development of 
homogeneous hybridization assays. The advantages of a homogenous hybridization 
assay are its speed and simplicity. In these assays the unbound probes do not need 
to be removed and they provide real-time detection and visualization of target nucleic 
acid molecules. Molecular beacons and other nano-structured probes have been used 
to detect RNA in living cells (5). The molecular beacon contains one terminal quencher 
molecule and one terminal fluorophore molecule or one terminal donor fluorescent 
molecule with an acceptor fluorophore at the other terminus to give target-dependent 
fluorescence when the two termini separate upon target recognition. Because of the 
low energy level of fluorescence, it can not penetrate tissue and the whole body. This 
limits the use of molecule beacons to cultured cells. 
Integrating the aptamer/ribozyme into the design of molecular beacon produces the 
aptamer/ribozyme TRAP (8, 9). The aptamer is a single nucleic acid molecule that can 
bind its ligand with high specificity and affinity (10, 11). Aptamers are selected in vitro 
using a procedure named systematic evolution of ligands by exponential enrichment 
(SELEX) (10). Aptamers have been used fora broad range of in vitro as well as in vivo 
applications (12-22). For imaging RNA molecules in living cells, the aptamer ligand can 
be labeled with fluorescence, quantum dots (23) or radioactive isotopes (79) to provide 
the signal output needed for detection and visualization. It is possible to apply aptamer-
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based probes for imaging RNA molecules in tissues or whole organisms by labeling the 
aptamer ligand using quantum dots or radioactive isotopes. 
RESEARCH AIMS AND SIGNIFICANCE 
Verification of the Practicality of the Aptamer-Based TRAP Design 
After the TRAP idea was formed in the year 2000, the proof of principle was first 
performed by the work done on the ribozyme-based TRAP (9). Selecting the ATP 
DNA aptamer as a starting point, I designed and tested a series ATP DNA TRAPs in 
vitro. Two functional ATP DNA TRAPs were developed. The 8att-cmRas20-TRAP was 
shown to be activated by a sequence-specific regDNA in a dose-dependent manner. 
The 9att-cmRAs15-TRAP was able to distinguish single nucleotide mismatches (8). I 
then chosen the malachite green (MG) RNA aptamer to develop an RNA TRAP 
targeting uterocalin/Lcn2 mRNA. By rational design and screening a series of MG 
TRAPs, aptamer activity of the 32MG1-9 RNA TRAP was shown to increase 20-fold 
upon interacting with a sequence specific regDNA complementary to the intervening 
sequence of the TRAP. 
The Influence of Structure and Stability of the Aptamer to TRAP Design 
Because the ATP DNA aptamer undergoes a global ligand-induced conformational 
change (24), I was able to use full length of ATP DNA aptamer to develop functional 
ATP DNA TRAPs. By contrast, the MG RNA aptamer has a stable structure as shown 
in the folding of aptamer itself predicted by Mfold (25) and by the X-ray crystal structure 
with ligand-tetramethylrosamine (TMR) (1). The binding pocket is located in a central 
bulge loop flanked by two stems. Because of the stability and lack of a global ligand-
induced conformational change of 38nt MG aptamer when it binds MG, the MG 
aptamer structure was destabilized by truncation and by introducing mutations to get 
a functional MG RNA TRAP. These two examples indicate that the choice of aptamer 
had big impact on the subsequent design and optimization of a TRAP. The overall 
stability of the aptamer itself and the conformational changes upon the ligand binding 
are important factors to be considered for effective TRAP design. 
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The Need and Function of Attenuator 
The attenuator was designed to interact with the aptamer and inhibit the aptamer 
activity in the absence of target RNA. Obviously, the length and composition of the 
attenuator is critical for a successful TRAP design. In the ATP DNA TRAPs and MG 
RNA TRAPs, I tested different attenuator lengths. The attenuator was not able to 
inhibit the aptamer activity if it was too short. On the other hand, the TRAP had low 
regDNA-dependent aptamer activity if the attenuator was too long. The effective 
targets of the attenuator were the residues of the aptamer that were involved directly 
in the interactions with the ligand and were crucial for the aptamer binding activity. By 
analyzing the Oatt-cmRas ATP DNA TRAP, I showed that besides inhibiting the 
aptamer, the attenuator was also needed for guiding the TRAP to fold into the desired 
conformation. Without the attenuator, the intervening sequence can interact with the 
aptamer and inhibit its activity. But by doing so, the heavily base paired intervening 
sequence may not be able to interact with target nucleic acid molecules efficiently. 
Thus the absence of an attenuator resulted a TRAP with low regDNA-dependent 
aptamer activity. 
The Choice of Intervening Sequence 
The function of the intervening sequence is to interact with the target nucleic acid 
molecule and this interaction helps to overcome the inhibition by the attenuator of the 
aptamer in TRAP. To choose an intervening sequence for a target mRNA, the first 
consideration was whether the region it targeted was available in the folded mRNA. 
mRNA has a secondary structure and it folds into one or more tertiary conformations. 
If the target region of intervening sequence is heavily involved in base pairing in the 
folded mRNA, most likely it would have low availability for interacting with the 
complementary intervening sequence in the TRAP. There were several computational 
tools available to predict the antisense availability of certain regions on mRNA 
molecules (26, 27). Experimentally, I used a tiled microarray to identify regions on the 
mRNA that were easily targeted by 20nt antisense oligonucleotides. The results 
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showed that the microarray results provided a better match with the in vivo antisense 
experiments than the computer analysis. 
The Involvement of Intervening Sequence in TRAP Folding 
As the part of TRAP molecule, the intervening sequence is involved in 
intramolecular interactions. In the TRAP design a strong interaction was needed 
between attenuator and aptamerso that binding activity of aptamer was inhibited by the 
attenuator in the absence of target nucleic acid molecules. To achieve the effective 
inhibition, the attenuator was designed to be fully complementary to the residues of 
aptamer. As shown in 8att-cmRas20, 9att- cmRas15 ATP DNA TRAP and 32MG1-9 
RNA TRAP, the attenuator was fully involved in the interaction with aptamer. There 
was no interaction between the intervening sequence and attenuator. But, by 
interacting with the aptameror base pairing within itself, the intervening sequence could 
have big impact on TRAP folding and therefore function. In the 8att- cmRas20, 9att-
cmRas15 ATP DNA TRAP and 32MG1-9 MG RNA TRAP, the intervening sequences 
were found to interact with aptamer and to provided extra force to inhibit the aptamer 
activity in the absence of target nucleic acid molecules. Without this interaction 
provided by the intervening sequence, the length of attenuator needed to inhibit the 
aptamer needs to be longer and consequently, the TRAP will be less responsive. The 
structure of the target nucleic acid also needs to be considered. Interaction of the 
TRAP with the 20nt linear regDNA as the target molecule may be energetically more 
favorable than its interaction with a folded mRNA as the target. 
Rational Design and In vitro SELEX for TRAP 
Through rational design, the ATP DNA TRAPs and MG RNA TRAPs with regDNA-
dependent aptamer activity were successful developed. Compared to the rational 
design, the SELEX procedure can be used to examine a much bigger sequence pool. 
If the randomized region on the TRAP was less than 20nt, theoretically, all the possible 
combination of TRAP sequences can be screened in SELEX. I tested several 
parameters for rational design such as the choice of aptamer, intervening sequence 
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and attenuator sequence. The insights gained could be useful for further TRAP 
developed. I also tested using SELEX for selecting an effective MG RNA TRAP. The 
experience so far indicates that the most critical parameter for successful selection of 
a TRAP by SELEX might be establishing a means of efficient negative selection to 
eliminate TRAPs with weak attenuators. 
In vivo Selection of TRAPs Developed In vitro 
The TRAP was developed in vitro and it was not guaranteed to be functional in 
vivo. I designed a yeast selection system for testing and selecting a TRAP that 
functions inside cells. The preliminary data suggested that the design was practical 
and that, following the further testing, it could be used to test the MG RNA TRAP in the 
yeast cells. 
Expression of TRAP Inside the Cells 
Expression of a TRAP inside the cells using an expression vector is one way to 
test and select for a TRAP with the desired properties. I designed an HH-
aptamer/TRAP- HDV expression cassette for producing the RNA sequences inside the 
yeast cell with the desired 5' and 3' ends. The in vitro cleavage assay indicated the 
successful release of RNA sequences with homogenous ends under defined 
conditions. 
Sequence and Thermodynamics Parameters for Systematic Developing of 
TRAP by Computational Design 
Through computational design and experimental validation, oligonucleotide-sensing 
allosteric ribozymes have been developed (28). A similar strategy is needed to identify 
the sequence and thermodynamics parameters for effective TRAPs. In the process of 
developing the ATP DNA TRAPs and MG RNA TRAPs, we have begun to understand 
the parameters that are important for designing TRAPs in general. 
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CHAPTER 2. LITERATURE REVIEW 
SELEX 
SELEX, the abbreviation for "Systematic evolution of ligands by exponential 
enrichment", was first introduced around the 1990s. In 1990, Larry Gold's lab used a 
procedure they named SELEX to select the RNA that interacts with T4 DNA 
polymerase (10). Around the same time, Jack W. Szostak's lab developed a similar in 
vitro selection procedure to select RNA molecules that bind a specific ligand from a 
variety of organic dyes (11). The selection procedure developed in these two labs 
followed the same principle although they were independently created for different 
purposes. The name SELEX was chosen and from then on, this in vitro selection 
procedure has been widely used to select ssDNA and RNA molecules called aptamers 
that can bind desired target with high specificity and affinity. 
The SELEX procedure begins with a synthesized random DNA sequence library. 
If we want to synthesize a random pool that has one copy of each possible 40 
nucleotide (nt) random ssDNA (single strand DNA), in theory, we will have 440 (1.2 X 
1024) different sequences in that pool. For 1.2 X1024 40 nt ssDNA molecules, the mass 
is about 23,920 g (300 g/mol * 40 x 1.2 X 1024) / (6.02 x 1023). It is about 24 kg of 
ssDNA. In practice, a typical combinatorial oligonucleotide library obtained from a 
1pmol scale solid phase DNA synthesis is limited to 1014 - 1015 unique sequences. 
This is about 1-20 ug of ssDNA. Even so, the diversity of the library presented by 
different ssDNAs is much higher than in other combinational libraries, such as peptide 
libraries used for phage display and libraries made up of small molecules (29). 
The SELEX procedure places a high evolutionary pressure on the nucleic acid 
library and an aptamer is selected that binds specifically to a given ligand. The 
resulting aptamer has high affinity and specificity for the given ligand. Examples 
include the two tobramycin RNA aptamers have dissociation constants (KD) about 9 nM 
and 12 nM (30). The DNA ATP aptamer has KD about 6 pM (31). The two RNA 
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aptamers for the HIV Rev peptide have 4 nM KD (32). The DNA aptamer for thrombin, 
a protease functioning in coagulation, has a 25nM KD (33). 
The general procedure for SELEX is shown in Fig. 1 (34). The random ssDNA pool 
is synthesized such that every sequence has a contiguous random sequence in the 
middle and a fixed sequence region in each end ( • ). To obtain a DNA aptamer, the 
ssDNA library is placed directly into the selection cycle. For an RNA aptamer, a 
promoter for an RNA polymerase (such as the 17 RNA polymerase) is attached 
immediately after one of the two fixed sequence regions of the library sequence in order 
to synthesize the RNA sequence by in vitro transcription ( ea ). Under defined 
conditions (including buffer, temperature etc.), the ssDNA or RNA library is incubated 
with the target molecule of interest. Sequences that bind to the target are separated 
from unbound sequences by the chosen partitioning method. If the target is 
immobilized on an affinity matrix such as a column or membrane, the column or 
membrane is eluted with the chosen buffer after washing to remove unbound 
sequences. The sequences obtained after eluting are a mixture of sequences with high 
and low affinities for the target molecules. To obtain high-affinity binding molecules, 
the low-affinity binding molecules need to be eliminated by sequential rounds of 
selection. The selected sequences are amplified for the next round. If it is a ssDNA 
library, the mixture is amplified directly by PGR using the two fixed sequences at the 
ends of all sequences in the library. After PGR, a standard method is used to separate 
the two strands of the PGR products (such as one primer being labeled with biotin and 
then the PGR product run through a streptavidin affinity column). The amplified ssDNA 
is then prepared to be taken through the next selection. For RNA aptamer selection, 
RNA sequences are first converted to DNA by reverse transcription. The corresponding 
DNA sequences are amplified by PGR. The amplified RNA library is obtained by in 
vitro transcription. After amplification, the ssDNA library or the RNA library will be 
mixed with fresh target molecules to go through the second round of selection. With 
increasingly stringent conditions, the selection will be continued until affinity saturation 
is observed, which means that the affinity of the library could not be improved any more 
by selection. The percent of oligonucleotides left on the column after washing can be 
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used to indicate the number of molecules in the population with a relatively high affinity 
for the target. The PGR product after the final selection round is cloned and a number 
of clones are sequenced. In Fig. 1, the black arrows show steps in a DNA-based 
aptamer selection; gray arrows show the steps in a RNA-based selection (34). Usually, 
it is necessary to go through 8-15 cycles in the SELEX procedure to select a group of 
aptamers with high affinities for the target molecule. 
Since SELEX was introduced, many modifications have been made to improve this 
technique to meet the need for broader applications of aptamers. The purpose of 
SELEX is to get an aptamer that binds a target molecule with high specificity and 
affinity. The high specificity can be achieved by including a negative selection during 
the SELEX procedure. Usually, the negative selection is done by applying the ssDNA 
or RNA pool to the support used in the SELEX procedure for partitioning the target-
nucleic acid complexes from the remaining nucleic acid pool. For example, in the 
selection of an RNA aptamer that targets a protein, filters are often used as the support 
to separate RNA molecules that bind to target from RNA molecules do not bind. A 
negative selection against the support can successfully eliminate sequences that bind 
to the support instead of the target molecule. Negative selections are routine 
procedures in SELEX to give the selected aptamer high specificity for the target 
molecule. 
Another way to improve the specificity of selected aptamers is to do the selection 
against a structural analog of the target molecule in order to eliminate nucleic acid 
sequences that do not recognize the target molecule with high specificity. The 
theophylline RNA aptamer has 10,000-fold greater binding affinity to theophylline than 
for caffeine (35). Caffeine differs from theophylline by a single methyl group at nitrogen 
atom N-7. Negative selection against caffeine was used to achieve high specificity. 
After eight rounds of selection using a theophylline affinity column, caffeine was applied 
to the bound RNAs to elute any RNA sequence that could bind caffeine. This approach 
was named "counter-SELEX" by the authors (35). 
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Specificity seems to be easy to achieve using SELEX. Then what about affinity? 
Typically, aptamers have dissociation constants in the pM range when directed against 
small molecules such as ATP and in the low nM to pM range when directed against 
proteins. To achieve a dissociation constant in the low nM range, the target 
concentration used in the SELEX rounds should be limited and gradually decreased 
with subsequent rounds. Also, the non-specific binding should be minimized. New 
developments of SELEX procedure, such as PhotoSELEX, could be used to lower the 
non-specific binding during the SELEX because extensive washing can be applied after 
the cross-linking. In PhotoSELEX, a modified nucleotide that can be activated by light 
replaces a native base in either ssDNA or RNA randomized oligonucleotide libraries 
(36). The crucial part of PhotoSELEX is the choice of modified nucleotide to be one 
that is activated by light, reacts with the target molecule and remains non-reactive and 
stable without light activation. Also, the modified nucleotide needs to be recognized by 
the polymerases in order to allow the PGR and in vitro transcription reactions to work. 
In photoactivatable nucleotides 5-bromo-2'deoxyuridine usually replaces thymidine. 5-
bromouracil is also used but it is less reactive than 5-bromo-2'deoxyuridine. Both 
modified nucleotides will react with aromatic groups or thiols when exposed to the 
appropriate wavelength of light (~310nm). A nucleic acid:protein adduct is formed 
through cross-linking. Using polyacrylamide gel electrophoresis (PAGE), aptamers that 
cross-link to the target are partitioned from those that did not. The protein component 
is digested to generate sequences that could be amplified by PGR. Even with efficient 
digestion, not all of the protein is removed. This limits the number of usable templates 
in the PGR reaction. A mixture of Taq and Pwo polymerase enzymes was shown to 
amplify the low copy number templates more efficiently and accurately than Taq 
polymerase alone (37). Reasonable amplification of sequences in photoSELEX was 
achieved by a combination of Taq and Pwo polymerase enzymes. Both Pwo and Taq 
DNA polymerase can incorporate 5-bromouracil. The Pwo polymerase possesses 
proofreading activity and its efficiency is lower compared to the Taq DNA polymerase, 
which does not have proofreading activity. To achieve efficient amplification and keep 
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the low level of errors, Taq and Pwo polymerase were used together as a 1:1 mixture 
(38). 
In the process of PhotoSELEX, the oligonucleotide library and protein target 
mixture are exposed to a laser of a certain wavelength to activate the modified 
nucleotide. The activated nucleotide will react with an aromatic group or thiol in the 
protein target molecule to form a permanent covalent bond. The protein target 
molecule with covalently bound oligonucleotide is separated from other molecules 
(proteins and unbound oligonucleotides) by PAGE. After extraction from the gel, a 
protease is used to digest the protein. After digestion, PGR is used to amplify the 
sequences that were covalently bound with the protein. Further rounds of selection can 
then be carried on. 
After 6 rounds of PhotoSELEX selection, an aptamer binding to human basic 
fibroblast growth factor (bFGF) with a low pM dissociation constant was selected using 
a ssDNA oligonucleotide library (38). There are two reasons why PhotoSELEX is very 
effective in selecting high affinity aptamers. First, in order to efficiently form the 
covalent bond between the modified nucleotide and target protein molecule, the 
modified nucleotide must be within a certain distance of the amino acid side chain and 
the angle between modified nucleotide and aromatic or thiol group must be in a certain 
range. These requirements of the coupling reaction exclude the capture of 
oligonucleotides and proteins that are transiently or nonspecifically interacting. Second, 
because of the permanent covalent bond formed between oligonucleotide and bound 
protein target, more stringent washing conditions can be used during the selection. 
This will further eliminate non-specific binding. 
Another similar approach to selecting aptamers with high affinity and specificity is 
a SELEX procedure called blended SELEX (39). Human neutrophil elastase (hNe) is 
a target for an aptamer that could be used to inhibit acute respiratory distress syndrome 
(ARDS). Prior to the aptamer, various inhibitors of hNE had been developed but many 
of them suffered problems such as low specificity and low affinity. An RNA-based 
inhibitorfor hNe was developed through blended SELEX (39). A diphenyl phosphonate 
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derivative of valine (valP) that irreversibly inhibits h Ne by reacting with the serine in the 
active site of hNe to form a covalent bond with the 5' end of a ssDNA. The sequence 
at the 3'end of the ssDNA was complementary to the 5' end of an RNA pool with a 40 
nucleotide random sequence in the middle. Annealing the ssDNA and RNA brought 
the RNA random sequence close to the valP-hNe complex. During SELEX, a low 
concentration of target, in this case, hNe was used. The use of ssDNA-valP into 
SELEX allowed the selection of an RNA sequence-valP complex that gives an 
additional approximately 20-fold increase in inhibitory activity compared to the valP 
alone. Also, there was more than a 100-fold reduction in the relative rate of 
cross-reaction of this inhibitor with another serine protease, cathepsin G (39). 
Natural ssDNAs and RNAs are easily degraded by endonucleases and 
exonucleases present in the blood and inside the cell. For example, in the 
bloodstream, nucleic acids are degraded with half lives from seconds to minutes (40). 
The major mechanism by which RNA is degraded is an attack of 2' hydroxy I of 
pyrimidine by pyrimidine-specific endonucleases, which appear to be the most 
abundant nucleases in the blood and inside the cell (41, 42). For in vivo applications, 
the half-lives of aptamers made of natural nucleotides are too short. However,, there 
are many ways to make modified RNA molecules that are resistant to nucleases. 
Modification of the 2' position of the sugar of the RNA is an efficient way to achieve 
nuclease-resistance (42). RNAs with 2'-NH2 and 2'-F functional groups have 
enhanced life times in biological fluids (43, 44). The enzymes used in PGR and in vitro 
transcription can use as their substrates pyrimidine nucleotides substituted with amino 
(NH2) and fluoro (F) functional groups at the 2' position of the sugar and modified 
nucleotide bases have been used in SELEX to improve RNA stability. For example, 2' 
-amino and 2'-fluoro-2'-deoxypyrimidine RNAs have significantly increased stability 
compared with unmodified RNAs. These modified RNAs are resistant to nucleases and 
are well suited for both diagnostic and therapeutic applications. 
A 2'-amino-2'deoxypyrimidine RNA aptamer was selected to bind basic fibroblast 
growth factor (bFGF). The dissociation constant for the aptamer is about 0.5 nM and 
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the stability is at least 1,000 fold higher than the natural RNA in human serum (45). 
The affinity of this 2,amino-2'-deoxypyrimidine RNA aptamer for bFGF is similar to a 
natural RNA aptamer selected for bFGF (46). So far, 2'-amino and 2'-fluoro -2'-
deoxypyrimidines are the modified nucleotide bases most widely used in SELEX. 
Nucleoside5'-(a-P-borano) triphosphates (47) and nucleoside5'-(a-thio) triphosphates 
(48) also have been used as the basis of modified triphosphates for SELEX. Although 
they confer nuclease resistance, 2-amino and 2,-fluoro-2'-deoxyribopyrimide have 
some disadvantages compared to the natural nucleotide bases. These disadvantages 
include that the 2'-amino-2'-deoxyribopyrimidine does not have 2' hydroxy! group. The 
2' -hydroxyl group on the natural nucleosides can participate in hydrogen bonding and 
provide support for nucleic acid structural stability. The amino group is much bigger 
than the hydroxyl group, and 2' amino-2'-deoxyribopyrimidine RNA suffers from a low 
melting temperature in the duplex structure because the large amino group destabilizes 
the duplex structure. On the other hand, 2'-fluoro-2'-deoxyribopyrimidine RNA has 
comparable duplex stability with natural RNA because the fluorine is not as big as the 
amino group. But both 2-amino and Z-fluoro-deoxyribopyrimidine RNA are less 
efficient substrates for 17 RNA polymerase compared to the natural pyrimidine 
nucleotides. Additionally, people suspect that the modified nucleotide bases interfere 
with Watson-Crick interactions, which makes the secondary structure less stable. 
Recently, 4'-thioUTP and 4'-thioCTP were synthesized and successfully used in SELEX 
(49). These two new NTP analogues are better substrates for 17 RNA polymerase 
compared to 2'-amino and 2'-fluoro-2'deoxypyrimidine. RNAs with incorporated 4'-
thioUTP and 4'-thioCTP are 50 times more stable than the natural RNA (49). 
There is another expensive but clever method that improves the RNA aptamers' 
stability. Spiegelmers are specialized aptamers made of L-nucleic acid instead the 
natural D-nucleic acid (50-53). L-nucleic acids can not be recognized by 
endonucleases, so they are more stable in plasma compared to their mirror images, 
the natural D-nucleic acids. To select a spiegelmer, the aptamer for the mirror image 
of the true target is first selected by conventional SELEX procedure. For example, if 
the target is a protein, a mirror image of the natural protein will be chemically 
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synthesized first. The natural amino acids are all L -isomers. So, instead of using L-
amino acids as the building block, D-amino acids are used to synthesize a target for 
SELEX. After an aptamer made of natural D-nucleic acid is selected for the target 
made of D-amino acids, the mirror image of the aptamer is chemically synthesized. 
The interfaces between the D-nucleic acid/D-amino acid complex interaction are 
maintained in the L-nucleic acid/L-amino acid complex. The synthesized L-nucleic acid 
aptamers are named spiegelmers, as spiegel means mirror in German. Spiegelmers 
can be made for any target that is a chiral molecule for which its chiral isomer (mirror 
image) could be chemically synthesized. These requirements limit the number of 
available spiegelmers. Natural nucleic acids have half-lives from seconds to minutes 
in plasma (54). The biggest gain of the spiegelmer is its half-life in plasma which 
reportedly is 60h (50). 
Besides improving the selected aptamers' affinity and stability, another important 
aspect of SELEX is how fast it can be done. In the laboratory, special care is need to 
be taken to avoid degradation and loss of RNA during each round of SELEX. This 
might increase the time consumed in each round of SELEX. The transcription reaction, 
PGR and isolating the binding sequences in each round may take several days. 
Usually, 8-14 rounds of SELEX are needed for a significant binding increase. It usually 
takes weeks and months to complete a SELEX experiment and the successful isolation 
of an aptamer is not guaranteed. These drawbacks prevent more wide use of this 
procedure. Consequently, there have been considerable efforts made to improve the 
throughput of the SELEX procedure. 
Ellington and colleagues brought a robot into the picture and successfully 
automated the SELEX procedure (55, 56). In the automated SELEX, a mechanical 
system handles all the operation including the PGR, in wfro-transcription, partition of 
binding species and RT-PCR. In the demonstration of automated SELEX, an RNA 
aptamer targeting lysozyme was selected using automated SELEX. Lysozyme was 
biotinylated and the RNA binding to the lysozyme was captured by streptavidin-
magnetic beads. After 12 rounds of selection, the aptamer with the highest affinity had 
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a dissociation constant of 65nM for biotinylated lysozyme, and 31 nM for the 
unbiotinylated lysozyme (55). In a further development of automated SELEX, the 
biotinylated protein from in vitro transcription and in vitro translation was used in the 
automated selection (57). This optimization relieves the SELEX process from requiring 
a purified biotinylated protein . The cDNA sequence encoding the target protein was 
used to synthesize biotinylated protein for use in the automated SELEX. In this 
procedure, biotinylation is catalyzed by biotin protein ligase and the biotinylation site is 
at the N-terminus of the target protein which has a 24 amino acid biotin acceptor 
peptide sequence. The biotin protein ligase is produced as a fusion protein with the 
target protein for aptamer selection. This allows for uniform and targeted biotinylation 
of the aptamer target compared to the nonuniform and random biotinylation of purified 
protein achieved through a chemical reaction. 
In SELEX protocols that use affinity chromatography and filter capture to separate 
the binding from the non-binding species, there is always potential that the nucleic acid 
sequence could interact with the linker or the supporting material. Browser and 
colleagues used capillary electrophoresis (CE) to perform SELEX and named the 
process CE-SELEX (58, 59). In CE-SELEX, the target is mixed directly with a nucleic 
acid pool without any modification and there is no support material as in affinity 
chromatography and filter capture. The separation is based on the different migration 
rates of the unbound nucleic acid and the nucleic acid target molecule complex. 
Without a support material, there are no non-specifically bound sequences and the 
resolving power is great increased. As few as two rounds of SELEX resulted in an 
aptamer with high affinity. This technique greatly increases the throughput of the 
SELEX procedure. If automated SELEX could be combined with CE-SELEX, it may 
provide further boost for the more broad use of SELEX technique. 
Clearly, SELEX is a procedure with great potential. Many problems existing in the 
procedure have been resolved. Further optimization of this fast-spreading technique 
will provide a solid foundation for the development and application of its product 
aptamers. 
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Usually, the nucleic acid used in the SELEX is a random pool that has been 
chemically synthesized in vitro. There is another SELEX procedure developed to use 
fragments of genomic DMAs as the beginning materials for SELEX. Genomic SELEX 
is a SELEX procedure developed to find the binding sites of a certain protein on the 
genomic DMAs or the transcripts (mRNA) (60). 
Fragments of genomic DNAor RNA transcripts from the constructed genomic DNA 
library can be used in genomic SELEX to identify the interaction network between a 
particular protein and nucleic acids in a pool of molecules (genomic DNAs or 
transcripts). In this process, there is no random sequence pool. The complexity of the 
pool comes from the genome. The potential binding sites in genomic DNA of a 
nucleic acid binding protein could be acquired through genomic SELEX. Thus, through 
genomic SELEX, we can get more insights into the regulation of the transcription and 
translation by the nucleotide acid binding proteins. 
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APTAMERS 
The most important biological role of nucleic acids (DNA and RNA) in the living 
organism is as the genetic "hard disk", which is the genetic material that transfers the 
genetic information from generation to generation. Transfer RNAs, messenger RNAs 
and ribosomal RNAs are the functional nucleic acids to "output" genetic information in 
the form of proteins. Recently, small RNAs were recognized as the regulatory 
components hiding behind the central dogma. It took a long time and luck to discover 
that short RNA sequences are very powerful in gene regulation. At the same time, 
many non-natural short nucleic acid molecules have been developed to fulfill the needs 
of biological and biomedical research and applications. Aptamers were one of many 
types of such non-natural short nucleic acid molecules. 
The specificity and affinity of aptamers makes them very attractive biological tools. 
The term aptamer, is derived from the Latin word "aptus", means "to fit" (11). As the 
name implies, aptamers are RNAs and DNAs derived by an in vitro procedure (SELEX) 
that, starting from random sequence libraries, optimizes the nucleic acid for high affinity 
binding to a given ligand (61). The SELEX procedure is now generally recognized as 
a powerful tool for obtaining a nucleic acid for almost any target molecule that binds to 
that target with high specificity and affinity. Target molecules that have been used to 
select aptamers include aminoglycosides and antibiotics (30, 62-64), theophylline (35), 
citrulline (65), ATP (31, 66 ), amino acids (67-70), peptides (71-73), FMN and FAD (74, 
75), vitamins (76) and carbohydrates (77). Because SELEX is an in vitro selection 
procedure, there is almost no limit to the target molecule and the conditions of 
selection. More and more aptamers are reported for various target molecules. The 
fastest growing group of aptamers is for protein molecules. All kinds of proteins have 
been selected as the target molecules: viral proteins (78-83), enzymes (76, 84), 
proteases (81, 85-93), growth factors (94-96), cytokines ((97), transcription factors (73, 
98, 99) and cell adhesion proteins (77, 100-102). 
Some of the aptamers selected to various targets are listed above. Since the 
SELEX procedure was introduced in 1990, there have been hundreds of aptamers 
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selected through SELEX. Most of them are RNA aptamers. Along with the growing 
number of aptamers, at least two databases were created to keep track of functional 
nucleic acids as well as natural aptamers, named riboswitches {103, 104). One 
database, SELEXDB, can be found at http://wwwmqs.bionet.nsc.ru/mas/svstems/ 
SELEX/ (104). The other database, the Aptamer Database, can be found at 
http://aptamer.icmb.utexas.edu/ (103). The SELEX DB focuses on how in vitro 
selection could help to define the natural DNA and RNA sequences that are recognized 
by proteins. Although there is some overlap, the Aptamer Database is a more complete 
database for aptamers produced through SELEX compared to the SELEX DB 
database. The Aptamer Database is updated monthly and by August, 2005 it 
contained 3,498 sequences from 306 articles in the Aptamer Database. 
Three-dimensional structural analyses (NMR and X-ray crystallography) have been 
used to establish the characteristics of ligand-binding pockets in aptamers and the 
molecular interactions that occur between aptamer and target. In aptamers binding to 
aminoglycoside ligands, electrostatic interactions, shape complementarity and 
hydrogen binding provide the strength for the highly specific ligand discrimination (105-
107). For the flat targets, such as molecules with aromatic rings, the specificities and 
binding affinit ies are achieved by a combination of stacking and hydrogen-bonding (61). 
A comparison of DNA and RNA ATP aptamers shows how two independently selected 
aptamers can vary in structure yet bind the same target molecule. The base sequence 
and secondary structures of these aptamers are different. Each DNA aptamer binds 
to two ATP molecules (24) while each RNA aptamer binds only one ATP molecule 
(108, 109). But the binding pockets of the DNA and RNA aptamers and the interactions 
between ATP and nucleic acid are almost the same (44). There is a reverse 
Hoogsteen G-G pair as a stacking platform in both the aptamers, the ATP pseudo-base 
pairs with one guanine located in a pocket between a G-G pair and the adenosine. 
There is also extensive stacking interaction among ATP • G, and the G-G pair and 
adenosine. Similar to the interaction between aptamer and ATP, specific and high 
affinity binding of aptamers to peptides or proteins is also based on multiple 
interactions. When RNA aptamers bind to the HIV-1 Rev peptide, an arginine-rich 
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peptide from the human immunodeficiency virus (HIV-1) Rev protein, non-specific 
interactions between thearginineguanidinium groups of the peptide and the phosphate 
groups of the RNAs provide strength to stabilize the complex. Then specific hydrogen 
bonds between RNAs and arginine pairs of the peptide make specific recognition 
possible (110). 
In summary, aptamers can be generated for a broad range of targets. By 
investigating the interactions of aptamers with their target molecules, the general 
structural elements critical for these types of interaction can be derived. Knowledge 
about the interaction between aptamer and its target can help to explain how natural 
nucleic acids, consisting of four kinds of nucleotide bases, can participate and play 
important roles in so many biological processes inside cells. In the end, it might be 
possible to design nucleic acid molecules with desired functions and required properties 
to be used in the biological and biomedical research and applications. 
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PRINCIPLES OF THE TRAP DESIGN 
Targeted Reversibly Attenuated Probe (TRAP) 
The TRAP is a single stranded DNA or RNA sequence (Fig. 2). Every TRAP has 
three modules. At one end of the TRAP there is a ligand-binding aptamer sequence. 
At the other end of the TRAP is the attenuator sequence that is the reverse 
complement of the aptamer sequence. In the middle of the TRAP, there is an 
antisense sequence, which is complementary to the target mRNA sequence. 
Aptamers are between 10-1 OOnt in length. One DNA aptamer for thrombin is 15nt 
(111). The ATP DNA aptamer is 25nt (31). The ATP RNA aptamer is 40nt (66). Two 
tobramycin RNA aptamers are 26ntand 27nt (112) and the neomycin B RNA aptamer 
is 23nt ( 113). There are two considerations for choosing an aptamer for a TRAP. One 
consideration is affinity; the higher affinity, the more sensitive the TRAP. The other 
consideration is specificity; the aptamer should bind very specifically to the ligand. 
The attenuator sequence of the TRAP is 5-10 nt. Because the TRAP has 5' end 
and 3' ends that are reverse complementary sequences like molecular beacons (6), 
that adopt a stem loop structure. 
In the middle of the TRAP sequence is a 15-30 nt antisense sequence. The 
function of this intervening antisense sequence is to anneal with the complementary 
sequence on the target mRNA and to provide the energy to separate the stem of the 
TRAP. 
The Theoretical Basis of the TRAP 
The rigidity of short double strand DNA ( dsDNA) 
Molecular beacons have a stem-loop structure (6). The loop is about 15-30nt. It 
has been shown in vitro and in vivo that after the loop has annealed with its 
complementary sequence, the stem is opened (6, 114). The idea is that a single 
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stranded DNA can easily bend and has no rigidity. So the two ends of an 
oligonucleotide can come together to create a stem. 
Knowledge of the inflexibility of dsDNA is very important for understanding the 
activation of transcription, chromosome structure and the recognition of DNA-binding 
proteins (115). In the elastic model, DNA is regarded as a stiff elastic rod (116). The 
bending free energy (AGbend) represents the DNA flexibility and describes the bending 
motion of the helix (115). The free energy for DNA bending can be expressed as 
follows: ag^= R'^F-(àéi) . Where R is the gas constant, T is the absolute 
temperature, L is the length of the DNA under strain, AG is the bending angle in 
radians, and the P is an experimental estimated constant called the persistence length 
of the DNA duplex (115). The experimental estimation of the persistence length, P, 
of bulk DNA was about 150 base pairs (bp) or 500 A (117). Early studies provided the 
data to calculate the AGbend for a certain length of DNA. Energy is needed to bend 
short dsDNAs. In the stem-loop structure, if the loop is annealed with its 
complementary sequence and becomes dsDNA, the tendency of this dsDNA to be 
straight will compete with the stability of the stem. If the AGbend is high enough, then the 
stem will come apart. For the TRAP, the situation is more complicated than it is for the 
molecular beacons. The aptamer itself has the potential to fold into a certain structure. 
The attenuator must destroy the aptamer's natural folding. On the other hand, the 
interaction between aptamer and attenuator should not be too strong. Otherwise, 
AGbend may not be large enough to open the TRAP. 
Intermolecular and intramolecular interactions in the TRAP 
For a single stranded DNA or RNA with a stem loop structure, one question is 
about the intermolecular interaction. Because the 5' and 3' ends are complementary, 
it is possible that two molecules could anneal with each other through their terminal 
sequences. A recent study showed that both DNA and RNA complementary strands 
preferentially form intramolecular hairpin structures (118). In the 3' noncoding regions 
of the chicken glutamine synthetase gene, there is an A-T rich DNA sequence region. 
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Within this region there are several sequences that could conceivably form 
intramolecular hairpin structures. Riccelli et al. (118) used optical and calorimetric 
melting and gel electrophoresis to investigate the intermolecular and intramolecular 
interactions of the hairpin-forming sequences. The DNA and RNA oligomer sequences 
synthesized were: DNA, 5'd-T-T-T-T-T-T-A-A-T-A-A-T-T-A-A-A-A-A-A-3'; and RNA, 5'r-
U-U-U-U-U-U-A-A-U-A-A-U-U-A-A-A-A-A-A-3'. The DNA and RNA oligomers alone 
and in various mixtures with their DNA and RNA complementary strands were analyzed 
using gel electrophoresis. The experiments revealed that both strands alone 
preferentially form intramolecular hairpin structures (118). In mixtures in which their 
complementary strands were in vast molar excess (stoichiometric ratios > 10:1), the 
intramolecularstructures were converted to intermolecular duplexes. For the DNA and 
RNA strands examined, the conversion was not complete until over a 1,000-fold excess 
of the complementary strand was added (118). 
It is important for proper function of the TRAP that it forms an intramolecular 
structure that includes the attenuator hybridized with the aptamer. The evidence 
provided by the experiments consistently indicate that TRAP will strongly preferentially 
form intramolecular hairpin structures. 
The enhanced specificity of a stem-and-loop structure 
Antisense probes can identify their complementary sequences in the presence of 
unrelated nucleic acid sequences. But they cannot discriminate targets that differ from 
one another by only a single nucleic acid. However, probes with a stem-and-loop 
structure have the ability to recognize targets with an accuracy of a single difference 
in a nucleic acid sequence (6, 7). The thermodynamic basis of the enhanced specificity 
of stem-and-loop DNA probes was investigated in a molecular beacon with a 
fluorophore attached to one end and a fluorescence quencher attached to the other 
end, in which the fluorescence of the fluorophore is quenched when the quencher 
becomes located a close within 100Â of the fluorophore (119). The stem-and-loop 
structure, such as in molecular beacons, can exist in three different states: bound to its 
target; free in the form of the hairpin structure; free in the form of random coils (119). 
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The results showed that the structural constraints on the molecular beacon's 
conformational change resulted in enhanced specificity. The unstructured probe does 
not experience conformational changes when it binds to its targets. At 37°C or lower 
temperatures, the unstructured probe can not differentiate the perfect target from the 
single mismatch target. On the other hand, when the molecular beacons binds to its 
target, it undergoes a conformational change from a hairpin structure to an open 
structure. In this transition, hybridization of the target to the molecular beacon needs 
to be strong enough to open the stem structure of the probe. So even though the 
difference in the binding energy between the perfectly matched target and one single 
mismatch target is small, it can be differentiated by stem-and-loop structure probes, 
such as molecular beacons, in a much low temperature range compared to that 
required for the unstructured probe. The experiment evidence obtained from 
thermodynamic analysis showed that the nucleic acid probes with stem-loop structures 
had enhanced specificity compared to the non-structured linear nucleic acid probes 
(779). 
The sequence and length of attenuator 
The function of the attenuator in the TRAP is to prevent the natural folding of 
aptamer and to hold the aptamer in an inactive state until the TRAP is annealed with 
its target mRNA. The attenuator should interact with key residues of the aptamer. The 
attenuator should be adjusted to a length that will shield the aptamer binding activity 
totally in the absence of target mRNA and release the aptamer after the binding of the 
target mRNA. Too long or too short an attenuator will not function properly. 
ALLOSTERIC NUCLEIC ACID MOLECULES 
Artificial Allosteric Nucleotide Acid Molecules 
Allosteric regulation was first recognized in enzymes involved in metabolism (120). 
Under allosteric regulation, the catalytic activity of an enzyme can be regulated by a 
small molecule called an effector. The binding site of the effector on the enzyme is 
different from the substrate's binding site. Binding to the effector induces a 
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conformational change of the enzyme that regulates the enzyme's activity by altering 
the structure or availability of the enzyme's active site. 
The TRAP functions by allosteric regulation. The regulatory nucleotide sequence 
interacts with the antisense segment on the TRAP and this interaction regulates the 
aptamer's binding activity to its target through allosteric regulation. Allosteric regulation 
is also observed in other small non-coding nucleic acid sequences. 
The broad and important functions of small non-coding RNA molecules in the cell 
have just begun to be fully appreciated in recent years. Because of the limited 
knowledge and awareness of the capabilities of natural small RNAs, allosteric nucleic 
acid molecules were first developed through rational design. Only more recently have 
many natural RNA sequences under allosteric regulation been discovered. There are 
three kinds of artificial allosteric nucleotide acids: allosteric ribozymes (aptazymes, 
maxizymes), allosteric deoxyribozymes and allosteric aptamers. 
To this day, the hammerhead ribozyme is the most widely used for developing 
allosteric ribozymes. In 1995, an allosteric ribozyme activated by a single strand DNA 
(ssDNA) effector was created through rational design {121). In the inactive state, the 
RNA molecule containing ribozyme could not cleave its substrate. After the ssDNA 
effector hybridized withthe complementary RNA sequence on the ribozyme, the 
ribozyme was activated and the substrate was cleaved. In this case, strictly speaking, 
it was not a true allosteric ribozyme. The reason was that the sequence on the 
ribozyme with which the effector ssDNA interacted prevented the substrate from 
binding by base pairing with the substrate binding site. The effector ssDNA released 
the inhibition of ribozyme by forming a long stable helix with the sequence that 
occupied the substrate binding site. A later developed ribozyme-based TRAP is an 
actual allosteric ribozyme (9). In a hammerhead (HH) ribozyme TRAP, a 20nt polyAC 
sequence was used as the intervening sequence in the TRAP design to link the 
attenuator and HH ribozyme. By annealing to conserved bases in the catalytic core of 
HH ribozyme, the attenuator keeps the ribozyme inactive. Binding of RNA or DNA to 
the intervening sequence that links the ribozyme and attenuator frees the ribozyme 
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core to fold into an active conformation, even though the intervening sequence itself 
does not interfere with the ribozyme. HH ribozyme TRAPs were shown to be activated 
more than 250-fold upon addition of the regulatory RNA oligonucleotide (9). 
In another approach to developing an allosteric ribozyme, an aptamer is linked to 
the ribozyme to provide allosteric regulation by the ligand of the aptamer. This kind of 
aptamer-ribozyme hybrid is named as "aptazyme" or "maxizyme". An allosteric 
aptamer-hammerhead ribozyme was developed in 1997 by Jin Tang and Ronald 
Breaker using ATP as the effector molecule (722). They linked an ATP RNA aptamer 
to a hammerhead ribozyme through a designed linker. Through rational design, 
different linker sequences were found that resulted in ribozymes with catalytic activity 
inhibited or activated by ATP. In the allosteric ribozyme with cleavage activity inhibited 
by ATP, the cleavage rate of ribozyme was reduced by 180 fold in the presence of ATP. 
Allosteric regulation is realized in the aptazyme by interaction between the aptamer 
domain and stem I of the hammerhead ribozyme (723). The secondary structure of the 
hammerhead ribozyme forms three stems. Stem I and III are formed by annealing with 
the substrate. The ATP RNA aptamer was linked with the ribozyme to form an 
aptamer-ribozyme hybrid through stem II. In the active form of the ribozyme, stem II 
and stem I form a certain angle. After the aptamer domain was linked to the ribozyme 
through stem II, stem I and stem II could still form the required angle for the ribozyme 
to be active. The reason is that in the absence of its ATP ligand, the RNA ATP 
aptamer does not form a rigid and homogenous secondary structure (724). The lack 
of a defined structure in the ATP RNA aptamer without its ligand leaves the ribozyme 
active. Upon the binding of ATP to the aptamer, the aptamer and ATP now have a 
more rigid and uniform structure (125). This structure prevents the stem II and stem 
I from reaching the relative spatial position required for activity of ribozyme. By altering 
the spatial position of the target RNA relative to the active site of the ribozyme, ATP 
complexed with the aptamer portion of the aptazyme is able to inhibit the activity of the 
ribozyme. 
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The stability of stem II of the hammerhead ribozyme is important for ribozyme 
catalytic activity. By increasing the length of stem II, the ATP-aptamer domain and 
stem I will be far enough apart that the ATP-aptamer domain does not prevent stem II 
and stem I from forming the angle needed for ribozyme activity. If non-Watson-Crick 
base pairs are introduced into stem II then, in the absence of ligand, the loop structure 
of the aptamer will destabilize stem II. After ATP is bound by the aptamer, the ATP-
aptamer domain has a uniform and stable structure and stabilizes stem II to support the 
ribozyme's activity. In this way, the aptamer-ribozyme hybrid that is catalytically 
activated by ATP was developed (122). 
Through rational design, many other allosteric ribozymes have been developed. 
An FMN (flavin mononucleotide) RNA aptamer was attached to a hammerhead 
ribozyme through stem II (126). As described previously, when stem II is short (4bp), 
the ATP aptamer binds ATP and inhibits the ribozyme activity by spatial interference. 
But if the ATP aptamer is replaced by the FMN RNA aptamer, the situation is changed. 
When the FMN aptamer binds to its ligand-FMN there is no spatial interference that 
requires a longer stem II as for the ATP aptazyme. The reason is that the tertiary 
structure of FMN aptamer with its ligand is different from the ATP aptamer with its 
ligand. With only 3 bp in stem II, the FMN aptamer-ribozyme hybrid is positively 
regulated by FMN. Without FMN, the short stem II cannot form the stable structure that 
is necessary for activity of the hammerhead ribozyme. The structure of the FMN 
aptamer without its ligand is also heterogenous, which is similar to the ATP RNA 
aptamer (75, 126). Upon the binding of FMN by the FMN aptamer, the structure 
becomes more rigid and homogeneous. This conformational change in the FMN 
aptamer due to FMN binding makes stem II much more stable. The increase in the 
stability of stem II results in an increase in the catalytic activity of the hammerhead 
ribozyme. 
The combination of rational design and combinational selection has resulted in the 
development of many allosteric ribozymes. In combinatorial selection, a region in an 
RNA molecule containing the ribozyme is randomized. Usually an allosteric selection 
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is performed by applying negative selection first, followed by positive selection. For 
example, in the allosteric selection of an effector-activated allosteric ribozyme, the RNA 
molecule that is active in the absence of the effector molecule will be eliminated by 
negative selection. After negative selection, the effector molecule is added to the RNA 
pool and the RNA effector molecules are added to activate the ribozyme. The active 
molecules are separated from others by a partition method such as denaturing 
polyacrylamide gel and then amplified by RT-PCR. Breaker and colleagues applied 
allosteric selection to the hammerhead ribozyme and generated a ribozyme with 
catalytic activity that is regulated by the second messengers cGMP and cAMP (127). 
In this selection, the linker region was not randomized. Instead, a 25nt randomized 
region replaced the FMN aptamer sequence in the allosteric FMN-hammerhead 
aptazyme. The linker region was unchanged from that in the FMN-hammerhead 
aptazyme. The RNA pool was put through allosteric selection and RNAs isolated from 
this pool exhibited a 5,000 fold increase in ribozyme activity upon addition of cGMP or 
cAMP. 
Other ribozymes than the hammerhead ribozyme, like the ribozyme ligase, were 
also used to develop three different allosteric ribozymes activated by the small effector 
molecules: ATP, theophylline and FMN, respectively (128). DNA enzymes activated 
by ATP have also been created by fusing the ATP DNA aptamer with deoxyribozyme 
ligase (129). In table 1, the allosteric ribozymes thus far developed in vitro are 
summarized. 
Most allosteric ribozymes developed so far are activated by a small effector 
molecule. Although the detailed mechanism of allosteric regulation is different for each 
allosteric ribozyme, in general the attachment of the effector binding module (the 
aptamer) inhibits the catalytic activity of ribozyme through direct base pairing or indirect 
destabilization of the structure needed for activity. After the aptamer binds to its 
effector molecule, the inhibition is released and the ribozyme is activated. 
Fewer allosteric aptamers have been created through rational design and in vitro 
selection than allosteric ribozymes. In table 2, the artificial allosteric aptamers so far 
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developed are summarized. The development of allosteric aptamers has usually been 
done by rational design combined with allosteric selection. Even though allosteric 
selection has greater potential to produce a molecule with the required properties, 
rational design is still very efficient. 
An example of an allosteric selection procedure was carried out to select an 
allosteric RNA aptamer that binds to the DNA repair enzyme, formamidopyrimidine 
glycosylase (Fpg) in the absence of neomycin but dissociates from Fpg upon the 
addition of neomycin (130). In the first six rounds of selection, urea was used in the 
elution buffer to elute any RNA that bound to the Fpg, which was captured on filter 
paper. Starting with the seventh round, neomycin was used to elute the RNA from the 
filter paper. This produced an aptamer that binds to Fpg but dissociates from Fpg upon 
the presence of neomycin. Structural probing of this aptamer indicated that the binding 
site for neomycin on the RNA aptamer and the binding site for Fpg on the selected 
RNA aptamer overlapped. This overlap makes neomycin a competitor for the binding 
of Fpg. Strictly speaking, this regulation is not allosteric regulation because neomycin 
acts as a competitive inhibitor of Fpg binding to the aptamer. The aptamer has a higher 
affinity for neomycin compared to Fpg, which explains why neomycin could make the 
aptamer dissociate from Fpg. Even though this regulation is not allosteric, the 
aptamer's activity is still regulated by a small effector molecule, in this case neomycin. 
The success of this regulation indicates that it is possible to design and select an 
aptamer that is under allosteric regulation. 
Malachite green (MG) undergoes a fluorescence change upon binding to its RNA 
aptamer. Free MG has a maximum absorbance at 617nm but does not fluoresce 
because the absorbed energy can be relieved through vibrations. After MG is bound 
by its RNA aptamer, the absorbing maximum moves to 630nm and the quantum yield 
of MG increases up to -2,000 fold (131). The secondary structure of the malachite 
green aptamer (MGA) includes a 6bp stem I that is formed by the 5' and 3' end, 
followed by a bulge loop closed by a 4 bp stem (stem II) with a hairpin loop. The 
binding site for MG lies in the bulge loop. The 6bp stem I and 4bp stem II at the two 
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ends of bulge loop provide the stability needed for binding MG. By varying the length 
and composition of stem I and II, the overall stability of the MGA can be increased or 
decreased. Furthermore, if the hairpin loop is removed and another aptamer is 
adjoined through stem II, the stability of MGA module in the aptamer-aptamer hybrid 
can be regulated by the attached aptamer. Taking this strategy of rational design, 
Stojanovic et al (132) developed a modular aptameric sensor by joining the truncated 
MGA module with ATP DNA , FMN RNA or theophylline RNA aptamer (ATPA, FMNA 
or THA). In the absence of their small aptamer ligand, the ATPA, FMNA and THA do 
not have homogenous and rigid structures, especially at the region connecting with the 
MGA module through short stem II. When it binds its ligand molecule, the aptamer 
ligand-induced conformation change provides a stem structure in the connecting region. 
With this structural help from the aptamer, the stem II now becomes stable enough to 
support binding of MG by the MGA module with the result that a fluorescence increase 
will be observed. The best sensor of the three constructs prepared by this group is the 
MGA-FMNA which has about 30-50 fold increase in the fluorescence upon the addition 
of MG. 
Recently, allosteric ribozymes regulated by binding to oligonucleotides were 
successfully developed by computational design and validated by experiments (28). 
Folding of nucleic acids is mainly guided by Watson-Crick base pairing for which 
thermal dynamic parameters for base pairing are well determined from experimentation. 
This makes a solid base for computational prediction of the secondary structure of RNA 
and ssDNA. Using the RNA secondary structure prediction method developed based 
on equilibrium partition function as described by McCaskill (133), Breaker and 
Penchovsky designed four different kinds of allosteric ribozymes with AND, YES, OR 
and NOT boolean logical functions (28). The computational design process began with 
inserting a short (16-22nt) random segment into the hammerhead ribozyme. The 
position of insertion of random segment was carefully chosen based on the previously 
developed allosteric ribozymes through rational design and allosteric selection (122, 
123,127, 134-136). The computer generated all possible sequence combinations. For 
example, a 22nt random region on the ribozyme will represent 1013 different sequences. 
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Each sequence was folded by software and the base pairing probability of each 
nucleotide on the sequence was calculated. By applying the criterion that a certain 
number of bases within the random region must pair with bases in the ribozyme 
catalytic core, sequences not matching this criterion were discarded. In the first 
selection process the random region on each sequence was allowed to freely pair with 
other bases in the sequence. After the first selection process the random region was 
not allowed to base pair with any other nucleotide in the sequence by including an 
effector ssDNA complementary to the random region which would form a stable duplex. 
Underthis restricted condition, each sequence from the first selection was folded again 
and the sequences matching the applied criterion were kept. 
The two stage selection process generated sequences that folded into different 
secondary structures with vs. without effector ssDNA. If one structure was set to 
deactivate the ribozyme and the other was fully active, the effector ssDNA regulated 
the ribozyme activity. 
The next selection criterion was that the free energy gap between the structures 
with and without effector ssDNA must be larger than -6 and less than -10 kcal.mol"1. 
This gap allowed the structure without effector ssDNA to be stable enough and at the 
same time, it was not too stable that it could not be overcome via the energy of the 
effector ssDNA binding. The final selected sequences were verified through 
experiments to behave as allosteric ribozymes with activity regulated by effector 
ssDNA. All four kinds of selected allosteric ribozyme showed >1000 fold difference in 
activity upon the addition of the effector ssDNA. 
Combining computational design with modular rational design opens up an exciting 
new approach for the development of allosteric nucleotide acid molecules. We can 
anticipate more advances in the field of developing of artificial allosteric nucleic acid 
molecules in the future. 
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Riboswitches; Natural Allosteric Nucleic Acid Molecules 
The word aptamer appeared as a description of an artificial nucleic acid molecule 
selected through the process of SELEX. More than ten years after SELEX was first 
introduced in 1990, the first example of an mRNA element that controls genetic 
expression by metabolic binding was discovered in bacteria (137). It turns out that 
Nature utilizes the binding capacity of nucleic acids to regulate transcription and 
translation. The natural allosteric nucleic acids that exist as mRNA elements and 
regulate transcription or translation were called 'riboswitches'. A riboswitch usually 
contains two parts: one is the binding module, which is a natural aptamer module that 
binds small molecules, the other is an expression platform that transmits the effect of 
the binding event to transcription or translation. To date, the majority of riboswitches 
have been found in bacterial RNAs. There are very few riboswitches yet found in the 
eukaryote. These are the mRNA elements in fungi and in plants that match the 
consensus sequence and structure of thiamine pyrophosphate-binding domains of 
prokaryotes (138, 139). In table 3, the riboswitches and their roles in regulation of 
bacterial metabolism are summarized. 
Regulation by a riboswitch of transcription and translation is unique in the sense 
that the process does not need any protein factors or tRNA. The riboswitch can utilize 
the structural change that occurs upon the binding of its ligand, usually a small 
metabolic molecule, to influence the interaction between mRNA and the transcriptional 
termination and/or translation complex. The riboswitch acts as a natural allosteric 
nucleic acid module of the mRNA that responds to the concentration of a small 
metabolite in the cell. Through these natural allosteric nucleic acid modules, the cell 
adjusts the metabolic pathway involving the riboswitch ligand. 
In the thiamine pyrophosphate(TPP)-sensing riboswitch in Gram positive bacteria, 
the thiamine genes are negatively controlled by thiamine and TPP. In the absence of 
TPP, the thi-box in the 5'UTR of thi operon participates in the structure of an anti-
terminator. Transcription continues in the absence of TPP. After TPP is bound by the 
thi-box, the anti-antiterminator and terminator both form and transcription is shut down. 
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This terminator—antiterminator—anti-antiterminator system is widely used in 
riboswitches that control transcriptional termination in both Gram positive and Gram 
negative bacteria. Flavin mononucleotide(FMN)-sensing, adenosylcobalamin-sensing 
and hypoxanthine, guanine-sensing riboswitches in Gram positive bacteria, S-adenosyl-
methionine-sensing and lysine-sensing riboswitches in Gram positive and Gram 
negative bacteria all utilize the terminator—antiterminator—anti-antiterminator 
configuration in the 5'UTR of m RNAs to regulate transcriptional termination of specific 
genes. 
Besides transcriptional termination, riboswitches can also control translational 
initiation. In most cases, riboswitches inhibit translational initiation upon binding to their 
metabolic ligands. For example, in E.coli, the flavin mononuleotide-sensing riboswitch 
(rfn-box) participates in a stem loop structure in the absence of FMN that excludes the 
Shine-Dalgarno (SD) sequence. Thus, the ribosome is able to recognize the SD 
sequence and begin translation. Upon binding to FMN, the FMN-sensing riboswitch 
changes its secondary structure and a new stem-loop structure is formed in which 
bases in the SD sequence base pair and participate in a double stranded stem 
structure. Because the SD sequence is part of the double stranded stem after FMN 
has bound, the ribosome can no longer recognize it and translational initiation is 
inhibited. The TPP-sensing riboswitch in Gram negative bacteria employs a similar 
strategy to the FMN riboswitch to inhibit translational initiation. 
Riboswitches can be not only allosteric aptamers but also allosteric ribozymes. In 
Gram positive bacteria, one riboswitch with a self-cleaving ribozyme activity has been 
discovered (140). Located in the 5'UTR of glmS (glutamine-fructose-6-phosphate 
amidotransferase) mRNA, the metabolite-responsive ribozyme element binds 
glucosamine-6-phosphate (GlcNGP) and self-cleaves. The gene glmS encodes an 
enzyme participating in GlcN6P synthesis. The ribozyme activity of this riboswitch 
requires the present of GlcN6P. Without binding to GlcNGP, the ribozyme self-cleavage 
activity is inhibited though folding into an inactive conformation. Upon binding to 
GlcNGP, a ligand-induced conformational change releases the inhibition and the 
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ribozyme becomes active. It is not clear how cleavage of glmS mRNA leads to the 
reduction of gene expression. It was speculated that the truncated mRNA was targeted 
for degradation by RNases or the translation of truncated mRNA was inhibited. 
So far, all but two of the known riboswitches inhibit translation upon binding the 
metabolite of the regulated metabolic pathway. One of the two known riboswitches that 
activate gene expression is the adenine riboswitch found in Bacillus subtilis. Upon 
binding to adenine, the adenine riboswitch prevents the formation of a premature 
transcriptional terminator in the ydhL (also know as pbuE) mRNA (141). In this case, 
the adenine riboswitch acts as an activator to suppress premature transcriptional 
termination. The second example of a ribozyme that is an ON switch is the glycine-
dependent riboswitch discussed next. 
Recently, a riboswitch has been found that binds to its ligand cooperatively (142). 
The glycine-dependent riboswitch found in gcvToperon in Bacillus subtilis consists of 
two similar glycine aptamers structurally linked by a short linker. The striking features 
of this glycine-sensing riboswitch are the short aptamer sequence and the cooperative 
binding to glycine. The length of aptamer structure is only 10nt, which is not common 
in aptamers produced through SELEX even after they have been reduced to their 
minimum effective length. After binding to the first glycine by one aptamer, the affinity 
of the other aptamer to the glycine increases about 1,000 fold. This is the first known 
natural nucleic acid molecule that binds to its ligand cooperatively. It was shown both 
in vitro and in vivo that upon binding to glycine, the glycine-dependent riboswitch 
activates transcription of the gcvT operon in Bacillus subtilis ( 142). So, this makes the 
glycine-dependent riboswitch also an 'ON' switch. 
Riboswitches are also found in fungi and plants where they appear to regulate 
splicing (138, 143). Through genomic and bioinformatics methods, we can anticipate 
that more and more natural allosteric nucleic acid elements will be discovered in a wide 
range of organisms. 
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SELECTION IN VIVO 
The power of SELEX procedure lies in its simultaneous access to a huge number 
of different sequences through random sequence pools combined with exponential 
amplification of the desired sequences by PGR. These two steps limit the use of 
SELEX procedure in vivo. To express the random pool in vivo, cloning and expression 
vectors need to be used. This reduces the possible complexity of the pool significantly 
because of the practical considerations of the mass of the pool and the number of 
individual cells that can be used in the selection. Also it limits the choice of the nucleic 
acid to RNA. To do SELEX in vivo, the broad range of target choice is lost compared 
to SELEX in vitro. Molecules that are toxic to the cell or molecules that can not easily 
enter the cells are not good targets for SELEX in vivo. So far, most in vivo related 
combinatorial selection has been done to target proteins. 
The yeast two-hybrid system is a combinatorial method for probing protein-protein 
interactions (144). Using the yeast two-hybrid system as a starting point, the yeast 
three-hybrid system was created to select aptamer and allosteric nucleic acid 
molecules (145-147)}. SenGupta et al. (148) created the yeast three-hybrid system to 
detect RNA-protein interactions in vivo. The yeast two-hybrid system has two fusion 
proteins: one has a DNA binding domain (BD) to provide the ability to bind the 
enhancer element of the reporter gene, the other has activation domain (AD) to activate 
the transcription of reporter gene. Each protein or protein pool for which interaction will 
be tested is fused with BD and AD, respectively. Interaction between the proteins of 
interest is verified by expression of the reporter gene. In the three-hybrid system, the 
protein fused with BD is the MS2 coat protein. The MS2 coat protein binds to MS2 
RNA elements with very high affinity. The protein of interest is fused with AD. The 
RNA molecule of interest is fused with the MS2 RNA elements. The RNA of interest 
could be a single sequence or a random sequence pool. Interaction between the RNA 
and protein of interest is verified by expression of the reporter gene. So, the yeast 
three-hybrid system is a modified version of the yeast two-hybrid system and was 
specifically designed to detect RNA-protein interactions. 
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An RNA decoy that binds NF-KB and inhibits its transcriptional activation activity 
was selected using the yeast three-hybrid system. An early-round in vitro NF-KB 
aptamer SELEX pool was cloned into a yeast vector and the RNA pool was expressed 
in yeast. After optimization and selection through the three-hybrid system, an RNA 
molecule that interacts with NF-KB in vivo was obtained. 
Recognition by the NF-KB aptamer of its target- NF-KB was verified through the 
yeast three-hybrid system in vivo (145). The yeast system was also used to select an 
RNA element with a transcriptional activation function (146). The random RNA library 
was cloned into a yeast expression vector in which the expressed RNA was fused with 
MS2 RNA element. The RNA element that could activate transcription of the reporter 
gene was selected through the yeast selection system. The RNA-based transcriptional 
activator selected through this in vivo evolution could activate expression without the 
protein factor. The fold increase upon the activation by this RNA transcription activator 
was comparable with the most powerful protein transcription activator (146). The 
detailed mechanism of the transcription activation by this RNA transcription activator 
is still unknown. However, by linking the RNA-based transcription activator to the 
malachite green aptamer through a randomized linker region, an allosteric RNA 
transcription activator was then selected using the yeast in vivo selection system (147). 
Transcriptional activation by the selected allosteric RNA molecule was regulated by 
tetramethylrosamine (TMR), a ligand of the malachite green aptamer. TMR stabilizes 
the helical region of the aptamer that is required for transcription activation and a 10-
fold increase in transcription activation was obtained. 
An in vivo SELEX procedure was also developed to reveal the critical elements on 
exons that define alternative splicing (149). In higher eukaryotes, alternative splicing 
of pre-mRNA has an important role in gene regulation. During alternative splicing, the 
pre-mRNA with multiple exons goes through different splicing processes. One or more 
exons are skipped for certain transcripts. In order to identify the cis-element in the 
particular exon that determines whether it will be kept or skipped, the exon of interest 
was partially or totally randomized. The random pool was cloned into an expression 
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vector and in vivo transcription of pre-mRNA was achieved after transfection. After 
splicing in the cell, the remaining exon sequence was amplified by RT-PCR. Then it 
was cloned into the same expression vector to go through in vivo SELEX again (150). 
This in vivo selection process is much more like the in vitro SELEX process than the 
yeast three-hybrid system. The surviving sequences after each round are preserved 
and amplified through RT-PCR. The only difference from the in vitro sequence was 
that selection was carried in the cell. This allowed the selection pressure to include the 
preservation of in vivo function as a requirement for the surviving sequences. 
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APTAMER APPLICATIONS 
As a molecule selected to bind its target with high affinity and specificity, the 
aptamer has been used for a broad range of applications. People naturally compare 
the aptamer with an antibody because the antibody has dominated the field of 
detection, imaging and inhibition of target protein molecules. Is it really necessary to 
develop aptamer-based application techniques? Especially to the protein targets, what 
is the advantages of an aptamer over an antibody? In table 4, the properties of 
aptamers and antibodies are compared. From this table, we can see that the aptamers 
are small and they can be made against a broader range of targets than can 
antibodies. The aptamer is much more easily modified compared to the antibody and 
its function is preserved after many different modifications. Once the sequence of an 
aptamer is determined, chemical synthesis can guarantee a consistent quality of the 
aptamer. It is not like an antibody, that will change from batch to batch unless it is 
monoclonal. The target of an aptamer could be any molecule or complex, such as a 
whole cell or even a tissue. Because the aptamer has great potential to outrun the 
antibody in many applications, the development of aptamer-based techniques have 
been growing rapidly. 
Bio-sensors and Imaging Applications 
An RNA aptamer that targets the Tat protein of HIV was selected and shown to 
inhibit Tat-dependent trans-activation of transcription, both in vitro and in vivo (80). 
Utilizing this Tat RNA aptamer, a molecular beacon aptamer that fluoresces in the 
present of the HIV Tat was created (151). The Tat RNA aptamer has a stem loop 
structure but the loop region is not essential for binding. After removing the loop region, 
two single stranded RNAs (A and B), each one of the two halves of the remaining 
aptamer, were synthesized, annealed and binding of the annealed RNAs to the Tat was 
confirmed by a gel shift assay. Furthermore, one RNA (A) was labeled with a 
fluorophore dye at the 5' end and a quencher dye at the 3' end and the RNA was 
designed to be able to form an internal stem loop structure in the absence of Tat. 
Therefore, in the absence of Tat, the fluorescence was quenched even though both 
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RNA (A and B) were present. In the presence of Tat, the A RNA undergoes a 
conformational change to form a duplex with RNA B. The fluorophore dye at the 5' end 
and the quencher dye at the 3' end of RNA A is separated and the fluorescence output 
is increased. 
Signaling aptamers were also engineered by replacing the bases on an aptamer 
by fluorescent reporters ( 152). Many aptamers, such as the ATP aptamer, are believed 
to go though an 'induced fit' conformational change after binding to the target molecule 
(124). In the presence of adenosine, the engineered DNA and RNA ATP fluorescent 
reporter aptamers show increases in fluorescence that are presumably due to 
conformational changes induced by the interaction of aptamer and adenosine. 
Blank et al used a FITC-18C -conjugated DNA aptamer to visualize a rat brain 
tumor using fluorescence microscopy (153). The FITC-18C -conjugated DNA aptamer 
could selectively bind to tumor micro vessels but not normal blood vessels. The 
theophylline-dependent allosteric ribozyme was also used to give fluorescence in the 
presence of theophylline (154). Here, the substrate of the ribozyme was modified to 
have a fluorophore in the 5' end and a quenching dye in the 3' end. Upon substrate 
cleavage in the presence of theophylline, the quencher dye was separated from the 
fluorophore and a 4-fold fluorescence increase was observed. 
To develop a sensor for cocaine, thirty five dyes were screened for changes in 
spectrum upon adding cocaine to a mixture of the cocaine aptamer and a given dye. 
Thereby an aptamer-based colorimetric probe for cocaine was developed using the 
dye, diethylthiotricarbocyanine iodide, with the cocaine aptamer (155). In the presence 
of cocaine, an immediate attenuation in the absorbance of dye was observed. 
The thrombin aptamerforms a loose random coil in the absence of thrombin. Upon 
binding to thrombin, the aptamer forms a compact unimolecular quadruplex. Labeling 
the aptamer with a fluorophore dye in the 5' end and a quencher dye in the 3' end 
creates a molecular aptamer beacon (156). Without thrombin, the two dyes were not 
close in space and the fluorescence was not quenched. In the presence of thrombin, 
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the two dyes were brought close together and the quencher dye quenched the 
fluorescence. Replacing the two dyes with a pair of dyes that participate in 
fluorescence resonance energy transfer gives a molecular aptamer beacon that 
increases in fluorescence in the presence of thrombin. 
An RNA aptamer that targets the variant surface glycoprotein of African 
trypanosomes was selected using SELEX ( 157). Biotin-labeled RNA aptamerwas used 
to image the live trypanosomes, which were visualized by Alexa Flour 488-conjugated 
streptavidin. 
Modular aptameric sensors were developed utilizing the fluorescence increase that 
occurs after malachite green is bound by its RNA aptamer (132). Using rational 
design, the ATP RNA aptamer, theophylline RNA aptamer orflavine mononucleotide 
RNA aptamer, respectively were fused with the truncated malachite green RNA 
aptamer. The presence of adenosine, theophylline orflavine mononucleotide could be 
detected by an increase in the fluorescence of malachite green. 
A signaling aptamerwas designed to fluoresce in the presence of adenosine (158). 
Two short single stranded DNA (ssDNA) oligonucleotides were designed to interact with 
a ssDNA that includes the sequence of a DNA adenosine aptamer. One ssDNA oligo 
(FDNA) had a fluorophore at the 5' end and included the sequence of the DNA 
adenosine aptamer, the other ssDNA oligo (QDNA) had a quencher dye at the 3' end. 
QDNA is complementary to part of the FDNA and anneals with part of the DNA 
adenosine aptamer in FDNA. When they are annealed, the fluorophore on FDNA is 
adjacent to the quencher in QDNA so the fluorescence is quenched in the absence of 
adenosine. In the presence of adenosine, the DNA adenosine aptamer sequence 
undergoes a conformational change that separates the QDNA from the FDNA. Thus, 
the fluorescence increases upon adding adenosine. This signaling aptamer can also 
be used to detect ADP and AMP because the DNA adenosine aptamer also binds ADP 
and AMP. 
41 
Gold nanoparticals have distance-dependent optical properties that can be used 
to detect polynucleotides (159). A colorimetric sensor was created by combining the 
adenosine-dependent DNAzyme and gold nanoparticles (160). The adenosine-
dependent DN Azyme cleaves its substrate in the presence of adenosine. Gold 
particles were cross-linked at a close distance by the substrate of the adenosine-
dependent DN Azyme to form aggregates. The separated gold particles have a blue 
color that changes to red when they aggregate. In the presence of adenosine, the 
substrate of the DNAzyme is cleaved, the gold particles dispersed and the color of gold 
particles changes to reveal the presence of adenosine. 
When the single stranded DNA thrombin aptamer binds to thrombin its 
conformation changes from a loose random coil to the compact G-quartet (161). Mario 
Leclerc and colleagues developed a water-soluble, positively charged polymer named 
"polymeric stain" that can transduce the binding of the DNA thrombin aptamer to 
thrombin into an optical signal (162). In the absence of thrombin, the polymer forms 
a duplex with the negative charged ssDNA thrombin aptamer. Upon addition of 
thrombin, the aptamer forms a compact structure. The polymer still interacts with the 
aptamer, but due to the conformational change of the aptamer upon binding thrombin, 
the optical signal of the polymer changes and it reflects the presence of thrombin. 
Recently, a novel strategy was used to develop a small-molecule-based sensor 
(163). N-(p-methoxyphenyl) piperazine (MRP) was chemically synthesized to link with 
dichloro-fluorescein and form a new chemical with one dichloro-fluorescein and two 
MPP in one molecule. MPP quenches the fluorescence of dichloro-fluorescein. An 
RNA aptamer targeting MPP was selected through SELEX. Upon adding the MPP 
RNA aptamer, the fluorescence increased. The reason for the increased fluorescence 
is thought to be that quenching by MPP of the fluorophore is greatly reduced after the 
MPP is bound by the RNA aptamer. Thus binding by the aptamer results in a strong 
fluorescent signal from the MPP-linked dichloro-fluorescein. 
DNA and RNA aptamers have also been successfully used to develop microarray 
assays to detect proteins (38, 164-170). Compared to the microarrays using antibodies 
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to detect proteins, aptamer arrays have been verified to have a similar level of 
specificity and sensitivity (164). An aptamer array can usually tolerate repeated 
washing and harsh denaturing conditions, which cannot be applied to an antibody 
array. This feature allows a nucleic acid array to be used many more times than an 
antibody array. Also, in the photoSELEX-based array, the washing conditions can be 
very stringent, which lowers the non-specific binding (38). 
Analytical Applications 
Aptamers hold great potential as analytical tools in molecular recognition and 
separation technologies (13, 34, 171). 
Immobilized aptamers can be used to separate enantiomers (172). For example, 
a D-peptide was separated from an L-peptide by HPLC or through small columns 
containing an immobilized DNA aptamer selected specifically for binding to the D-
peptide. In another study, an adenosine DNA aptamer was biotinylated and linked to 
streptavidin-glass beads. The resulting beads were used as the stationary phase in a 
packed capillary tube for liquid chromatography to monitor the adenosine levels in 
samples collected from the somatosensory cortex of chloral hydrate anesthetized rats 
( 173). The results showed that the adenosine was strongly retained in the column and 
that it could be detected by UV absorbance. Moreover, the aptamer-based column 
showed good scalability after more than 200 injections. 
Aptamers that recognize proteins have also been developed as probes to detect 
their target proteins. Murphy et al. (174) used the thyroid transcription factor 1 (TTF1) 
aptamer to purify TTF1. The TTF1 aptamer was biotinylated and attached to 
streptavidin magnetic beads. The affinity chromatography purification assay on protein 
mixtures from bacteria lysates showed good specificity for TTF1. A fluorescence-
labeled aptamer targeting HIV type 1 reverse transcriptase was used in affinity capillary 
electrophoresis (775). HIV type I reverse transcriptase (HIV-1 RT) could be specifically 
detected in the affinity complex formed by aptamer and HIV-1 RT. Non-equilibrium 
capillary electrophoresis of equilibrium mixtures (NEC-EEM) was developed to detect 
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a protein using an aptamer that does not form a stable complex with its target protein 
{176). Aptamers also have been shown to work in affinity mass spectrometry (171). 
With the thrombin aptamer immobilized to the matrix surface thrombin was specifically 
detected through MALDI-TOF-MS. 
Utilizing aptamers, an impressive method was developed to detect zeptomole (40 
x 10-21 mol) amounts of platelet-derived growth factor (PDGF) without washes or 
separations (177). The method employed proximity-dependent DNA ligation to 
transduce the present of PDGF into a ligated a long single stranded DNA. DNA 
aptamers were designed to form the affinity probes. Because PDGF forms a 
homodimer one aptamer affinity probe will bind to each monomeric unit in the dimer, 
which brings the ends of the two probes close enough so that the T4 DNA ligase can 
ligate the two ends together in the present of a common connector. The resulting long 
ssDNA can be detected by real time PGR. 
In vivo Applications of Aptamers 
Aptamers are developed in vitro through SELEX. To apply ssDNA and RNA 
aptamers for//? vivo application, the first challenge is the short half-life of natural nucleic 
acid in biological fluids. Tested in vitro in plasma, the half-life of a typical RNA 
molecule is about few seconds and a typical DNA molecule is about 30 to 60 minutes 
(178). During SELEX, 2'-fluoro, 2'-amino or 2'-0-alkyl nucleotides can be used to 
increase the stability of the resultant aptamer (45). Recently, 4'-thioUTP and 4'-
thioCTP were synthesized and successfully used in SELEX (49). The half-lives of RNA 
oligonucelotides that are synthesized from these modified nucleotides are dramatically 
longer compared to the half-lives of the natural RNAs. In plasma, the in vitro half-life 
of modified RNA oligonucleotides was in the 5 to 15 hour range (179). 
Many aptamers have been selected without using non-natural nucleotide 
triphosphates as substrates. Post-SELEX modification of aptamers has been widely 
used to improve not only the stability, but also the pharmacokinetics of these aptamers 
(12, 180). Some modifications are also needed for immobilization and signaling 
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purposes (12, 180). In table 5, the most often used post-SELEX modifications of 
aptamer for in vivo application are summarized. 
In most cases, aptamers have been used as antagonists to their target molecules. 
For this kind of application, aptamers can be separated into two categories based on 
the target type. One is for extracellular targets and the other is for intracellular targets. 
Until today, most in vivo applications of aptamers have been done by targeting 
extracellular molecules, membrane marker molecules and whole organisms. All these 
targets could be considered as extracellular. For intracellular targets, the aptamer 
needs to be delivered across the cell membrane, which is still a difficult task today. 
This makes the extracelluar application of aptamers easier compared to intracellular 
application. In table 6, in vivo applications of the selected aptamers, which were used 
against extracellular targets, are listed. As shown table 6, in most cases, the purpose 
of in vivo applications of aptamers targeting the extracellular molecules was to inhibit 
the target protein by the aptamer. In several cases, the aptamer was used as an 
imaging tool. 
An aptamer can function inside a cell whereas an antibody cannot. As it was in the 
extracellular application, an aptamer can act as an antagonist of its target protein. By 
inhibiting the target protein's function, the aptamer could be used to determinethe 
biological function of natural cellular proteins. Inside the cell, many RNA-protein 
complexes, such as ribosomes and spliceosomes, fulfill important biological functions 
(181). Intracellular aptamers can be used as a decoy to interact with the RNA-binding 
proteins to reveal the important structural elements on natural RNA transcripts as well 
as on RNA-binding proteins. A riboswitch is a natural aptamer sequence located in the 
5' or 3' UTR of mRNA transcripts to regulate transcription or translation processes. By 
mimicking the functions of riboswitches, aptamers can be inserted into the 5' or 3' UTR 
of the expressed genes' transcripts to regulate transcription or translation. For 
biomedical applications, aptamers can be used to inhibit the disease-related targets as 
well as to image cells. Aptamers binding intracellular targets were used to inhibit 
human immunodeficiency virus (HIV) type I (HIV-1) infection (182, 183) . An 
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oligonucleotide encoding a 33nt pseudoknot RNA aptamer selected in vitro for targeting 
an HIV-1 reverse transcriptase (RT) was cloned into a retroviral vector between mutant 
tRNA gene and a polymerase III termination signal (TER) (182). The tRNA-aptamer 
transcripts generated by the polymerase III were found in the cytoplasm after being 
transiently expressed in various human cell lines. In the human 293T cell that wereco-
transfected with a tRNA aptamer expression vector and a proviral HIV-1 DNA, HIV 
particle release was inhibited by more than 75%. The viral particles derived from the 
transfected 293T cells were used to infect human T-lymphoid C8166 cells that also 
expressed chimeric tRNA-aptamer RNA. The subsequent viral production was inhibited 
by more than 75% compared to the controls (182). 
In another study done by Joshi etal. (183), aptamers and small hairpin RNAs (sh 
RNAs) directed against HIV-1 RT was compared for blocking HIV-1 replication in the 
cell. Oligonucleotides encoding the aptamer and the shRNA were cloned downstream 
of an RNA pol III driven U6 promoter in the MMP-eGFP retroviral vector, respectively. 
To produce the desired aptamer sequence after transcription, the aptamer was cloned 
along with a flanking, self cleaving ribozyme at both 5' and 3' end. GFP on the retroviral 
vector was used to selected cells that had been transduced by the retroviral vector. 
The transduced CEMX 174 cells was challenged by the HIV virus. The results showed 
that the aptamer decreased the levels of the early RT products by about 86-96% as 
early as 2 h after infection, whereas the shRNAs had about 42-62% inhibition of the 
same early RT products. The aptamer efficiently inhibited HIV replication at the higher 
multiplicities of infection. By contrast, although the shRNAs could inhibit HIV-1 
replication as efficiently as the aptamers at low viral input, they did not block HIV at the 
high viral input as the aptamers did. Due to the encapsidation of aptamers into the 
virion particles, aptamers were able to inhibit two consecutive rounds of reverse 
transcription of HIV-1 virus. Using an RNase protection assay (PRA), about 52% to 
85% of aptamer RNAs and shRNAs were found present in the cytoplasm (183). 
Recently, a study of RNA aptamers targeting an intracellular protein and inducing 
cell killing was demonstrated in C.elegans (184). Through in vitro SELEX five RNA 
46 
aptamers targeting the C. elegans Bcl-2 homolog CED-9 with high affinity and 
specificity were selected. Two of the five selected aptamers were shown to bind CED-9 
inside the cell. Over-expression of either of the two aptamers in six touch receptor 
neurons in C.elegans induced efficient killing of these neurons. Several examples 
listed above are examples of the most recent developments of in vivo applications of 
aptamers targeting intracellular proteins and inhibiting the targets as an antagonists. 
In the study done by Hu et al. (185), in vitro SELEX-derived aptamers were used to 
distinguish critical and non-critical residues for the initiation of reverse transcription in 
the duck hepatitis B virus (DHBV). A plasmid encoding the complete genome of DHBV 
was used to test the interaction between DHBV reverse transcriptase and the selected 
aptamers recognized by DHBV reverse transcriptase. Different aptamer sequences 
were cloned into the DHBV genome reverse transcriptional initiation site. Plasmids with 
different aptamer sequences in the genome were transfected into LMH cells, 
respectively. The cells were harvested 4 days later and the successful replication of 
virus was verified from cell lysates. The critical consensus sequence for binding 
reverse transcriptase and supporting viral replication was identified from comparison 
of the ability of each aptamer to promote replication. This showed the diversity of 
intracellular applications of aptamers and that they are not necessarily only useful as 
antagonists. 
Another way for an aptamer to function inside the cell is for it to behave as a 
regulatory element to control the expression of genes. For example, the RNA aptamer 
that targets the HIV RT was cloned into a position adjacent to the Shine-Dalgarno (SD) 
sequence of the lacZ gene in E. coli. In the presence of the HIV RT protein, the 
aptamer bound to the expressed HIV RT and blocked access of the 30S ribosomal 
subunit to the SD sequence of LacZ gene. In the absence of the HIV RT the 
expression of lacZ was normal (186). The translational initiation of bacteria requires 
base pairing interaction between the SD sequence and 16S RNA in the 30S ribosome 
subunit. After the aptamer bound to its ligand, RT, the access to the SD sequence was 
blocked by steric hindrance and expression of lacZ was inhibited (187). Following a 
similar strategy, ligand-regulated translation was also realized in eukaryotes (188). In 
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the Cap-dependent translation of eukaryotic mRNAs, after 40S ribosomal subunit binds 
to the cap structure, it begins to scan along the 5' UTR sequence and the translation 
is initiated at the AUG start codon. By inserting three copies of a tobramycin aptamer 
or kanamycin A aptamer into the 5' UTR of reporter gene, the expression of a reporter 
gene was regulated by the aptamer's target. In the presence of 60 pM target molecule, 
more than 90% expression of reporter genes were inhibited compared to the controls 
(188). In the following studies, three copies of an antibiotic aptamer in the 5' UTR of 
reporter gene was replaced by three copies of an aptamer selected to bind two related 
Hoechst dyes, H33258 and H333342. The two Hoechst dyes were used because they 
were permeable to the cells and were not toxic. Ligand dependent translational 
regulation was observed in wheat germ extracts and in Chinese hamster ovary (CHO) 
cells that were transfected with DNA encoding the lacZ gene bearing 3 copies of the 
aptamer to Hoechst dyes in the 5' UTR (188). 
The malachite green (MG) RNA aptamer was selected by SELEX for use in RNA-
chromophore-assisted laser inactivation (189). By inserting the MG RNA aptamer 
before the AUG of a cyclin transcript in S. cerevisiae, translation of a modified cyclin 
transcript was regulated by tetramethylrosamine (TMR, 190). TMR is a structural 
analog of MG with an oxygen to bridge two of the benzyl rings. Studies showed that 
the affinity of the MG RNA aptamer for TMR is more than ten times higher than its 
affinity for MG (~ 40nM to 800nM, 191). In the absence of TMR, translation of the 
modified cyclin transcript was not inhibited. In the presence of TMR, the MG RNA 
aptamer-ligand complex in the 5'UTR of cyclin transcripts was stable enough to inhibit 
translation of cyclin by more than 90%. Another example of how a MG RNA aptamer 
and TMR can work in vivo was by engineering a TMR-dependent transcription activator 
through in vivo selection in S. cerevisiae (147). The transcriptional activation activity 
of the engineered RNA molecule increased 10-fold in the presence of TMR. 
A more detailed description and summary of the extracellular as well as intracellular 
applications of aptamers can be found in several reviews (12, 14, 178, 192). There are 
still many obstacles on the way to successful application of aptamers in the challenging 
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biological environment, both extracellular and intracellular. For example, to this day, 
delivery is still a bottle neck for the successful application of aptamers in the 
intracellular environment. There are two ways to deliver aptamers into cells. One way 
is by an expression vector. The second delivery route is microinjection, electroporation 
or transfection reagents such as liposomes. Both of them are applied in cell culture 
and do not have guaranteed high efficiency in vivo. There is still a long way to go for 
systematic delivery of aptamers to the living organism and specific targeting to desired 
organs or tissues. At the same time, there are safety and ethical challenges for further 
applications in drug development and therapeutic application. We can expect further 
developments in this field and more aptamers for in vivo applications. 
Therapeutics 
At the end of 2004, the Food and Drug Administration approved the first aptamer 
drug 'Macugen" (pegaptanib sodium injection, by Pfizer and Eyetech). 
(http://www.fda.aov/bbs/topics/news/2004/new01146.html). This is a breakthrough in 
the application of aptamers in therapeutics. The drug Macugen, developed to 
recognize the VEGF165 aptamer, is also called NX1838 or pegaptanib sodium. The 
VEGF165 aptamer is a potent angiogenesis inhibitor and is used to treat age-related 
macular degeneration (AMD, 96, 193). During its development, the aptamer underwent 
several modifications to improve its stability. The aptamer is 27nt and includes 2'fluoro 
pyrimidine and 2' O-methyl purine modifications to protect it against endonucleases. 
Also, the 5' end was modified with polyethyleneglycol and a 3' dT was attached through 
a 3-3' linkage. All these modifications makes the final drug more stable in vivo and to 
also have better pharmacological kinetic properties in treating AMD in humans (194). 
Aptamers are being developed as therapeutics in the areas of anti-microbials, 
anticoagulation, anti-inflammation, antiangiogenesis, antiproliferation, and immune 
therapy (reviewed in 14, 15, 16). For example, the aptamer that inhibits HIV replication 
has entered clinical trials (195). Another anti-thrombin aptamer is being developed as 
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an anticoagulant for use in the coronary artery bypass surgery 
(http://www.archemix.com/press/pr iun04.html ). 
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DETECTION AND IMAGING OF RNA IN LIVING CELLS 
In 1982, Cech et al. (196, 197) reported the first catalytic RNA or ribozyme: the 
self-splicing intron of the Tetrahymena pre-rRNA. Over the past twenty years more 
and more research discoveries that describe the functions of RNAs in biological 
processes have begun to reveal more fully the kingdom of RNAs hiding from the central 
land. Now we know RNAs not only play the role of messengers (mRNAs, tRNA) to 
convey and interpret genetic information stored in DNA, but also have an essential 
catalytic activity as well as providing a structural basis for the molecular complexes that 
regulate gene expression (ribosome, spliceosome). Recently, small non-coding RNAs 
were found to participate in the regulation of gene silencing (siRNAs, microRNAs). The 
expression levels and stabilities as well as the temporal and spatial distributions of 
specific RNAs in a cell are directly related to their functions. In order to fully interpret 
the biological mechanisms of RNA molecules in fulfilling their functions, the dynamics 
and localization of RNA molecules in the living cell must be understood. 
Using purified DNA or RNA samples obtained from cell lysates, gene expression 
levels can be measured by many in vitro methods. An early method used to detect the 
level of gene expression was Northern blotting (198) where RNA is first separated by 
electrophoresis and then transferred onto a membrane. Labeled nucleic acid probes 
are applied to the membrane and hybridized with the membrane containing the RNA. 
Besides Northern blotting, labeled oligonucleotide probes are also used to in in situ 
hybridization to detect intracellular mRNA (199). In the process of in situ hybridization, 
the cell are fixed and detergent is used to permeabilize the cells. Fluorescent- or radio­
labeled probes are applied to the permeabilized cells and unbound probes are removed 
by washing. The sites of hybridization between labeled probes and target RNA 
molecules can be visualized by microscopy. 
Without any amplification of target RNA molecules, labeled probes have limited 
sensitivity. Polymerase chain reaction (PCR) is most widely used to amplify the targets 
(200, 201). In the case of target RNA molecules, reverse transcription is first used to 
generate a ssDNA from the RNA target. The ssDNA can be amplified in a PCR 
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reaction (RT-PCR). Guatelli et al. (202) introduced the method named nucleic acid 
sequence based application (NASBA) to amplify rare RNA target molecules. During 
NASBA, the T7 promoter sequence is attached to the cDNA by reverse transcription 
(RT). The T7 RNA polymerase is then used to generate RNA target molecules. 
Because the newly synthesized RNAs serve as the templates for a subsequent RT and 
newly synthesized ssDNA serves as a template for PCR after RT, this method can 
amplify low copy rare target molecules. It was reported that one copy of RNA molecule 
can be amplified to 109 copies in a NASBA reaction in 90 mins (203). After RNA target 
molecules are amplified, they can be detected as dsDNA by gel electrophoresis or by 
hybridization with labeled nucleic acid probes. 
There are several other in vitro methods for identifying RNA target molecules. 
Expressed sequence tags (ESTs) is a method for the rapid characterization of 
expressed genes by partial DNA sequencing. An EST is produced by one-shot 
sequencing of a cloned mRNA, and the resulting sequence is a relatively low quality 
sequence of a fragment whose length is approximately 500 to 800 nucleotides. ESTs 
are useful tools in gene discovery and sequence determination. Some recently 
developed in vitro methods for identifying RNA target molecules include serial analysis 
of gene expression (SAGE) (204), differential display (205), and DNA microarrays 
(206). Along with the rapidly increasing knowledge of genomic sequences for many 
organisms, the in vitro methods mentioned above enable fast, accurate and systematic 
detection and quantification of RNA targets in the cell. But these in vitro methods can 
not provide temporal and spatial information about the RNA target in the cell, 
especially in the living cell. 
Methods for imaging the nascent transcripts in the living cells by incorporating Br-
UTP (207) or FITC-CTP (208) into RNA transcripts by RNA polymerases I , II and III 
label all mRNAs in general and can not be applied to specific RNA species. To image 
a specific RNA inside living cells, fluorescence-labeled RNA molecules synthesized by 
in vitro transcription reactions can be microinjected into the cells (209-211). But this 
method can not be applied to the endogenous RNA molecules. 
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Using GFP as a reporter, an indirect method for imaging a specific RNA in living 
cells was created. Bertrand et al. (212) made a construct from Ash1 m RNA was 
expressed that included an insertion of six tandem copies of the stem-loop binding site 
for the bacteriophage MS2 coat protein. A second construct encoded the MS2-GFP 
fusion protein containing a nuclear-localization signal. When the two constructs were 
co-expressed in cells, the MS2-GFP fusion protein bound to the MS2 binding sites on 
the chimeric Ash1 mRNA. After chimeric Ash 1 m RNA was synthesized in the nucleus, 
it was found to co-localize with the particles that had fluorescence emitted by GFP. By 
tracking the fluorescence of GFP, the movement and localization of particles in which 
chimeric Ash1 mRNA molecules were associated with other proteins related to the 
transportation and localization of Ash1 mRNA could be traced and observed in the 
living cells. This strategy has been used in several other studies in which the selected 
RNA targets were imaged through GFP in living cells (213,214). In another study done 
in Drosophila in which GFP was also used as a reporter to trace specific mRNA, GFP 
and Exu were expressed together as a fusion protein. Exu binds specifically to 
Drosophila bicoid mRNA. When the GFP-Exu fusion protein was expressed inside 
living cells, the endogenous bicoid mRNA was visualized by the localization of GFP 
fluorescence. A drawback of this method was that Exu can only used for bicoid mRNA 
to which it binds specifically. The method using MS2 can be used for any RNA of 
interest. A general drawback of this latter method is that can it only be used to image 
the redistribution of GFP in the cell and cannot be used to image the level of RNA 
expression. The same amount of GFP remains in the cells whether or not the RNA 
exists. 
Besides GFP, fluorescent nucleic acid probes have also been used to image 
specific RNA in the living cells. Fluorescence in vivo hybridization (FIVH) is a method 
using fluorescent labeled unstructured linear nucleic acid probes to detect and image 
specific RNAs in the living cells (2-4). Unlike the in vitro in situ hybridization 
experiments, the washing step to remove excessive probes can not be done in FIVH 
experiments. It is also difficult to differentiate the true signal from background caused 
by unbound probes in the cell. To solve this problem, dual probes for a specific RNAs 
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were designed (4). In the dual probe design for FIVH, one probe has a fluorescence 
molecule attached to the 3' end to act as a donor in the fluorescence resonance energy 
transfer (FRET) pair, The second probe has a different fluorescence molecule attached 
to the 5' end to act as an acceptor. The two probes were designed to target adjacent 
regions on the selected RNA molecule. The FRET signal was only produced when 
both probes interacted with the RNA target. Although the dual probe FIVH suffers from 
the problem of background due to the direct excitation of the acceptor and emission of 
donor, it was considered an improvement in reducing the high background in FIVH. 
Besides the high background, another drawback of the linear probe is that it is 
unstructured and therefore, unlike the stem-loop structured probe, it does not go 
through a conformational change upon binding to the target. It is difficult to use the 
FIVH method to detect single base differences. Also, micro-injection of the probe is 
necessary in order to have a high enough concentration of the chemically modified 
probes in the cells because the probe can not be produced by the cells. This limits the 
use of FIVH method to cell culture and to relatively small numbers of cells due to the 
intense labor requirement. 
Because of the advantages of stem-loop structured probes over linear unstructured 
probes, it is reasonable to use stem-loop structured probes in the detection and 
imaging of specific RNA in living cells. One widely used stem-loop structure probe that 
has also been used in real-time RNA imaging is the molecule beacon (6). Molecular 
beacons are single stranded oligonucleotides containing a 15-30 nt loop region closed 
by a stem that is usually 5 to 6 base pairs long. A quencher is attached to one end and 
a fluorophore is attached to the other end. In the absence of target RNA, molecular 
beacons form stem-loop structures so that the fluorophore is quenched. Hybridization 
with the target nucleic acid opens the stem and the fluorescent signal from the 
fluorophore is emitted upon excitation. For detecting the mRNA, which is located in the 
cytoplasm, the location of nucleic acid probe is important. It was found that 
microinjected oligonucleotides were rapidly transported into the nucleus from the 
cytoplasm (215, 216). Conjugating molecular beacons to a peptide that crosses 
membranes provided efficient delivery and prevented the molecular beacons from 
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accumulating in the nucleus. Nitin et ai (217) conjugated the Tat peptide to molecular 
beacons to detect human GAPDH and survivin mRNA in living cells using fluorescence. 
Nuclease-resistant molecular beacons were conjugated with streptavidin and used to 
target native P-actin mRNA in living and motile chicken embryonic fibroblasts. The 
native p-actin mRNA was visualized by fluorescence microscopy (218). In a recent 
study, a molecular beacon with 2'- O - methyl - ribonucleotide backbone was linked to 
tRNA and injected into the nuclei of Hela cells. The chimeric tRNA-molecular beacon 
RNA was exported from the nucleus into the cytoplasm (219). When it was first 
injected into cytoplasm this chimeric tRNA-molecular beacon RNA remained in the 
cytoplasm. This new strategy can help to keep molecular beacons in the cytoplasm if 
needed. 
Despite the advances made in using nucleic acid probes it remains a big challenge 
to develop effective probes for real-time detection and imaging of native RNA targets 
in living cells. For the system using the MS2-GFP fusion protein, even though the 
mRNA detected being produced inside the cell, it is still different from native mRNA. 
Even more importantly, this procedure is a means of imaging the location of a specific 
mRNA in a cell by way of the redistribution of the GFP, but it is not a method for 
imaging cells that express the mRNA. The molecular beacon is considered as the front 
runner in the field of living cell imaging. However, because they are chemically 
modified, the molecular beacons must be microinjected. 
There are a number of challenges for detecting and quantifying RNA targets in 
living cells. For example, whether the probes introduced into the cells can interfere with 
normal cell functions is not known. The hybridization between probe and RNA target 
could have some impact on the translation and stability of RNA target. In living cells, 
without any amplification, the real-time measurement and imaging of some low copy 
RNA targets will be difficult. Most nucleic acid probes are fluorescently labeled. 
Therefore, it is necessary to distinguish the true signal from background, such as the 
auto-fluorescence of the cell. Although very challenging, the successful detection and 
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imaging of RNA molecular in living cells will prove to be a significant technical advance 
for biological and biomedical research. 
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BRIEF REVIEW OF RNA SECONDARY STRUCTURE PREDICTION 
RNA secondary structural models have existed since 1960 (220).  The major 
breakthrough in computational predictions of RNA secondary structure came from work 
done by Nussinoc et al. (221) in which the maximum base pairing was calculated 
through dynamic programing. The brief introduction of the dynamic programming used 
in base pair folding is presented here (222). For a given RNA sequence r with length 
N, let ra represents the ath residue in r and let rb represents the bth residue in r. The 
maximum number of base pairing of sequence that begins with ra and end with rb is 
represented by r(a, b). A general recursive definition of maximum number of base 
pairing, r (a, b), can be written as formula below: 
r(a,  b)  = max 
r(a + 1,6-1) + S(a,  b)  case 1 
r(a + \ ,b)  case 2 
r(a,  b-1) case 3 
maxfl<t<6[ r(a,  k)+r(k + l ,b)  ] case 4 
Simply summarized, there are four possible ways that r (a, b) can be calculated as 
shown in the formula above. In case 1, ra base pairs with rb. So in case 1, r(a, b) 
equals r (a+1, b-1) plus one more base pair represented by 5 (a, b) and here 5 (a, b) 
equals 1 . In case 2, ra does not participate any base pairing, but rb forms base pairing 
. So r(a, b) equals r (a+1, b). In case 3, rb does not participate any base pairing, but 
ra forms base pairing. So r(a, b) equals r (a, b-1). In case 4, ra and rb are both base 
pairing, but not with each other. rk is any base between ra and rb. The r(a, b) can be 
calculated by taking the maximum value of [r(a,k)+r(k+1 ,b)]. 
So, in order to calculate the number of base pairs in four cases, we need to know 
four numbers : r(a+1,b-1), r(a+1, b), r(a,b-1)and max [r(a,k)+r(k+1 ,b)]. And to calculate 
these four numbers, we need the solutions for more smaller problems. We can keep 
separating each problem into its smaller subproblems and until we reach tiny base 
pairing subproblems with obvious solutions (the value r(0,0) for base pairing nothing to 
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nothing is zero). During this dissecting process, the recursive definition of maximum 
base pairing listed above will provide guidance for every step along the way. 
Once we work out the recursive definition of maximum base pairing, we need a 
dynamic programming matrix for remembering the solutions of subproblems, which are 
the numbers of maximum base pairing for each subproblem. This is the key difference 
between dynamic programming and simple recursion: a dynamic programming 
algorithm remembers the solutions of subproblems in an organized matrix, so each 
subproblem is solved only once (223). In dynamic programming a bottom-up approach 
is used to fill the matrix by using the recursive definition of r(a,b). In this process, the 
smallest subproblem will be solved first and eventually the r(1, N) will be calculated. 
After the matrix is filled, we will know the maximum number of base pairings of RNA 
sequence r, which is r(1,N), but the folding which has r(1,N) base pairings is not known 
yet. The folding is recovered by using a recursive traceback of matrix that starts with 
r(1,N), determines which of four cases was used to reach the r(1 ,N) and records the 
choice as part of final folding of RNA sequence r. This step is repeated , until r(0, 0) 
is reached and finally the folding that has maximum number of base pairing has been 
constructed. More detailed descriptions of the dynamic programming algorithm used 
in base pairing folding can be found in publications listed here (222-225). 
Unfortunately, while the dynamic programming approach maximizes the base pairs, 
it does not create viable secondary structures because the maximum base pairing was 
found not to correspond to viable secondary structures (226). But the dynamic 
algorithms presented by Nussinoc et al. opened the door for the further development. 
People realized that optimization for maximum base pairs is not necessarily valid for 
correct RNA folding. Another criteria for folding is to use the equilibrium Gibbs free 
energy where the folded structure with the minimum equilibrium Gibbs free energy is 
considered to be the optimal secondary structure. Mfold, the RNA folding tool most 
widely used today, is the incorporation of dynamic programming and experimentally 
obtained thermodynamic parameters (25). In Mfold, thermodynamic parameters are 
used to calculate each subsequent equilibrium Gibbs free energy. The optimal 
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secondary structure is chosen based on the minimum equilibrium Gibbs free energy 
instead of the maximum calculated base pairings (226-228). The free energy 
minimization method can be as much as 73% accurate in predicting the secondary 
structure of a single sequence without the use of any homologous sequences (27). 
Different from the free energy minimization method, new methods for RNA 
secondary structure prediction have been developed based on computing the partition 
function of an RNA s secondary structure. The partition function is a measure of the 
number of states accessible to the system at a given temperature. For an RNA 
secondary structure, the partition function is defined by 
where Q is the measure of the number of structures accessible to an RNA sequence 
at temperature T. F(S) is the equilibrium Gibbs free energy of a give folding S. K is 
Boltzmann's constant. For a particular structure S, the probability of S, P(S) is given 
The partition function was calculated using dynamic programming algorithms as 
first shown by McCaskill et al. (133). The Vienna RNA package 
(http://www.tbi.univie.ac.at/~ivo/RNA/) implements the partition function algorithms 
(229, 230). The Vienna RNA package includes RNALfold, RNAfold, RNAinverse, 
RNAalifold and several other programs. A detailed description can found at the 
package's website mentioned above. The Vienna RNA package uses the classic 
algorithms of Zuker and Stiegler (226) to calculate the minimum free energy (MFE) for 
each single sequence and gives the corresponding predicted secondary structure 
based on the MFE. In addition, the server also calculates the equilibrium base pairing 
probability using the partition function algorithms developed by John McCaskill in 1990 
(133). In this package, the structure is still predicted by using MFE algorithms. The 
equilibrium partition function only provides the base pairing probability and it can not 
by P(S) =J-e-<F<s>/kr' 
Q 
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yet accurately produce valid secondary structures. Also, it cannot be used to predict 
the single-stranded probability profile of an RNA sequence. 
Ding et al. (231) further exploited the partition function algorithms for the RNA 
secondary structure prediction using statistical sampling algorithms. Utilizing some 
experimentally obtained thermodynamic parameters also used in Mfold algorithms, the 
forward step of the algorithm used dynamic programming to calculate the equilibrium 
partition function of the RNA secondary structure. Then the partition function was used 
to calculate the conditional probability of each probable structure. Using these 
calculated probabilities, the backward step is a recursive sampling process according 
to the Boltzmann equilibrium distribution (231). The important improvement in using 
the equilibrium partition function for RNA secondary structure prediction is the 
development of the statistical sampling algorithm. The statistical sampling algorithm 
samples exactly and strictly from the Boltzmann ensemble of secondary structures. 
This sampling method enables the estimation of any structural motif. For example, the 
algorithms provide the probability profiling of single-stranded regions in RNA secondary 
structures. This is one of the areas that the MFE algorithms alone could not handle 
very well. Based on the statistical sampling algorithm, the web server 
(http://sfold.wadsworth.org/index.pn was set up to perform several tasks. A detailed 
description of each program and the Sfold manual are both available from the Sfold 
website. 
The dynamic programming algorithms set the stage for the development of other 
methods for predicting RNA secondary structure. However, the most used algorithm, 
the classic MFE algorithm that was developed mainly by Zuker, is still the most widely 
used RNA folding algorithm. Other methods based on the calculation of equilibrium 
partition functions of RNA secondary structures provide statistical representations of 
RNA secondary structure. But, so far there is not enough evidence to show that one 
method is superior than the other. Further development and experimental validation 
may result in more accurate folding algorithms. 
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TABLES AND FIGURES 
Table 1. Summary of artificial allosteric ribozymes 
Allosteric Effector Specificity Ribozyme motif Fold Reference 
Activation Oligonucleotide Hammerhead 10 (?27) 
ATP Hammerhead 8 (722) 
FMN Hammerhead 6 (726) 
FMN Hammerhead 100 (232) 
Theophylline Hammerhead 40 (232) 
Oligonucleotide Hammerhead - (233) 
Oligonucleotide L1 ligase 10,000 (234) 
Oligonucleotide and L1 ligase 800 (234) 
FMN Hammerhead 270 (232) 
Theophylline Hammerhead 110 (232) 
ATP Hammerhead 40 (232) 
cGMP Hammerhead 5000 (727) 
cCMP Hammerhead 500 (127) 
cAMP Hammerhead 300 (727) 
Theophylline Hammerhead 2300 (235) 
FMN Hammerhead - (235) 
3-Methylxanthine Hammerhead - (235) 
ATP L1 Ligase 800 (728) 
FMN L1 ligase 1600 (728) 
Throphylline L1 ligase 260 (728) 
Various metal ions Hammerhead 50,000 (236) 
Theophylline HDV ribozyme - (237) 
Theophylline Tetrahymena group I - (237) 
Theophylline X-motif ribozyme - (237) 
FMN Hammerhead 29 (238), 
ERk2 protein Hammerhead 50 (239) 
ppERK2 protein Hammerhead 230 (239) 
Oligonucleotide Hammerhead 1760 (9) 
Oligonucleotide Hammerhead 1000 (28) 
Inhibition ATP Hammerhead 180 (722) 
FMN Hammerhead 250 (232) 
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Doxycycline Hammerhead 50 (240) 
HIV-RT Hammerhead ™ (241) 
* fold modulation gives the ratio of the catalytic rate constant determined in the 
presence (k +) and absence (k _) of effector. For allosteric activation and inhibition, 
fold modulation is k+ /kr and k~ /k+, respectively. Dashed indicate values not 
determined (expanded from table originally published by 134). 
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Table 2. Summary of artificial allosteric aptamers 
Allosteric Part Effector Allosteric Effect Reference 
Cibacron 
Blue/Cholic Acid 
Aptamer 
Cholic 
Acid/Cibacron 
Blue 
Binding of either ligand is 
mutually exclusive 
(242) 
Cytochrome C 
Aptamer 
Hemin Binding of hemin 
increases the aptamers 
affinity for Cytochrome C 
by 15X 
(243) 
Formamidopyrim 
idine 
Glycosylase 
(Fpg) Aptamer 
Neomycin Binding of neomycin 
demolishes the binding of 
Fpg 
(730) 
Activation 
Domain 
(AD) 
Tetramethylrosa 
mine (TMR) 
Binding of TMR releases 
the inhibition of AD. 
Results in 10 fold 
activation of transcription 
(746) 
Malachite Green 
Aptamer 
ATP Binding of ATP increases 
the fluorescence by 5 fold 
(732) 
Malachite Green 
Aptamer 
FMN Binding of FMN increases 
the fluorescence by 30-50 
fold 
(732) 
Malachite Green 
Aptamer 
Theophylline Binding of ATP increases 
the fluorescence by 8 fold 
(732) 
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Table 3 . Riboswitches and their role in the regulation of bacterial metabolism1 
Metabolite RNA Target Target Where 
senso process genes found 
r 
Refs 
(ligand) 
TPP thi-box 
FMN rfn- box 
Transcript! 
on 
termination 
or 
translation 
initiation 
Transcript! 
on 
termination 
or 
B1 synthesis 
and transport 
B2 synthesis 
and transport 
Gram(+) and 
Gram(-) 
bacteria, 
some fungi and 
plants" 
Gram(+) and 
Gram(-) 
bacteria 
(137-139, 244-247), (138, 
139f 
(244, 248, 249) 
translation 
initiation 
Ado-Cbl B12- T ranscripti B12 Gram(+) and (250, 251) 
box on synthesis and Gram(-) 
termination transport bacteria 
and/or 
translation 
initiation 
SAM S-box Transcript! Sulfur Gram(+) and (252-254) 
on metabolism Gram(-) 
termination bacteria 
Lysine L-box Transcript! lysC Gram(+) and (141, 255, 256) 
on Gram(-) 
termination bacteria 
Guanine, HX G-box Transcript! Purine Gram(+) (257) 
on metabolism bacteria 
termination and transport 
and 
antitermina 
tion 
Adenine ydhL A- antitermina ydhL gene Gram(+) (141) 
box tion bacteria 
GlcN6P glmS glmS glmS gene Gram(+) (140) 
RNA mRNA self- bacteria 
cleavage 
Glycine gcvT translation Glycine Gram(+) (742) 
RNA termination cleavage bacteria 
gene 
a Abbreviations: Ado-Cbl, adenosylcobalamin; B1, thiamine; B12, riboflavin; B12-box, 
G-box, glmS RNA, gcvT RNA, L-box, rfn-box, thi-box and ydhL A-box , evolutionarily 
conserved RNA structures that bind Ado-Cbl, guanine, GlcNP, glycine, lysine, FMN, 
TPP and Adenine, respectively. FMN, flavin mononucleotide; gcvT, glycine cleavage 
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system protein T;GlcN6P, glucosamine-6-phosphate; glms, glucosamine-6-
phosphate synthase gene; Gram (+), Gram positive; Gram (-), Gram negative; HX, 
hypoxanthine; Met, methionine; SAM, S-adenosyl-L-methionine; TPP, thiamine 
pyrophosphate. 
b The thi-box were also found in eukaryotes (information compiled from 258, 259). 
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Table 4. Comparison of aptamer and antibody properties 
Features Aptamer Antibody 
Target Selection Fewer limitations 
compared to Antibodies 
Non-toxic and 
immunogenic targets 
Specificity and Affinity High, Kd: pico-low 
nanomolar 
High, Kd: pico-low 
nanomolar 
Molecular Weight 5-25 kDa 150 Kda 
Target site of protein Investigator decides Immune system 
determines 
Immune Responds 
and Toxicity 
None observed Immune reaction observed 
Chemical Modification Convenient Not convenient 
Physicochemical 
Stability 
Stable after temperature 
insult 
Temperature sensitive 
Reversibility Aptamer-based antidote No rational method to 
reverse 
Shelf-life Longer compared to 
Antobody 
Limited 
Quality Control Uniform activity Vary from batch to batch 
Functional Range Extra- and intracellular Extracellular 
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Table 5. Summary of post-SELEX modifications of aptamers for in vivo applications3 
Modification position/method Purpose Reference 
2' OMe Pyrimidine and 
purines 
Protection against minor 
endonucleases 
(194, 260, 261) 
dT-CAP 3' end Improved resistance against 
exonuleases 
(101, 262, 263) 
Locked Nucleic 
Acids 
defined position Improved resistance against 
nucleases 
(264, 265) 
Hexaethylene 
glycol 
loop region Improved resistance against 
nucleases 
(260) 
Polyethylenegly 
col (PEG) 
5' end Improved pharmacokinetics 
(reduced plasma clearance) 
(194, 260) 
Diacylglycerol 5' end Improved pharmacokinetics 
(reduced plasma clearance) 
(266) 
Streptavidin 3' end extends aptamer lifetime in blood 
circulation 
(267) 
Biotin 3' end extends aptamer lifetime within a 
thrombus 
(267) 
Cholesterol 5' end Improved pharmacokinetics 
(reduces plasma clearance) 
(268) 
Poly( lactic-co-
glycolic) acid 
Microspheres 
aptamers 
embedded in 
microspheres 
Local sustained release of aptamer (269) 
Drug 
conjugation 
3' end or base 
pariing 
Aptamer targeting the drug to the 
desire location 
(270, 271) 
[123l or1251] 5' end Thrombus imaging (267) 
[18F] 2'-Py in vivo imaging (272) 
[99mTc] 5' end in vivo imaging (273) 
a Abbreviations: 2' OMe, 2' -oxygen-methyl; 2'-Py: 2' -pyrimidine (information compiled 
from 72, 180). 
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Table 6. Summary of in vivo applications of aptamers for extracellular targets a 
Targets in vivo applications Chemistry 
Thrombin 
Anticoagulant ssDNA(54, 85, 274, 275) 
Thrombus imaging agents + streptavidin +[1231 or125 I] labeling 
(267) 
Coagulation factor 
IXa 
Antisense antidote-controlled 
anticoagulant 
2' F- Py RNA (268, 276) 
Human VEGF 165 
Pathological neoangiogenesis 2' NH2-Py RNA + 2' OMe-Pu (261) 
+ liposome anchoring (266) 
Age-related macular degeneration 
2' F-Py- RNA + 2-OMe-Pu + 40 kDa 
PEG (96, 194, 277-279) 
+ microspheres (269) 
PDGF Progressive rental disease ssDNA (280) 
Intimai hyperplasmia ssDNA + 2'F-Py +2'-OMe-Pu + PEG 
(260, 281-284) 
Reduction of intratumoral pressure 
to improve chemotherapeutic drugs 
uptake 
Angiopoietine 2 Corneal neovascularization, cancer 2'F-Py -RNA (179) 
GnRH sex steroid-dependent diseases Spiegelmer (285) 
Rat mAb 198 Autoimmune disease: myasthenia 
gravis 
2'F-Py -RNA + 5' PEG (286) 
Neutrophil 
elastase 
Inhibition of lung injury and 
neutrophil influx 
ssDNA + drug conjugation (287) 
Inflammation imaging + [99mTc] labeling (273) 
Human L-selectin Anti-inflammatory agent ssDNA + 3' cap + 5' PEG (101) 
2'F-Py -RNA + 3'-3' dT + 5' PEG (262) 
CTLA-4 Cancer immunotherapy 2'F- Py -RNA + tetrametric 
construction (288) 
Hemagglutinin Viral infection prevention ssDNA (289) 
U 251 cells 
(tenascin C) 
Cancer 2'F-Py -RNA (263) 
[2'F-Py/2'-OM e-Pu/LNA] + 3'-3' dT 
(265) 
a Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived 
growth factor; GnRH, gonadotropin-releasing hormone; mAb, monoclonal 
antibodies; CTLA, cytotoxic T cell antigen-4;PEG, Polyethyleneglycol; 2' OMe, 2' -
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oxygen-methyl; Py: pyrimidine ; Pu, purine; LNA, locked nucleic acid (expanded 
from table originally published by 180). 
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Figure 1. Generalized scheme indicating the key steps in the SELEX process. 
Reproduced with the permission from Clin Chem, 1999; 45; 1628-1650. 
70 
TRAP concept 
attenuator 
inactive 
aptamer or regulatory 
ribozyme nudeicacid 
s-(e.g. mRNA) 
miinnmimimiiiiiinnMiiium 
aptamer 
target 
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activev^ 
aptamer or 
ribozyme 
Figure 2. Design of the TRAP. The TRAP consists of three segments: aptamer, 
intervening antisense, and attenuator. Binding of the complementary sense regulatory 
nucleic acid to the antisense sequence in the TRAP forces the aptamer and attenuator 
apart, providing the aptamer sequence with an opportunity to fold and interact with its 
target molecule. 
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CHAPTER 3. ALLOSTERIC APTAMERS; TARGETED REVERSIBLY 
ATTENUATED PROBES (TRAPS) 
A paper published in Biochemistry, 44(22):7945 - 7954, 2005. 
Xiangyu Cong and Marit Nilsen-Hamilton 
ABSTRACT 
Aptamers are unique nucleic acids with regulatory potentials that differ markedly 
from those of proteins. A significant feature of aptamers not possessed by proteins is 
their ability to participate in at least two different types of three-dimensional structure; 
a folded structure that makes multiple contacts with the aptamer target and a double-
helical structure with a complementary nucleic acid sequence. We have made use of 
this structural flexibility to develop an aptamer-based biosensor (a Targeted Reversibly 
Attenuated Probe, TRAP) in which hybridization of a cis-complementary regulatory 
nucleic acid (attenuator) controls the ability of the aptamer bind to its target molecule. 
The central portion of the TRAP, between the aptamer and the attenuator, is 
complementary to a target nucleic acid, such as an mRNA, which is referred to as a 
regulatory nucleic acid (regDNA) because it regulates activity of the aptamer in the 
TRAP by hybridization with the central (intervening) sequence. The studies reported 
here of the ATP-DNA TRAP suggest that, as well as inhibiting the aptamer, the 
attenuator also acts as a structural guide, much like a chaperone, to promote proper 
folding of the TRAP such that it can be fully activated by the regDNA. We also show 
that activation of the aptamer in the TRAP by the complementary nucleic acid at 
physiological temperatures is sensitive to single base mismatches. Aptamers that can 
be regulated by a specific nucleic sequence such as a in an mRNA have potential for 
many in vivo applications including to regulate a particular enzyme or signal 
transduction pathway or to imaging gene expression in vivo. 
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ABBREVIATIONS: 
regDNA, regulatory DNA; TRAP: Targeted Reversibly Attenuated Probe 
INTRODUCTION 
Transcriptional changes are some of the earliest events that signal the presence 
of disease or change in the differentiated state of a cell. Consequently there is great 
interest in developing probes that can be used to identify altered gene expression or 
that can be triggered by a specific mRNA to initiate a cellular activity. Here we describe 
a novel nucleic acid probe design that contains an aptamer linked to a complementary 
attenuator via an intervening sequence. The aptamer is activated by hybridization of 
the intervening sequence with a complementary nucleic acid sequence that disrupts the 
aptamer:attenuator stem (Fig. 1A). We refer to these probes as TRAPs (Targeted 
Reversibly Attenuated Probes). The design of the TRAP relies on the ability of single-
stranded nucleic acids to adopt alternative structures. In its primary structure the TRAP 
includes the sequence of an aptamer that can interact with its target molecule with high 
specificity and affinity. In the absence of complementary nucleic acid sequence the 
TRAP folds to hinderaptamer activity by virtue of hybridization between a portion of the 
aptamer and its complementary sequence, the attenuator. The presence of a nucleic 
acid that is complementary to the intervening antisense sequence results in 
hybridization and the formation of a rigid double-stranded DNA structure. The resulting 
structural constraint on the intervening sequence forces apart the shorter terminal stem, 
releases the aptamer from its attenuation constraint and allows it to fold into its active 
configuration. 
Ribozymes that are regulated by molecular interactions at an allosteric site have 
been reported on several occasions. Various extensions to the hammerhead ribozyme 
have rendered it regulated by oligonucleotides (1-3), ATP (4), theophylline (5), FMN 
(6) and cyclic nucleotides (7). Similarly RNA and DNA ligases have been produced that 
are regulated by ATP and theophylline (8, 9). Aptamers have been used to form 
riboswitches that regulate translation or transcription in bacteria oryeast (70-72). They 
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have also been applied as part of the allosteric mechanism for regulating ribozyme 
activity (5, 13). At least two examples of allosteric aptamers have been described. 
The one, a hemin-regulated aptamer, binds cytochrome c more tightly when hemin 
binds to a region of the aptamer that does not interact with cytochrome c (14). The 
likely mechanism for this allosteric regulation proposed by the authors on the basis of 
their studies is that the aptamer adopts an alternative structure when hemin binds to 
a G-quartet that is adjacent in the aptamer sequence to the cytochrome c-binding 
region. A second allosteric aptamer involves regulation by the aminoglycoside, 
neomycin, which inhibits binding of an aptamer to E. coli formamidopyrimidine 
glycosylase (15). As for the hemin-binding aptamer, binding of neomycin alters the 
activity of the ligand-regulated aptamer (LIRA). In both cases cited, the allosteric 
regulators of aptamer activity were small molecules, either hemin or neomycin. 
Regulation of an aptamer activity by an allosteric mechanism involving a nucleic 
acid regulator has not yet been reported. Here we describe a general approach to 
developing an aptamer that is regulated by a specific nucleic acid sequence. In this 
report, as an example, we have used the DNA ATP aptamer (16). We show that, in 
a TRAP configuration, activity of the ATP aptamer is specifically and quantitatively 
regulated by its target nucleic acid. 
Previous studies of the TRAP concept were done with the hammerhead ribozyme 
in place of the aptamer in figure 1A. In these studies also, a simple polyAC intervening 
sequence was used. Studies of the ribozyme in this configuration showed that we 
could regulate the activity of the ribozyme by an attenuator (2, 3). But, they did not 
evaluate the use of natural sequences in the intervening sequence. The critical 
distinction is that natural sequences are likely to fold into a variety of structures that 
might coexist and could involve interactions of the intervening sequence with the 
aptamer or ribozyme or with the attenuator to create three-dimensional structures that 
differ from that proposed in figure 1A. To understand the structural considerations that 
guide formation of regulated nucleic acids such as the TRAPs, it is important to 
evaluate the distribution of folded structures in the population fold. These questions 
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cannot be evaluated with a ribozyme as the functional nucleic acid in the TRAP 
because, in assays for ribozymes, the substrate is the only radiolabeled component, 
the ribozyme is in excess (often 10-fold or more) of the substrate, and the assay follows 
the cleavage of the substrate RNA. Thus, the only ribozyme TRAPs that have folded 
"properly" and hybridized to the substrate are detected. Ribozyme TRAPs that adopt 
alternate three-dimensional structures that do not bind the substrate are not detected 
by the assay even if they constitute 90% of the molecules in the population. With an 
aptamer as the functional nucleic acid, the assay involves radiolabeling the TRAP and 
all molecules in the population are detected. Thus, with an aptamer, aspects of 
uniformity of folding can be addressed with the TRAP design. The results of this study 
of aptamer TRAPs show that the attenuator inhibits aptamer activity and also suggest 
that the attenuator serves as a structural guide for forming the correct TRAP structure 
and to prevent unproductive folding of the oligonucleotide. We also show that the 
TRAP design allows discrimination at a physiological temperature between nucleic 
acids that differ by only a single nucleotide in sequence. 
MATERIALS AND METHODS 
Materials and Equipment 
ATP-Agarose affinity resins and ATP were purchased from Sigma (St. Louis, MO). 
[y-32P ]ATP was purchased from ICN (Costa Mesa, CA). Biotinylated ATP (Adenosine 
^'-triphosphate [y] Biotinyl-3,6,9,-trioxaundecanediamine) was from Affinity Labeling 
Technologies, Inc. (Lexington, KY). Streptavidin Agarose CL-4B was from Sigma (St. 
Louis, MO). HT-450 Tuffryn® membrane filters (0.45 pm pore size) were from Pall (Ann 
Arbor, Ml). ITC experiments were performed using a VP-ITC isothermal titration 
calorimeter (Microcal, Inc., Northhampton, MA). Imagequant software (Amersham-
Pharmacia) was used to analyze radioactive bands in gel scans obtained using a 
Typhoon scanner (Amersham-Pharmacia). 
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Oligonucleotides 
The oligonucleotides used in this study are represented in figure 1B. The sequences 
of the three TRAPs most frequently used in the work are given here. All other 
sequences can be found in the Supporting Information. 
8att-polyTG20 TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCCGCAATA 
8att-cmRas20TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCGGCGGCCGCAATA 
9att-cmRas1 STRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCCCGCAATAC. 
Oligonucleotides were purchased as PAGE purified preparations.(Integrated DNA 
technologies, Coralville, IA). 
ATP Binding Assays 
Single-stranded ATP DNA TRAPs or that ATP DNA aptamer (2 - 20 pmoL, 5' 
labeled with 32P) were incubated in the presence or absence of other ssDNAs, as 
defined in each experiment, at 75°C for 5 min in binding buffer (20 mM Tris-HCI, 300 
mM NaCI, 5 mM MgCI2, pH7.6)then cooled to room temperature slowly for 40-60 min. 
These samples were either loaded onto an ATP affinity column for the column assay 
or mixed with 40 pM biotinylated ATP and 10 pM streptavidin-agarose for the filter 
assay. For the column assay, each sample was incubated for 10 min on the column 
then washed with 20 ml of binding buffer and the retained DNA was eluted with 15-16 
ml of 5 mM ATP in binding buffer. For the filter assay, each sample was equilibrated 
at room temperature for 10 min then filtered through an HT-450 filter and washed with 
5 ml of binding buffer. For both assays, fractions were analyzed by scintillation 
counting or measuring Cerenkov radiation. The radioactive cpm bound to ATP was 
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divided by the total cpm in the sample to give the fraction bound. Reported error values 
are the standard deviations of the averages. 
Isothermal Titration Calorimetry 
Titrations of 50mM regDNA-cmRas20 into a cell containing 5mM 20mer Oatt-
cmRas20 TRAP or 8att-cmRas20 TRAP, respectively, were carried out at 37 °C in 
titration buffer (300 mM NaCI, 5 mM MgCI2 and 20 mM HEPES (pH 7.6 at 23°C). For 
each titration, 5 pi (250 nmoL) of regDNA-cmRas20 was injected from a computer-
controlled syringe at intervals of 300 or 600 s into the reaction cell that contained an 
initial volume of 1.43 ml of the appropriate oligonucleotide in the same buffer as the 
regDNA. Reverse titrations (oligonucleotide tritrated into regDNA) were also run. The 
syringe was rotated at 310 rpm. Data points were collected every 4 s. Each titration 
involved a total of 25 injections. Control experiments to determine the heats of dilution 
were performed using the same injection protocol of regDNA into a cell containing 
buffer but no oligonucleotide. The heat of dilution for each titrating oligonucleotide into 
buffere was determined experimentally. These values were subtracted from the 
corresponding experimentally obtained values for the appropriate oligonucleotide pairs 
to obtain the heats of interaction of each pair. The subtraction of the heats of dilution 
did not significantly change the values for heats of interaction for the oligonucleotides. 
All titrations were carried out at least three times to ensure consistency of the data. 
Before each titration the oligonucleotide was heated to 85°C and incubated for 5 min 
in the titration buffer. The oligonucleotide was then cooled to room temperature slowly 
for 40 min. The data were analyzed using Origin 7.0 (Microcal, Inc.) with AH (enthalpy 
change in kcal/mol), Ka (association constant in M"1) and N (numberof binding sites per 
molecule in the sample cell) as adjustable parameters. Thermodynamic parameters 
were calculated from the equation AG = AH - TAS, where AG, AH and AS are the 
changes in free energy, enthalpy and entropy of binding, respectively. T is the absolute 
temperature. 
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Polyacrylamide Gel Electrophoresis 
Nucleic acids and their hybrids were separated by electrophoresis through 12% 
non-denaturing polyacrylamide gels under a constant current of 35 mAmp at room 
temperature. The gel buffer and electrode buffers consisted of 89 mMTris-HCI,89 mM 
boric acid and 2 mM EDTA. The relative amounts of radiolabeled DNA in each band 
were quantified using Imagequant software after scanning the gel using a Typhoon 
scanner. Reported errors are the standard deviations of the averages. 
RESULTS 
Allosteric Regulation of the ATP Aptamer by a Regulatory Nucleic Acid 
To determine if an aptamer activity could be controlled in the TRAP design by an 
oligonucleotide complementary to the intervening antisense loop, we tested an 
allosteric DNA TRAP (8att-cmRas20 TRAP) containing an ATP aptamer at the 5' end, 
followed by a 20 nt antisense that is complementary to a portion of a mutant Ras 
oncogene mRNA then an 8-nt attenuator sequence at the 3' end. As predicted, 
incubation with a 20nt regulatory DNA oligonucleotide (regDNA-cmRas20) resulted in 
increased aptamer (ATP-binding) activity of the TRAP (Fig. 2). Oligonucleotide 
sequences that were not complementary to the attenuator or to other portions of the 
TRAP were not effective in increasing TRAP activity (Fig. 2). These results show that 
the TRAP functions as designed. Regulation of aptamer activity is achieved by the 
presence of an oligonucleotide with a sequence complementary to the intervening 
antisense portion of the TRAP. The TRAP aptamer was also activated by regDNAs 
without prior melting and cooling (Fig. 2), suggesting that this form of regulation could 
occur in vivo. 
Proportionality and Reversibility of TRAP Activation 
To be useful as a sensor for a complementary nucleic acid such as a cellular 
mRNA, allosteric regulation by the antisense sequence in the TRAP should be 
proportional to the concentration of the complementary regulatory nucleic acid and 
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reversible. This was shown for the 8att-cmRas20 TRAP that was activated in a linear 
fashion by an increasing concentration of complementary regDNA-cmRas20 (Fig. 3A). 
Control experiments showed that the regDNA itself did not display aptamer-like activity 
and that sequences that were not complementary to the TRAP did not increase 
aptamer activity (Fig. 2 and data not shown). The increase in TRAP activity is stable 
for at least 24h (data not shown) but can be readily reversed if an equilibrium is 
established with a third single stranded nucleic acid that has a higher association 
constant for the regDNA than the regDNA has for the antisense segment of the TRAP. 
In vivo, reversal would be achieved by expressing an RNA that included additional 
sequence of the targeted regulatory mRNA that surrounds the sequence 
complementary to the intervening sequence of the TRAP. Here, we have demonstrated 
this property by using a regDNAext containing a central sequence that is 
complementary to the TRAP intervening sequence and 15 As on either end. Reversal 
of TRAP activation occurred at 23°C within 20 min of adding the complement of the 
regDNAext (crDNAext) to the TRAP that had been activated by a 10 min incubation with 
regDNAext (Fig. 3B). The observed proportional increase in TRAP aptamer activity 
with increasing regDNA/TRAP molar ratio and the ability to reverse this activation 
shows that the TRAP could be used to report the presence of an mRNA sequence or 
to mediate a signal from a particular mRNA sequence and that the activity of the TRAP 
can be reversed. 
Attenuator Regulation of Aptamer Activity in the TRAP 
The TRAP design dictates that allosteric regulation by the regDNA involves a 
balance of the strength of hybridization of the attenuator:aptamer stem and the 
antisense:regDNA hybrid. The impact of this balance of stability between two 
alternative structures was tested by varying the length of the attenuator (Fig. 4). As 
predicted, the ability of the regDNA to activate the aptamer in the TRAP decreased with 
increasing length of the attenuator (Fig. 4, gray bars). In this set of experiments a 
polyTG20 TRAP was used in place of the cmRas20 TRAP. Whereas, an internal 
structure is predicted for the cmRas intervening sequence by the Mfold software (17), 
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no structure is predicted for polyTG. By using the polyTG20 TRAP, we were able to 
test the effect of varying the length of attenuator in the absence of complications that 
could be introduced by the inclusion of structure in the intervening sequence. A 
practical advantage of the polyTG20 TRAP was also that, under the conditions tested, 
the basal activity was high enough to observe the incremental decrease in aptamer 
activity as a result of increasing the attenuator length (black bars). 
If, as these data suggest, the TRAP is activated by disrupting hybridization between 
aptamer and its complementary attenuator, then a sequence complementary to the 
attenuator (cAtt) should also activate the aptamer in the TRAP by competing for the 
attenuator sequence as shown (Fig.4, white bars). Activity of the TRAPs with 12 and 
14nt attenuators increased more with cAtt than did the activity of the TRAPs with 
shorter attenuators. The likely explanation for this observation is that the base 
compositions of the cAtts for these TRAPs were higher in %GC and therefore the 
TRAP:cAtt hybrids were more stable than for TRAPs with shorter attenuators. Another 
factor is that the ratio of cAtt:TRAP for these two TRAPs with the longest attenuators 
was 10:1 compared with 5:1 for the remaining TRAPs. However, this change in ratio 
is unlikely to be responsible for the much higher activity of these latter two TRAPs in 
the presence of cAtt because the ATP binding activity of the SattpolyTG TRAP was 
identical at a ratio of cAtt:TRAP equal to 10:1 and 5:1 (data not shown). 
Effect of the Intervening Sequence on TRAP Activity 
Previous studies of the hammerhead ribozyme TRAP were exclusively done with 
intervening antisense sequences designed not to interact with the ribozyme or the 
attenuator (2, 3, 18). We have also examined the activity of the polyTG20 TRAP with 
a similar noninteracting intervening sequence for which there are no predicted hydrogen 
bonded pairs between bases in the aptamer and in the intervening sequence. 
However, the use of the TRAP to detect or respond to mRNA sequences will require 
that the mechanism function with a variety of base sequences in the intervening loop. 
Some of these intervening loop sequences will provide options for hydrogen bonding 
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between the aptamer and the intervening sequence in addition to the hybridization 
between aptamer and attenuator. 
To examine the effect of the intervening antisense sequence on the ability of the 
TRAP to detect the presence of the a variety of regDNAs, we compared three TRAPs: 
1) the 8att-polyTG20 TRAP with an intervening sequence of a polyT sequence 
interspersed with 3 Gsfor maintaining register with the regDNA (structure 1, Fig. 5A), 
2), the 8att-cmRas20 TRAP with an intervening sequence containing all four nucleotide 
bases and with options for base pairing within the sequence (structures 2a, b, c, Fig. 
5A) and 3) the Oatt-cmRas20 TRAP (structure 3, Fig. 5A) with the same sequence as 
the 8att-cmRas20 TRAP except lacking the Bnt attenuator. The polyTG intervening 
sequence is similar to that which was used with the hammerhead ribozyme TRAP and 
does not correspond to a known RNA sequence (2). The cm Ras intervening sequence 
corresponds to a portion of a mutant Ras mRNA and is predicted by the Mfold software 
(17) to have internal structure. 
Compared with the 8att-polyTG20 TRAP the activity of the 8att-cmRas20 TRAP 
was lower in the absence of the complementary regDNA (Fig. 5B). However, both 
TRAPs were activated to about the same maximum activity by excess complementary 
regDNA. These results suggest that action of the attenuator to inhibit aptamer activity 
might be aided by interactions within the intervening sequence that stabilize the closed 
(aptamer inactive) form of the TRAP but that these latter interactions do not prevent the 
regDNA from hybridizing with the intervening antisense sequence and fully activating 
the aptamer. 
Role of the Attenuator as a Structural Guide for regDNA Hybridization with the 
TRAP 
In the course of these studies we discovered that in some instances, the Oatt-
cmRas20 TRAP being an example, the antisense sequence can interact with the 
aptamer and strongly suppress its activity in the absence of an attenuator (Fig. 5B). 
However, unlike the TRAP that includes an attenuator, the aptamer linked to the 
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antisense in the absence of an attenuator (0att-cmRas20 TRAP) was not fully activated 
by regDNA. Even by a 100-fold excess of regDNA only increased the 0att-cmRas20 
TRAP aptamer activity to 50% of the aptamer binding activity achieved by the Batt-
cmRas20TRAP or of the ATP aptamer alone (Fig. 5B). This same inability of the Oatt-
cmRas20 TRAP to be fully activated was observed at 23°C and 37°C. 
Analysis by the Mfold program of the 2-dimensional structure of the 0att-cmRas20 
TRAP predicted that the folded structure of this oligonucleotide (AG, -4.2) was less 
stable than for the 8att-cmRas20 TRAP, which has the same sequence with the 
addition of the 8nt attenuator (AGs, -5.5 to -5.8). If correct, this analysis suggested 
that the thermodynamic basis for the resistance of the Oatt-cmRas2O TRAP to 
activation by the regDNA-cmRas20 could not be accounted for by a much more stable 
secondary structure of the former. We also tested the possibility that the observed 
difference in maximal activation of the Oatt- and 8att-cmRas20 TRAPs was due to a 
kinetic difference in the rate of hybridization with the complementary regDNA. 
However, even after a 24h incubation of the TRAPs with the regDNA-cmRas20, the 
same relative activations of the Oatt- and 8att-cmRas20 TRAPs were observed. 
To examine furtherthe basis for the inability of the 0att-cmRas20 TRAP to be fully 
activated, we used isothermal titration calorimetry (ITC) to compare the thermodynamic 
parameters of the interaction of the regDNA with three oligonucleotides: 1) a 
complementary oligonucleotide corresponding to the intervening antisense sequence 
of the TRAP, 2) the 8att-cmRas20 TRAP and the 3) 0att-cmRas20 TRAP. The results 
(Table 1) showed that the calculated stabilities (AGs) of the complex between the 
regDNA-cmRas20 and either the Oatt- and 8att- cmRas20 TRAPs were similar. 
However, whereas the thermodynamic parameters for the 8att-cmRas20 
TRAP:regDNA-cmRas20 interaction could be fit assuming a single hybrid molecular 
species, the 0att-cmRas20 TRAP:regDNA-cmRas20 data could only be fit if it was 
assumed that there were two types of interaction, each representing about 50% of the 
DNA molecules. Representative data from which the values for this table were 
obtained are shown in Fig. 6. From this analysis it seems that the 0att-cmRas20 TRAP 
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can adopt at least two tertiary conformations that interact differently with the regDNA 
for hybridization. Such structures were not predicted by the Mfold program and may 
involve more complex structural elements than are entertained by this algorithm for 
2-dimensional structural predictions . 
Alone, the ITC analysis does not explain why only 50% of the aptamer activity is 
activated on hybridization with the regDNA. Although there are at least two predicted 
interactions that might involve two or more folded structures of the 0att-cmRas20 
TRAP, neither interaction shows a very different stability from the other or from the 8att-
cmRas20 TRAP. The most likely explanation for these results is that one or more of 
the hybridized 0att-cmRas20 TRAP structures involves interaction between the 
regDNA-cmRas2O and the aptamer that inhibits aptamer activity. Thus, the presence 
of the attenuator in the 8att-cmRas20 TRAP may act as a structural guide to 
appropriately align the antisense sequence in the "closed" TRAP making it available for 
invasion by the regDNA to form the correct structural intermediate for the subsequent 
separation of the attenuator and aptamer. 
To test the hypothesis that the 8att-cmRas20 TRAP forms predominantly one 
structure and the Oatt-cmRas2O TRAP forms more than one structure when hybridized 
with the regDNA-cmRas20 , hybridized and radiolabeled oligonucleotides were 
separated by non-denaturing acrylamide gel electrophoresis. The results demonstrate 
that the vast majority of the 8att-cmRas20 TRAP runs as a single band, in the presence 
and absence of regDNA-cmRas20, suggesting the presence of a predominant structure 
(Fig. 7). By contrast, the 0att-cmRas20 TRAP, with or without regDNA-cmRas20, 
separates into one major band with the remainder distributed amongst four to nine 
bands and sometimes in a smear of unresolved bands near the major band. The 
results suggest that the Oatt-cmRas2O TRAP exists as multiple structural species. 
These experiments were performed with variations in incubation temperature (10 min 
incubation at 23°C vs. 37°C), times of incubation (10 min and 24 h incubation at 23°C) 
and temperatures at which electrophoresis was performed (electrophoresis at4°C and 
23°C with samples that had been incubated at either 23°C and 37°C). In all trials the 
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same observation was made that the 0att-cmRas20 TRAP separated into many bands 
on the gel whereas the 8att-cmRas20 TRAP remained mainly as a single band. An 
average of 86 ±7.8% (N=8)and 89 ±5.6% (N=12) of the total 8att-cmRas20 TRAP DNA 
resolved as a single band in the absence or presence of a 1 to 100-fold excess of 
regDNA respectively. By contrast, 46 ± 15% (N=10) and 57 ± 8.5% (N=30) of the Oatt-
cmRas20 TRAP was found in the most intense band in the absence and presence of 
a 1 to 100-fold excess of regDNA respectively. Thus, these results, along with the ITC 
data and the measurements of TRAP aptamer activity after hybridization with regDNA 
suggest that only about 50% of the Oatt cmRas20 TRAP molecules adopt a structure 
that is able to interact with the regDNA in a productive way to activate the aptamer. 
The TRAP'S Ability to Distinguish Single Base Mismatches 
Although not practical with oligonucleotides, single base mismatches can be 
detected by molecular beacons, nucleic acids with a similar stem-loop structure to the 
TRAP (19-21). However, optimal conditions for distinguishing single base mismatches 
by molecular beacons are at temperatures well above 37°C and also generally include 
high concentrations of Mg++. Whereas the molecular beacon is generally regulated by 
a stem of 5 to 6 bases, the TRAP has a longer stem by which it is regulated. We 
reasoned that the apparent higher stability of the TRAP structure would make its 
activation more likely to be influenced at physiological temperatures by single base 
mismatches between the regDNA and the antisense intervening sequence of the 
TRAP. Therefore, regDNAm-cmRas15 with one or two base-pair mismatches were 
tested for their ability to activate a 9att-cmRas15 TRAP at 37°C and in the presence of 
only 5 mM MgCI2. The results showed that the 9att-cmRas15 TRAP was capable of 
distinguishing single nucleotide mismatches between the regDNAm-cmRasI 5 and the 
intervening antisense sequence over at least a 10-fold range (Fig. 8). 
DISCUSSION 
We have described an oligonucleotide design in which a complementary nucleic 
acid can regulate an aptamer activity by an allosteric mechanism. The aptamer activity 
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in the TRAP is increased by the presence of complementary regDNA. In the absence 
of regDNA, the aptamer is inhibited by the attenuator (Fig. 4). Activation of the TRAP 
is sequence specific and is proportional to the amount of regDNA present (Figs 2,3). 
Activation of the TRAP aptamer is determined by the balance in stability of the 
attenuatoraptamer stem and intervening sequence compared with the stability of the 
aptamer-target complex and regDNA: intervening sequence hybrid. This equilibrium 
resembles that established by the molecular beacon with its complementary DNA 
target. A systematic thermodynamic study demonstrated that the molecular beacon 
can discriminate between a complete match and a single mismatch in the target DNA 
sequence over  a  broader  temperature range than can a l inear  nucle ic  ac id probe (20).  
As the stem length was increased from 4 to 6 bases, the window of discrimination 
moved from a mid-value of about 65°C to about 50°C. Very little discrimination was 
observed at 37°C. By contrast, we found good discrimination between single base 
mismatches at 37°C using a 9att-cmRas15 TRAP (Fig 8). For optimizing the 
discriminatory capability of the TRAP, it was important to find the correct 
thermodynamic balance between the attenuatoraptamer heteroduplex and the 
antisense:regDNA hetroduplex. For example, 9nt in the attenuator and 15nt in the 
intervening sequence showed good discrimination single base-pair mismatches. 
Whereas the 8att-cmRas20 TRAP showed some discrimination between a complete 
match and a two position mismatch, there was no significant difference for the 8att-
cmRas20 TRAP between a complete match and a single basepair mismatch (data not 
shown). 
Although increasing the length of stem of the molecular beacons moved the 
window of sequence discrimination towards physiological temperatures, it also 
increased the response time such that a molecular beacon with a 6-stem base was only 
a little over 60% opened after 200 seconds compared with 4-stem beacon, which was 
completely opened by less than 10 seconds (20). By extension, an 8-stem molecular 
beacon would be expected to take many minutes to completely open. Our results 
suggest that the TRAP is not as sluggish in its response to the regDNA as the 
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molecular beacon is to its target DNA. Incubating the TRAP with its target molecule 
and the regDNA for 5 minutes results in the same amount of activity as obtained with 
the aptamer alone. The difference between TRAP and molecular beacon probably lies 
in the stability of the aptamer structure when bound to its target molecule. Whereas the 
beacon has only the AG of hybridization between antisense and target DNA to balance 
the AG of the stem helix, the TRAP equilibrium balances the AG of stem helix and 
against the combined AGs of aptamer interaction with its target molecule and regDNA 
hybridized with the intervening sequence. The additional stability of the released 
aptamer bound to its target molecule is expected to make the reverse reaction less 
favorable. 
Our results show that maximally activated TRAP has the same activity as the 
aptamer alone when the TRAP is tested at 37°C (Supporting Information). 
Consequently, maximizing the range of change in aptamer activity due to regDNA will 
be achieved by decreasing the background activity of the TRAP in the absence of 
regDNA. Here we show that the intervening sequence can play a role in optimizing 
TRAP activity (Fig 5). Identical except for the 20 nt intervening sequence, the 8att-
polyTG20 TRAP showed a much higher background activity than the 8att-cmRas20 
TRAP. Whereas there is no predicted internal structure of polyTG, the cmRas 
intervening sequence was predicted to have internal structure. The internal structure 
introduced by the cmRas intervening sequence may lower the background activity of 
the TRAP by stabilizing the attenuatoraptamer stem. 
Depending on its sequence, the intervening sequence can also interact with and 
inhibit the aptamer. In the 8att-cmRas20 TRAP example, the absence of an attenuator 
sequence in the TRAP resulted in an aptamer that was inhibited in the absence of 
regDNA. But the 0att-cmRas20 TRAP could not be fully activated by hybridization with 
regDNA even if the regDNA and TRAP were incubated together over a 24 h period. 
Analysis by ITC suggested that the Oatt-cmRas2O TRAP interacts with the regDNA to 
form more than one structure (Table 1, Fig. 6). By contrast, the 8att-cmRas20 TRAP 
showed evidence of only a single hybridized structure as did the two oligonucleotides 
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with sequences of the regDNA and the intervening antisense of the TRAPs. Further 
structural analysis by gel electrophoresis of the regDNA hybrids with these two TRAPs 
supported the hypothesis that the 0att-cmRas20 TRAP forms several structures both 
in the presence and absence of the regDNA, whereas the 8att-cmRas20 TRAP forms 
only one major structure in both instances (Fig. 7). We believe it is likely that one or 
more of the hybridized forms of the 0att-cmRas20 TRAP includes structural features 
that prevent the aptamer from properly folding and from recognizing its target ATP. 
These results suggest that the attenuator plays three important roles in the TRAP. The 
first role is to inhibit aptamer activity in the absence of the regulatory nucleic acid as 
demonstrated for the polyTG TRAP in Fig.4. The second role of the attenuator is to act 
as a structural guide, much like a chaperone, to promote the folding of the remainder 
of the molecule into a three-dimensional structure that can be effectively invaded by the 
regulatory nucleic in a single and productive mode to fully activate the aptamer. In 
acting as a structural guide, the attenuator also performs its third role, which is to 
prevent unproductive folding of the TRAP oligonucleotide. These latter two roles, which 
are interdependent, are proposed as an explanation of the results of the ATP binding, 
ITC and gel electrophoresis analyses of the 8att-cmRas20 TRAP and the Oatt-
cmRas20 TRAP (Figs 5-7 and table 1). 
The TRAP has many potential applications. One example is in imaging gene 
expression in vivo. Activation of the aptamer in the TRAP by a particular mRNA would 
provide a means of imaging cells in vivo that express the complementary mRNA. For 
imaging gene expression, molecular beacons make particularly good use of 
fluorescence options for signaling the presence of a specific sequence by coupling a 
fluorophore and a quenching agent, located at opposite ends of a nucleic acid probe, 
with a stem-loop structure. Although they can function in vivo, the molecular beacon's 
usefulness for in vivo applications is limited by the penetration of light through tissue 
and by the stability of the beacon inside cells (22-24). Not limited by the need for a 
fluorescent signal, the TRAP can be designed to bind a target molecule labeled with 
a radioisotope such as Tc"m or F18. The radiolabeled targets would be concentrated 
by the TRAP in cells in which the mRNA is expressed that is complementary to its 
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intervening sequence. Unlike for the molecular beacon, degradation of the TRAP in 
vivo will not create a background signal. Also, because of its sensitivity to a single 
base mismatch at temperature and salt concentrations close to those of the living cell, 
we anticipate that the TRAP might also be able to distinguish point mutations in mRNAs 
of living cells. 
Although they both rely on a similar stem-loop structural concept, there are some 
fundamental differences between the TRAP and the molecular beacon. Both the 
TRAP and molecular beacon can be taken in by cells as synthetic oligonucleotides. 
However, unlike the molecular beacon, a TRAP containing an RNA aptamer can be 
synthesized by a living cell to create a steady state intracellular concentration of TRAP. 
TRAPs could also be used to modify cellular processes in response to specific nucleic 
acid sequences. Aptamers have been selected to regulate enzyme activity, signal 
transduction cascades and protein structural transitions (25-29). The TRAP design 
described here would provide a means of regulating these aptamers by changes in 
gene expression. A normal gene expression pattern could be harnessed to regulate 
the activity of an enzyme or an intermolecular interaction by way of a TRAP containing 
the appropriate aptamer. 
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FIGURE LEGENDS 
Figure 1. Design and Function of the TRAP and Oligonucleotide Designs for this 
Study. 
A. Design of the TRAP: The TRAP consists of three segments: aptamer, intervening 
antisense and attenuator. Binding of the complementary sense regulatory nucleic acid 
to the antisense sequence in the TRAP forces the aptamer and attenuator apart 
providing the aptamer sequence with an opportunity to fold and interact with its target 
molecule. 
B. Oligonucleotide designs: The oligonucleotides used in this study are shown 
graphically. Parallel lines indicate complementarities between sequences. Lines of the 
same color have the same nucleotide sequence. Sequences of the TRAPs are found 
in Materials and Methods and all other sequences are found in the Table 2. 
Figure 2. Sequence specificity of activation of the TRAP Activity by regDNA. 
The 8att-cmRas20 TRAP was tested for its ability to bind ATP in the presence and 
absence of complementary regDNA-cmRas20 (5x, 10x) or noncomplementary NC20 
(NC) compared with its activity in the absence of any other nucleic acid (-). For some 
samples the TRAP and regDNA were not heated and cooled together prior to 
measuring aptamer activity (not preheated). The background binding activity was 
determined using a shuffled TRAP sequence alone (BK). The binding activity of 
aptamer alone was evaluated on the same column and on a N6-linked ATP sepharose 
(N6). Averages and standard deviations are shown. All but two values are averages 
from 4 or more independent experiments. For NC and N6, the results are the average 
of two independent experiments. Hatched bars, background; black bars, 8att-cmRas20 
TRAP that was melted and annealed slowly with the regDNA-cmRas20 or 
noncomplementary DNA before measuring aptamer activity; gray bars, 8att-cmRas20 
TRAP that was not melted and annealed before measuring aptamer activity. White 
bars, ATP aptamer. 
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Figure 3. Relation between TRAP activity and regDNA concentration and 
reversibility of TRAP activation. 
A. Relation between TRAP activity and regDNA concentration. The molar ratio of 
the regDNA-cmRas20 to the 8att-cmRas20 TRAP was varied to determine the effect 
of the regDNA on aptamer activity. The results are compiled from a series of 
experiments in which the TRAP concentration was a value between 0.075 |JM and 0.15 
|jM, depending on the experiment. In each experiment a similar linear relationship was 
observed between ATP binding activity to regDNA concentration. The filter assay 
employing ATP-biotin and streptavidin-sepharose was used to assess the ATP binding 
activity. The R2 obtained by linear regression for this line was 0.98. The molar ratio of 
regDNA-cmRas20 to 8att-cmRas20 TRAP (regDNA/TRAP), is plotted (•). 
B. Reversal of TRAP activation. The property of reversal (shown in the bars the far 
right) was tested by first incubating the 8att-cmRas20 TRAP for 10 min at 23°C 
regDNAext (same sequence as regDNA-cmRas20, but with 15 As on either end) then 
adding crDNAext (complementary to regDNAext) and waiting another 30 min. All 
conditions shown in this figure contained 0.067 pM 8at-cmRas20 TRAP. Control 
conditions were the TRAP without regDNA added (cont), with regDNA-cmRas20, or 
with regDNA-cmRas20 for 10 min followed by NCext (noncomplementary sequence 
with 15 Ts on either end) for 30 min. The purpose of the latter two controls was to test 
that, under the conditions of the assay shown in figures 2 and 3A (regDNA and TRAP 
interactions), the use of an oligonucleotide with polyT extensions had no effect on the 
interaction between TRAP and regDNA. The molar ratios of 
TRAP :regD NAext :crDN Aext was 1:5:25. These results are from a single experiment 
in which duplicate independent measurements were averaged to obtain each value. 
Similar results were obtained in three independent experiments. 
For both figures, a background value of 4% subtracted from each datapoint was 
determined from the average retention of oligonucleotides containing either random 
sequences or a shuffled 8att-cmRas20 TRAP sequence. Noncomplementary DNA was 
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unable to activate the aptamer in the TRAP. Background values were determined 
using random and shuffled oligonucleotides. 
Figure 4. Effect of blocking the attenuator sequence on TRAP aptamer activity. 
The polyTG20 TRAPs with 0,5,8,10,12 and 14 base-long attenuators were incubated 
in the absence of other oligonucleotides or in the presence of either 1 ) a 20 nt oligomer 
complementary to the entire attenuator region and a variable length of the adjacent 
intervening sequence (cAtt) or 2) the regDNA-polyAC20 complementary to the 20 nt 
intervening antisense sequence. The ratio of cAtt or regDNA to TRAP was 5 to 1 for 
TRAPs with attenuators of 0,5,8, and 10 and 10 to 1 for TRAPs with 12 and 14nt 
attenuators. Black bars: activity in the absence of other oligonucleotides; White bars: 
TRAP in the presence of cAtt; Gray bars: TRAP in the presence of regDNA. 
Figure 5. Impact of the intervening sequence and attenuator on TRAP function. 
A. Two-dimensional structures predicted by the Mfold program 
(http://www.bioinfo.rpi.edu/applications/Mfold/)for oligonucleotides containing the ATP 
aptamer and a cm Ras antisense sequence with or without an 8nt attenuator. 1 ) The 
poly TG 20 TRAP has a single predicted structure with a AG of -10.6. 2a-c) The three 
predicted structures for the 8att-cmRas20 TRAP with an 8nt attenuator have AGs of 
-6.2 (a) or -6.1 (b,c). 3) The single predicted structure for the 0att-cmRas20 TRAP with 
no attenuator has a AG of -4.2. 
B. The activities of four TRAP constructs are compared: 8att-polyTG20 TRAP with an 
8-nt attenuator (gray bars), 0att-polyTG20 TRAP (hatched gray bars), 8att-cmRas20 
TRAP with an 8-nt attenuator (black bars; middle section) or Oatt-cmRas2O TRAP with 
no attenuator (right and left slashed white bars; left section). The TRAPs were 
incubated alone (0), in the presence of 5, 10 or 100-fold molar excess of the 
complementary regDNA (either regDNA-polyAC20 or regDNA-cmRas20) or a 10-fold 
excess of noncomplementary NC20 (NO). The ability of the regDNA-cmRas20 to 
control activity Oatt-cmRas2O TRAP activity was tested at 23°C and 37°C (Right-hand 
section). All other incubations were at 23°C. 
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Figure 6. ITC data for hybridization of regDNA-cmRas20 with 8att-cmRas20 TRAP 
or 0att-cmRas20TRAP. 
Representative plots and the fitted ITC data are shown in this figure. The Oatt-
cmRas20 TRAP (A), 8att-cmRas20 TRAP (B) and the 20nt intervening sequence of the 
cmRas20 TRAPs (C) were titrated with regDNA-cmRas20 and the heats of reaction 
were measured by isothermal titration calorimetry. For these examples the first 
oligonucleotide was initially at 5 pM in 1.4 ml and the final concentration of regDNA-
cmRas20 was 7.6 pM in 1.65 ml with a resulting final molar ratio of 1.8 for regDNA-
cmRas20/first oligonucleotide. For all three of these examples regDNA-cmRas20 was 
titrated into the cell with 600 s between injections. The upper set of three graphs shows 
the time courses for the three titrations. The lower set of graphs shows the heat 
absorbed as a function of the molar ratio of the interacting species. The compiled data 
from these and other analyses are shown in Table 1. 
Figure 7. Effect of the attenuator on structural forms of cmRas20 TRAP: regDNA 
hybrids. 
End labeled Oatt- and 8att-cmRas20 32P-TRAPs (0.8 pM), were hybridized with the 
regDNA-cmRas20 in the absence of ATP by incubating the oligonucleotide pair 
together for 10 min at 23°C. The hybridized pairs were then resolved by non-
denaturing polyacrylamide gel electrophoresis and the distribution of 32P-DNA was 
determined. The Oatt cmRas20 TRAP or the 8att-cmRas20 TRAPs were incubated 
alone (-) or with a 10-fold excess of noncomplementary NC20 (NC) or complementary 
regDNA-cmRas20. The dashed line shows the position of 32P-ATP in the gel after 
electrophoresis. The numbers show the % of the total 32P-TRAP in the corresponding 
band in this experiment. Average numbers for all experiments are given in the main 
text. 
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Figure 8. Discrimination of single base mismatches by a 9att-cmRas15 TRAP. 
A 9att-cmRas15 TRAP with a 15 nt antisense intervening sequence and a 9 nt 
attenuator was tested for its ability to be activated at 37°C by four regDNA-cmRas15: 
a perfect match (black squares), a single base-pair mismatch at position 7 on the 15nt 
regDNAm-cmRasI5 in which the perfect match (G) was changed to A for a C::A 
mismatch (gray squares, regDNAm7A-cmRas15) or to C for a C::C mismatch (white 
triangles, regDNAm7C-cmRas15), orin which the perfect match (TG) at positions 6 and 
7 were changed to CA for a CA::AC mismatch (black circles, regDNAm6C7A-
cmRas15). The regDNA to TRAP ratio was varied over a 20-fold range. The 
incubations were performed at 37°C and the results are expressed as percent of 9att-
cmRas15 TRAP DNA bound to ATP with a background of 13% (nonspecific binding) 
subtracted. The background binding was determined using two oligonucleotides with 
randomized sequences, one of the TRAP and the other of the aptamer. The same 
average % bound was found for both randomized sequences. Each datapoint is an 
average of the results from between 2 and 8 experiments in which each experimental 
value was the average of two independent estimates. 
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TABLES AND FIGURES 
Table 1: Attenuator effect on the thermodynamics of the interaction of regDNA-
cmRas20 and 8att-cmRas20 TRAP 
Oligonucleotide Assumption 
of the Fitting 
model 
N AH 
(kcal/moL) 
AS 
(cal/moL) 
AG 
(kcal/moL) 
20mer 1n 1.0 -110 -313 -12.1 
0att-cmRas20 TRAP 2n 0.5 -81 -217 -14.0 
0.7 -67 -178 -12.1 
8att-cmRas20 TRAP 1n 0.9 -82 -225 -11.5 
Thermodynamic parameters were obtained from fitting ITC data for the 
interaction of the regDNA-cmRas20 with either the 0att-cmRas20 TRAP or the 8att-
cmRas20 TRAP (Materials and Methods). In each case the first oligonucleotide was 
placed in the cell at 2.5 or 5 pM initial concentration. The second oligonucleotide was 
titrated into the cell with 25 injections and to a final ratio of about 1.8 over the first 
oligonucleotide. Each oligonucleotide pair was tested in two protocols, each protocol 
using a different member of the pair titrated into the cell. The plots were fit 
mathematically using algorithms that assume a single (1 n) or two (2n) alternate binding 
complexes between the interacting oligonucleotides. The results from both protocols 
were averaged for the results shown in this table. 
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SUPPORTING INFORMATION 
A. Oligonucleotides Used in This Study 
The following tables list the sequences of the oligonucleotides used in this study and 
discuss the nomenclature for each. 
ATP DNA Aptamer: CCTGGGGGAGTATTGCGGAGGAAGG 
ATP DNA TRAPs 
The TRAPs cited in the manuscript differ by the length and sequences of their intervening 
sequences and the length of their attenuators. In the list below the intervening sequence is bolded 
and the attenuator is underlined. 
polyTG-TRAPs: 
All polyTG TRAPs used in this manuscript had 20 nt intervening sequences. Their attenuator 
sequences varied in length as decribed below: 
Oatt-polyTG TRAP: CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTT 
5att-polyTG TRAP: CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCCGCA 
8att-polyTG TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCCGCAATA 
10att-polyTG TRAP: 
CCT GGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCCGCAATACT 
12att-polyTG TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCCGCAATACTCC 
14att-polyTG TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGTTTTTTGTTTTTGTTTTGTTCTCCGCAATACTCC 
cmRas TRAPs: 
Two different lengths of intervening sequences were used for these TRAPs. Therefore they are 
identified by the length of the attenuator (#att) and the length of the intervening sequence 
(cm Ras20 or cm Ras15): 
0att-cmRas20 TRAP: CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCGGCGG 
6att-cmRas20 TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCGGCGGCCGCAA 
8att-cmRas20 TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCGGCGGCCGCAATA 
10att-cmRas20 TRAP: 
CCTGGGGGAGTATT GCGGAGGAAGGGTACTCCTCAGGGCCGGCGGCCGCAATACT 
9att-cmRas15 TRAP: 
CCTGGGGGAGTATTGCGGAGGAAGGGTACTCCTCAGGGCCCCGCAATAC 
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Regulatory DNAs: 
A) ssDNAs that are completely complementarity to the TRAP intervening sequence, where # is the 
nt length of the DNA: 
1) regDNA-polyAC20: AACAAAACAAAAACAAAAAA 
2) regDNA-cmRas20: CCGCCGGCCCTGAGGAGTAC 
3) regDNA-cmRas15: GGCCCTGAGGAGTAC 
B) ssDNAs that are complementarity to the TRAP intervening sequence but contain some 
noncomplementary bases: regDNA15m##, where the ## represents the positions(s) of 
mismatch(es) within the intervening sequence. Mismatches are also identified in the sequences by 
lower case letters. 
1) regDNA-cmRas15m7a: GGCCCT a AGGAGTAC 
2) regDNA-cmRas15m6a,7a: GGCCCc a AGGAGTAC 
3) regDNA-cm Ras15m7c: GGCCCT c AGGAGTAC 
C) ssDNAs that contain a central region of 20 bases complementary to the 8att-cmRas20 TRAP 
intervening sequence and that is surrounded by a terminal sequences of 15 As on each side 
1) regDNA-cmRas20-ext 
A AAAA AAAA A AA A A A CCGCCGGCCC TGA G GAG TAC AA AA A A A AAAA AA A A 
cmRas sequences 
ssDNAs that contain the 20 base sequence of cmRas that is also in the cmRas20TRAPs. This 
sequence is complementary to the regDNA-cmRas20 
1) cm Ras20: GTACTCCTCAGGGCCGGCGG 
1) crDNA-cmRas20-ext: 
TTTTTTTTTTTTTTTGTACTCCTCAGGGCCGGCGGTTTTTTTTTTTTTTT 
cAtts: 
ssDNAs containing a sequence that is complementary to the attenuator, where the first number is 
the number of bases in the complementary attenuator and the second number is the length of the 
oligonucleotide. The region complementary to the attenuator is underlined and italicized. 
0cAtt20: AACAAAACAAAAACAAAAAA 
5cAtt20: TGCGGAACAAAACAAAAACA 
8cAtt20 : TA TTGCG GAAC A A A AC A AAA 
10cAtt20: AGTATTGCGGAACAAAACAA 
12cAtt20: GGGAGTATTGCG AACAAAAC 
14cAtt20: GGAGTATTGCG G A G A AC A A A 
108 
Noncomplementary sequences 
Sequences that are not complementary to any of the other sequences listed above. These 
sequences were created by picking random sequences or by shuffling sequences listed above. 
Shuffled sequences are referred to with the prefix Sh followed by the name of the sequence that 
was shuffled. 
Random: 
1 ) NC30: TCGCCACTAAATCATCGACGGATGTGCGGT 
2) NC20: CTACAATGTCACCTCCATCC 
2) NC20ext15: TTTTTTTTTTTTTTTGGATGGAGGTGACATTGTAGTTTTTTTTTTTTTTT 
Shuffled: 
Sh8attcmRas20TRAP: 
GGGCCGGGACCATATAGCGGTTACGAGGGGGCGGAGACGGACCCGCGTATTTC 
ShATP DNA Aptamer: GGGGGTAAAGTATTCCGGGGCGGGA 
Sh8att-polyTG20 TRAP: 
GACTGTATTGGGTGCTGTCTTTTATAGGTCTGAGTAAAGTGGGCTTTGTGCTT 
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B. Comparison of the Activity of a Fully Activated TRAP with the Unmodified 
Aptamer. 
The activity (% total 32P-DNA bound) of the aptamer was compared with that of the 
8att-cmRas20TRAP and the 9att-cmRas15 TRAP in the presence of a range of 
concentrations of regDNA-cmRas20 or regDNAcmRas15 respectively are shown in 
Figure S1. The concentration of the TRAP ranged from 0.067-0.67 pM for different 
experiments. These experiments were performed at 37°C. In each experiment, 
independent duplicates were used to determine the percent of aptamer of TRAP bound 
to ATP. For the data shown, the results for the 8att-cmRas20TRAP are the averages 
of 2-6 experiments and the results for the 9att-cmRas15 TRAP are averages of 10-14 
experiments. In each experiment, the average result for activated TRAP was divided 
by the average result for aptamer to give a value for the activity of the TRAP as a 
percentage of the aptamer activity. The number of experiments contributing to each 
value are shown above each bar. White bars, 8att-cmRas20TRAP and regDNA-
cmRas20; Black bars, 9att-cmRas15 TRAP and regDNA-cm Ras 15. The results show 
that a fully activated TRAP has the same activity as the unmodified aptamer. 
20nt 
6 8 9 10 0 8 10 12 
attenuator length 
Figure S1. Activities of Activated TRAPs as 
a fraction of the activity of the unmodified 
ATP DNA aptamer 
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C. Effect of attenuator length on the ATP Binding Activity of cmRas TRAPs 
cmRas20 and cm Ras 19 TRAPs were prepared with a range of attenuator lengths and 
tested for the ability of the complementary regDNA-cm Ras to activate ATP binding 
activity. The cm Ras 15 TRAPs were tested at 37° C with and without regDNA-cm Ras 15 
and the cmRas20 TRAPs were tested at 23°C with and without regDNAcmRas20. For 
both TRAPs, the ratio of regDNA to TRAP was 2 to 1. The results demonstrate that, as 
for the polyTG20 TRAP, there is an optimal length of attenuator for aptamer regulation. 
For the TRAPs tested, the optimal attenuator length was 8 to 9nt. 
1.00 
0.75 
O) 
# 1-25 
c 
in 
0) 
E 
i 
o 0.50 
# 0.25 
2 10 20 
regDN A/TRAP 
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CHAPTER 4. THE USE OF TILED MICROARRAYS AND 
COMPUTATIONAL ANALYSIS TO SELECT ANTISENSE 
SEQUENCES FOR TESTING IN VIVO* 
A paper to be submitted to Nucleic Acid Research 
ABSTRACT 
The efficient identification of sequences in mRNAs that are effective targets for 
antisense oligodeoxynucleotides (ODNs) in vivo is an important goal. In vivo tests of 
antisense ODNs are time consuming and expensive. Therefore, we investigated 
computational and in vitro experimental methods to identify antisense sequences that 
are effective in vivo. The Lcn2 mRNA sequence was used for this analysis. Two 
computational programs with different RNA secondary prediction algorithms were 
tested and found to predict a range of potential antisense sequences. As an in vitro 
test of antisense activity, I determined the ability of the Lcn2 mRNA to hybridize with 
a tiled microarray of 20mers complementary to overlapping sequential sequences in the 
mRNA. Hybridization was performed under nondenaturing conditions and at salt 
concentrations that resemble those in the cell. From these preliminary computational 
and in vitro studies seven oligodeoxynucleotides (ODNs) were chosen to be tested 
further in vivo as antisense ODNs to target the Lcn2 mRNA. 
* The study done here is included in a manuscript which will be submitted to 
Nucleic Acid Research. The data in the manuscript done by other authors is not 
included here. In the manuscript, the worked done by other authors: Ahmed Awad and 
Xiaoling Song tested seven selected oligodeoxynucleotide as antisense ODNs to target 
the Lcn2 mRNA in mouse HC11 cells. Ahmed selected Bcl2 mRNA and with my help 
did similar tiled microarray experiments as I did here. Long Ou is finishing a more 
comprehensive statistical analysis for both Lcn2 mRNA and Bcl2 mRNA microarray 
data. Their results are briefly discussed with no data shown. 
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INTRODUCTION 
The sequence-specific silencing of gene expression by antisense 
oligodeoxynucleotides has attracted great interest in the development of effective gene 
therapies for a wide variety of diseases ( 1, 2). There are a number of requirements for 
successful oligodeoxynucleotide-mediated inhibition of protein biosynthesis through the 
antisense mechanism. These include high affinity and faithful base pairing specificity 
of the antisense-mRNA pair, intracellular delivery capability and stability of the 
antisense molecule to nucleases in the biological environment (3). All these 
requirements presuppose that the target site of the mRNA is accessible to the 
antisense oligodeoxynucleotides. During their synthesis RNA molecules quickly fold 
and arrange themselves into tertiary structures that can include a large variety of 
secondary structural motifs (4, 5) and are complicated by RNA-associated proteins (6). 
These secondary and tertiary structures of RNAs leave only a small fraction of RNA 
sequences available for efficient antisense oligodeoxynucleotide hybridization (7). 
Thus, the biological efficacy of each antisense oligodeoxynucleotide is strongly affected 
by its target site accessibility. Because of its fundamental importance to antisense 
technology, many approaches, experimental and computational, have been developed 
to identify optimum antisense accessible sites in mRNAs. 
In the direct test of in vivo efficacy oligodeoxynucleotides targeted to various 
regions of a mRNA are randomly chosen, synthesized individually and their antisense 
activities are measured (8, 9). However, this approach of empirically testing multiple 
oligodeoxynucleotides in vivo is expensive and very time consuming. The demands of 
time and expense limit coverage of the mRNA primary sequence investigated by this 
method and therefore a complete picture of the accessibility of all possible sites on a 
target mRNA is not obtained. 
Computer algorithms based on minimum free calculations (10-13) or partition 
function calculations followed by statistical sampling (14, 15) can predict secondary 
structures of RNA sequences to be used to identify target accessibility and the rational 
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design of antisense and nucleic acid probes (16-18). However, these computer 
programs do not predict tertiary structures that may also influence target accessibility. 
Moreover, long RNAs such as mRNAs, fold into many different structures with similar 
free energies that can each fold into one or more tertiary structures. The combined 
uncertainty of the in vivo distribution of secondary structures and their associated 
tertiary structures makes it very difficult to identify probable antisense sequences from 
a primary structure. 
Several in vitro approaches have been developed for identifying optimal target 
antisense sequences in mRNAs. One approach is to map the antisense-accessible 
sites on mRNAs by hybridization with random oligodeoxynucleotide libraries followed 
by either RNase H cleavage, or extension with reverse transcriptase (19-21). 
Hybridization of antisense oligodeoxynucleotides has also be analyzed by MALDI-TOF 
to identifying the accessible regions on an mRNA (22). 
Oligodeoxynucleotide arrays provide a simple tool for quantitative measurement of 
the binding of a set of complementary oligodeoxynucleotide sequences to a target 
RNA. In this method, an array of oligodeoxynucleotides covalently linked to a glass 
surface is used to measure heteroduplex formation with the corresponding target 
mRNA, which is radio- orfluorescently labeled. The results obtained with this approach 
show a good correlation between binding strengths and antisense activity in vivo (23, 
24). Since these studies were published computational methods for folding nucleic 
acids and identifying hybridization targets have been improved. 
As an in vitro test of antisense activity, I determined the ability of the Lcn2 mRNA 
to hybridize with a tiled microarray of 20mers complementary to overlapping sequential 
sequences in the mRNA. Hybridization was performed under nondenaturing conditions 
and at salt concentrations that resemble those in the cell. From these preliminary 
computational and in vitro studies seven oligodeoxynucleotides (ODNs) were chosen 
to be tested further in vivo as antisense ODNs to target the Lcn2 mRNA. The efficacies 
of oligodeoxynucleotides, identified by each method, were further tested as antisense 
oligodeoxynucleotides in vivo. 
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MATERIALS AND METHODS 
Oligodeoxynucleotides 
All oligodeoxynucleotides used in this study were purchased from Integrated DNA 
Technologies (Coralville, IA). The oligodeoxynucleotides used for the tiled microarray 
were 20mer oligodeoxynucleotides and were obtained in a 96-well plate at a total 
amount of 15 nmoles each. Eighty four oligodeoxynucleotides were designed as 
20mers that are complementary to the Lcn2 mRNA target from 5' to 3' in 10 nt 
overlapping intervals. 9 oligodeoxynucleotides with random sequences were also 
synthesized. Diethylpyrocarbonate (DEPC) treated-water was added to each well to 
give a final concentration of 100 mM per oligodeoxynucleotide. The plate was then 
stored at -20°C. 
Sequence and Materials Information 
Mus musculus lipocalin 2 (Lcn2) mRNA sequence is 853nt and the sequence can 
be obtained from NCBI.(NM_008491 ). The plasmid pcDNA3-Lcn2 has full length Lcn2 
cDNA sequence and T7 promoter upstream of Lcn2 cDNA. The sequence information 
of 84 antisense oligodeoxynucleotides can be derived from Lcn2 mRNA sequence 
easily. The antisense oligonucleotides were named by the position of the first 5' end 
nucleotide of the corresponding 20nt target sequences on Lcn2 mRNA. For example, 
oligodeoxynucleotide 1 targets 1-20 ntof Lcn2 mRNA, oligodeoxynucleotide 11 targets 
11-30 nt of Lcn2 mRNA, etc. The full name list of the 84 antisense 
oligodeoxynucleotides is in table 1. The sequences of the 9 random 
oligodeoxynucleotides are also listed in table 1. Corning Epoxide coated slides and 
Epoxide Coated Slide Starter Kit with 5ml Epoxide Spotting Solution are from Corning 
(Corning, NY). ChromsTide Alexa Fluor 546-14-UTP 1mM in TE Buffer and SYBR 
GREEN II are from Molecular Probes (Carlsbad, CA). The AmpliScribe T7 High Yield 
Transcription Kits is from Epicentre (Madison, Wl). The Micro Bio-Spin P30 
Chromatography Columns are from BioRad (Hercules, CA). The hybridization Cassette 
is from Arraylt Microarray Technology (Sunnyvale, CA). The cartesian PixSys 5500 
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Arrayer and General Scanning ScanArray 5000 is at Microarray Facility 
http://www.plantqenomics.iastate.edu/microarrav/eauipment/. 
Preparation of Fluorescently Labeled Lcn2 Transcripts 
Fluorescently labeled RNA transcripts for hybridization to the oligodeoxynucleotide 
arrays were synthesized by in vitro transcription. Lcn2 mRNA was prepared from the 
plasmid pcDNA3-Lcn2 that contains a T7 promoter sequence. The plasmid was 
linearized with EcoRI. Transcriptions of Lcn2 mRNA sequences were carried out in 20 
pi volume at 37°C for 2 hr in the presence of 2.5 mM each ATP, CTP, and GTP, 2.1 
mM DTP and 0.4 mM ChromaTide Alexa Fluor 546-14-UTP using AmpliScribe T7-
Flash Transcription Kit. After DNase I treatment, the RNA products were purified by 
Micro Bio-Spin P30 Chromatography Columns as described in the product protocol. 
The absorbances of RNA preparations (A260) and Alexa Fluor (A555) were measured 
and the base-to-dye ratio and concentration of the fluorophore-labeled RNA was 
determined according to the manufacturer's recommendations. 
Printing of The Oligodeoxynucleotides Arrays 
Antisense oligodeoxynucleotides were designed as 20mers that are complementary 
to the mRNA target from 5' to 3' in 10 nt overlapping intervals. The 
oligodeoxynucleotide solutions were transferred to a Corning 96-well microplate, dried 
by vacuum centrifugation and re-dissolved in two different printing solutions, Buffer A 
and Buffer B, to reach the desired concentrations. Printing solution A: Epoxide Spotting 
Solution from the Epoxide Coated Slide Starter Kit. Printing solution B: 150mM Dibasic 
Sodium Phosphate, DEPC treated H20, pH 8.5 at 23°C. Ninety three 20nt 
oligodeoxynucleotides were printed onto Corning epoxide coated slides according to 
the manufacturer's protocol (55% relative humidity during printing, followed by 
incubation at 70% relative humidity for 12-17 h). Some spots on the slides were printed 
with spotting solutions contain no oligodeoxynucleotides (as negative controls). 
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Pre-Hybridization 
Pre-hybridization was done immediately preceding the application of the 
oligodeoxynucleotides onto the arrays. This step has the purpose of blocking the 
unused surface of the slide and removing loosely bound oligodeoxynucleotides. The 
preparation of the hybridization solutions can be completed while the arrays are being 
pre-hybridized. Pre-hybridization solution consisted of 5 x SSC,0.1%SDS, and 0.1 
mg/mL acetylated bovine serum albumin (BSA). The 5 X SSC was diluted from 20 X 
SSC buffer. The 20 X SSC buffer contains 3M sodium chloride and 0.3M sodium 
citrate, pH 7.0 at 23 °C. The pre-hybridization solution was pre-warmed to 42 °C. 
Arrays were immersed in pre-hybridization solution and incubated at 42 °C for 45 to 60 
minutes. Pre-hybridized arrays were transferred into 0.1 xSSC diluted from 20 X SSC 
buffer and incubated at ambient temperature (22 to 25 °C) for 5 minutes to wash. The 
same wash was repeated twice for a total of three washes. The arrays were 
transferred to water and incubated at ambient temperature for 30 seconds then dried 
by centrifugation at 1,600 x g for 2 minutes. While completing preparation of the 
hybridization solution the arrays were maintained in a dust-free environment. 
Check The Printing Quality By SYBR GREEN II Staining 
To check whether the oligodeoxynucleotides had been successfully printed onto 
the glass slides, the procedure described by Simpson et al. (25) was used. 
Summarized briefly, the procedure uses SYBR GREEN II to stain the single stranded 
oligodeoxynucleotides on the array. After washing, the arrays were dried by 
centrifugation at 1,600 x g for 2 minutes. The arrays were scanned using the Scan 
Array 5000 scanner at the Microarray facility. SYBR GREEN II dye has a fluorescence 
excitation maximum at 494 nm and a fluorescence emission maximum at 512nm. After 
the slide was scanned, the SYBR Green II was removed according the procedure 
described in Simpson et al. (25) and used for hybridization. 
Array Hybridization And Image Analysis 
Arrays were hybridized under physiological conditions using the hybridization buffer 
117 
(25 nM Alexa Fluor 546-14-UTP labeled Lcn2 mRNA, 0.2ug/ul of yeast tRNA, 0.2ug/ul 
of polyadenylic acid, 1 U/ul RNase Inhibitor, 13.5 mM NaCI, 150 mM KCI, 0.22 mM 
Na2HP04, 0.44 mM KH2P04, 100 pM MgS04, 120 nM CaCI2, 120 |jM MgCI2, 6 mM 
glutathione, 20 mM HEPES, pH 7.25). The array was covered with a cover glass and 
100 pi hybridization buffer was pipetted onto the arrayed surface. The slide was then 
transferred to a hybridization chamber and left for hybridization at 37°C for 16 h. After 
washing twice in 1 X SSC buffer, 2 min each followed by washing twice in 0.1 X SSC, 
1 min each, the slide was dried by centrifugation at 1,600g for 2 min and scanned using 
a Scan Array 5000 scanner. Alexa Fluor 546-14-UTP dye has a fluorescence excitation 
maximum at 550nm and a fluorescence emission maximum at 570nm. The image was 
analyzed using the microarray analysis software (GridGrinder, a free microarray 
analysis software released by Corning. Free download 
http://qridarinder.sourceforae.net/ ). 
Lcn2 MRNA Secondary Structure Prediction 
The secondary structures of Lcn2 mRNAs were estimated using the Mfold and 
Sfold web servers for nucleic acid secondary structure prediction. The Mfold web 
server for RNA secondary structure predict ion is located at 
http://www.bioinfo.rpi.edu/applications/mfold/old/rna/ (12) and the Sfold web server is 
located at http://sfold.wadsworth.ora/index.pl (17). For both programs, the default 
setting were used to predict Lcn2 mRNA secondary structures. 
Prediction of Effective Antisense Oligodeoxynucleotide For Lcn2 MRNA 
In this study, I chose two programs to predict the effective antisense 
oligodeoxynucleotides for the Lcn2 mRNA. Both programs are freely available from 
internet. OligoWalk is part of a software package, called RNA structure, based on the 
Mfold algorithms to predict antisense affinity to mRNA (76). The free software package 
can be downloaded at http://128.151.176.70/RNAstructure.html. Sfold is a software 
package developed by Ding et al.(17). It is free to use at 
http://sfold.wadsworth.ora/index.pl . The algorithm for the Sfold is based on the 
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equilibrium partition function of RNA secondary structures and a statical sampling 
algorithm. Soligo is the program in Sfold developed for antisense target accessibility 
prediction and rational design of antisense oligodeoxynucleotides. 
The Lcn2 mRNA sequence was analyzed using OligoWalk and Soligo, respectively. 
For OligoWalk, the first RNAFold program in RNAstructure (version 4.2) was used to 
fold the Lcn2mRNA. When RNAFold was used, the default parameters for the 
suboptimal structures are: Max% energy difference: 10%. Max Number of structures: 
20. Window size: 15. The temperature was set to 37 °C. After the mRNA was folded, 
the OligoWalk program was used to predict the effective antisense oligonucleotides 
using default settings. The default selection for the mode is: Break local structure. 
Other parameters also need to be defined. As part of the default set up, the target 
(Lcn2 mRNA) suboptimal structures were not included in the free energy calculation. 
The antisense oligo was set to DNA. (RNA is another choice). The length of antisense 
oligo is 20nt and the concentration was set to 1pM (Default). 
The RNAstructure software package was a free download and installed on a PC. 
The Sfold software had to be used through the internet. The length of antisense 
oligodeoxynucleotides was also set to 20nt in Soligo. The temperature used in Soligo 
was also 37 °C. 
RESULTS 
Design of Antisense Oligodeoxynucleotide Microarray Targeting Lcn2 MRNA 
As shown in Fig. 1C, there are 96 spots on each subgrid. It included 84 antisense 
oligodeoxynucleotides, 9 random sequences and 3 spots that contain only buffer. Two 
different printing solutions: Buffer A and Buffer B were used to print the same set of 
oligodeoxynucleotides. For Buffer A, three oligodeoxynucleotides concentration were 
used: 200 pM, 150 pM and 80 pM. For Buffer B, only 80 pM oligodeoxynucleotide 
concentration was used. The arrangement of four subgrids: A200, A150, ABO and B80 
within one MegaGrid is shown in Fig. 1B. The MegaGrid was repeated 12 times on a 
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single slide as shown in Fig. 1C. In this design, each oligodeoxynucleotide was 
repeated 12 times each time with a different combinations of buffer and 
oligodeoxynucleotide concentrations. 
SYBR Green II Staining To Check Printing Quality 
The SYBR Green II staining results are shown in Fig.2. A picture of the slide is 
shown in Fig.2E. Examples of the staining results of subgrids A200, A80, A150 and 
B80 are shown in Figs.2 A, B, C, and D respectively. 
Hybridization Results of Alexa Fluor 546-14-UTP Labeled Lcn2 MRNA With 
Oligodeoxynucleotide Microarray 
After hybridization, the slide was scanned (Fig. 3 E). Examples of hybridization 
results of subgrids A200, ABO, A150 and B80 are shown in Fig.3 A, B, C, and D 
respectively. The subgrids shown here are the same as shown in Fig.2. The 
fluorescence intensity value of 4608 (96 X 12 X 4 = 4608) spots from 48 subgrids on 
one slide was read using GridGrinder. For each spot, the local background value was 
subtracted from the spot fluorescence intensity value. The local background value is 
the fluorescence intensity value just outside the defined spot area and was identified 
by the Gridgrinder program. This step was done for all the spots including the spots 
containing only buffer. After local background subtraction, the spots of ABO and B80 
were chosen to be analyzed further. For 1152 (96 X12) spots from 12 subgrids of ABO, 
the average readings from the spots that containing only buffer were subtracted from 
the readings of spots containing oligodeoxynucleotides. The negative values obtained 
after the subtraction were set to zero. The 8 random sequences (R2 to 9) were treated 
as one oligodeoxynucleotide and named as Random Oligo. The R1 was not included 
because from the printing results, R1 was printed on the row 1, column 5 of each 
subgrid and it was not well printed. Each oligodeoxynucleotide in ABO has 12 repeats 
on one slide. The 12 values of each antisense oligodeoxynucleotide were averaged 
and a normalized value was calculated for each oligodeoxynucleotide by dividing its 
averaged value by the average value of the Random Oligo defined above. The 
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normalized value for each of the 84 antisense oligodeoxynucleotides was plotted in 
Fig.4. For 1152 (96 X12) spots from 12 subgrids of B80, the same procedure was 
followed. The corresponding normalized values for B80 subgrids are plotted in Fig.5. 
Antisense Oligodeoxynucleotide Prediction By OligoWalk and Soligo 
853 nt Lcn2 mRNA was analyzed by Oligowalk and Soligo for antisense 
oligodeoxynucleotides prediction, respectively. There are total 834 20nt antisense 
oligodeoxynucleotides for Lcn2 mRNA because the last 19nt sequences on the 3' end 
of Lcn2 mRNA is not long enough for 20nt antisense oligonucleotide. For each 
antisense oligodeoxynucleotide, its predicted effectiveness for targeting Lcn2 mRNA 
was given in the form of the Gibbs free energy (AG). The lower the AG value, the more 
effective the antisense oligodeoxynucleotide. From the predictions of Oligowalk, the 
25 antisense oligodeoxynucleotides with the lowest AG values of the 834 antisense 
oligodeoxynucleotides are shown in Fig. 7A. From the predictions of Soligo, the 25 
antisense oligodeoxynucleotides with the lowest AG value of the 834 antisense 
oligodeoxynucleotides are shown in Fig. 7B. 
DISCUSSION 
In this study, I used tiled oligodeoxynucleotide microarrays combined with 
computational analyses to select antisense oligodeoxynucleotide candidates for further 
in vivo testing. The high throughput ability of oligodeoxynucleotide microarray 
experiments allows the screening of large number of oligodeoxynucleotides 
simultaneously. As shown in Fig. 1,1 was able to test 96 spots with 12 repeats for each 
spot in each of four different combinations of printing solution and oligodeoxynucelotide 
concentration on one slide. Because I only needed to test 83 antisense 
oligodeoxynucleotides for Lcn2 mRNA I could also test different printing solutions and 
vary the concentration of oligodeoxynucleotides. With the printing conditions optimized, 
further experiments can test many more oligodeoxynucleotides per slide. The 
hybridization was done at the physiological buffer condition and 37 C°. This maximizes 
the possibility of selected antisense oligodeoxynucleotides that work in vivo. 
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From the results shown in Fig.2, the printing was successful. For A200, the 
smearing of some of the spots indicates that the concentration of oligodeoxynucleotides 
was too high. For A150 and A80, even though there was some variation among spots, 
the overall printing quality was acceptable. ForBSO, the spots were small but appeared 
to be printed more evenly than B80 and B150. Notice that on the first row of all 
subgrid's there were several spots that were printed significantly less intensely than the 
majority. This was especially true for the B80 subgrids. As shown on Fig. 2D, on the 
B80 subgrid, the missing spots from row 1, column 5 to 12 corresponded to 
oligodeoxynucleotides: R1, 721, 601, 481, 361, 241 , 121 and 1, respectively. For the 
A200, A150 and A80 subgrids, the corresponding oligodeoxynucleotides were in the 
same positions. On the grids printed using buffer A, these same 8 
oligodeoxynucleotides were printed less intensely compared to others. On the grids 
printed using buffer B these 8 oligodeoxynucleotide can not be seen by the naked eye. 
This is because the amount of oligodeoxynucleotide printed by buffer B was less than 
it by buffer A. The possible reasons for the poor printing of these 8 
oligodeoxynucleotides could be errors in sample preparation or poor performance of 
certain printing pins of the Arrayer used to print the oligodeoxynucleotides. Because 
of the poor printing of these 8 oligodeoxynucleotides, the results got from these 
experiments may not reflect the true effectiveness of these 7 antisense 
oligodeoxynucleotides. Further experiments need to be carried out to address this 
issue. After examining the staining results using the color scale provided in Fig. 2F, 
except for the 8 oligonucleotides mentioned above, all the other oligodeoxynucleotides 
were found to be printed evenly with small variations between different spots. Buffers 
A and B both gave usable printing results at the 80 pM oligodeoxynucleotides 
concentration. Further optimization for buffer A should reduce the number of the 
donuts spot. For buffer B, even though the oligodeoxynucleotides were more evenly 
distributed in the spots, the spot morphology and the amount of oligodeoxynucleotide 
printed needs to be improved. 
The hybridization results shown in Fig. 3 showed large differences between 
antisense oligodeoxynucleotides in terms of fluorescence intensity after hybridization. 
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With the naked eye and based on the color scale in Fig. 3F, one can see that the 
intensity of several spots are close to saturation (white). These big differences can not 
be explained by the variations in oligodeoxynucleotides printed. For example, in Fig. 
2, the spot on row 5, column 8 of each subgrid has stronger signal compared to the 
other two spots on row 6, 7 of column 8. After hybridization, the two spots with less 
printing signal had much stronger hybridization signals than other spots with strong 
printing signals. Another example is the spot on row 2, column 2 that has very strong 
hybridization signal whereas its printing signal is not much different from the spots 
around it. Combining the results of visual examination on Fig. 2 and Fig. 3, the primary 
conclusion was that there were big differences in hybridization with Lcn2 mRNA among 
the tested antisense oligodeoxynucleotides on the microarray slides. 
Further quantitative analysis of the hybridization results supported the judgement 
based on the visual examination. The results shown in Figures 4 and 5 indicated 
antisense oligodeoxynucleotide 741 had the strongest interaction with Lcn2 mRNA. Its 
hybridization signal was the strongest in both sets of results. The top 10 antisense 
oligodeoxynucleotides from this analysis are listed in table 2. There were two 
differences in the predictions of optimal antisense oligodeoxynucleotides in the top 10 
list of the two printings (A80 and B80) of the microarray. Oligodeoxynucleotide 431 is 
in A80 top 10 list but not in B80 topi 0 list. Oligodeoxynucleotide 491 is in B80 top 10 
list but not in A80 top 10 list. The other 9 antisense oligodeoxynucleotides were 
common between these two analysis. The random oligodeoxynucleotides showed very 
low hybridization signals. The average fluorescence intensity of Random Oligo is 187 
in ABO and 128 in B80 whereas the average fluorescence intensity of 
oligodeoxynucleotide 741 is 55956 in A80 and 51820 in B80. This indicated that the 
assay was reproducible. All the top 10 antisense oligodeoxynucleotides in both A80 and 
B80 analysis had much larger hybridization signal than the others. This indicated that 
the assay had a sufficient range to allow identification of the best binders. For the 
purpose of this work, which was to select the antisense oligodeoxynucleotides 
candidates for further in vivo testing, the existence of several antisense 
oligodeoxynucleotides with very strong hybridization signals shown in Fig.4 and 5 made 
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the selection much easier. In support of the analysis shown here, Long Qu used the 
same original data from GridGrinder and independently did a similar data analysis. His 
results are consistent with the ones I describe here. 
In Fig. 6, the top 25 antisense oligodeoxynucelotides in the results of A80 and B80 
are shown in Fig. 6A and Fig. 6B, respectively. The overall normalized value of 
fluorescence intensity in A80 (Fig. 6A) is less than it in B80 (Fig. 6B). The average 
fluorescence intensity of Random Oligo is 187 in A80 and 128 in B80. It is about 1.5 
times difference in the average fluorescence intensity of Random Oligo between A80 
and B80. The overall lower normalized value of fluorescence intensity of A80 shown 
in Fig. 6A is most likely due to the higher fluorescence intensity of the Random Oligo 
used to normalize this dataset. Olgonucleotides 1, 361 and 601 are in Fig. 6A but not 
in Fig. 6B. Olgonucleotides 231, 391 and 611 are in Fig. 6B but not in Fig. 6A. The 
small number of differences in the lists of top 25 oligodeoxynucleotides between A80 
and B80 indicates the results from A80 and B80 are very similar. This is consistent with 
the results shown in table 2. 
Neither I nor Long included the quantitative value of the printing results in the 
analysis. Normalization of hybridization results to hybridization results of random 
sequences, based on the assumption that the printing efficiency is consistent 
throughout the microarray, is generally a good practice to improve the data quality. 
Given the large difference of the values for the top 10 antisense oligodeoxynucleotides 
shown in Fig.4, 5 and the considering the generally evenly printing results shown in Fig. 
2, normalization of hybridization results to printing results probably will not significantly 
change the results from these microarrays although it may reduce the errors. 
By contrast with the results from the microarray in which several antisense 
oligodeoxynucleotides stood out, the computational analyses did not produce similar 
results. In Fig. 7A, the top 25 antisense oligodeoxynucleotides in the results of 
Oligowalk prediction are shown. In Fig.7 B, the top 25 antisense oligodeoxynucleotides 
in the results of Soligo prediction are shown. In both results, the AG values of the 25 
antisense oligodeoxynucleotides are in a small range. All 834 antisense 
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oligodeoxynucleotides were tested computationally. The minimum difference between 
each antisense oligodeoxynucleotide was 1 nt for the computational analyses, whereas 
in the difference between antisense oligodeoxynucleotides in the microarray it was 
10nt. The 1 nt minimum difference may result the top 25 antisense 
oligodeoxynucleotides concentrating in several regions as shown in Fig. 7 for both 
programs. But even considering this difference between the two analyses, the two 
computational analysis did not clearly distinguish a small number of optimal antisense 
oligodeoxynucleotides such as the predictions of oligodeoxynucleotide 741 and 501 
that came from the microarray experiments. 
In table 2, the top 10 antisense oligodeoxynucleotides from the Oligowalk prediction 
did not match with the Soligo prediction. The different computational approaches taken 
by these two methods may result in their different predictions. Oligowalk is an Mfold 
based method {16). The secondary structure of the target mRNA is predicted using a 
free energy minimization algorithm. Based on the predicted secondary structure, the 
final overall AG (AG overall) value as shown in Fig. 7A was calculated for each antisense 
oligodeoxynucleotide based on the AG of several interactions. These interactions 
include the free energy needed to break the target's local folding (AGb), the free energy 
of antisense oligodeoxynucleotide self folding (AGs), the free energy of interaction 
between antisense oligodeoxynucleotides (AG|) and the free energy of duplex forming 
between antisense and its target sequences (AGDUP,EX) . The AGOVERA„ is calculated by 
subtracting the AGB, AGsand AG;from AGDUPLEX (16). Different from OligoWalk method, 
the Soligo method is based on the algorithms developed by Ding et al.(14, 15, 17). In 
Soligo, the single stranded probability profile of the target mRNA sequences was 
estimated by a statistical sampling algorithm according to the Boltzmann equilibrium 
distribution which uses the calculated partition function of the target RNA secondary 
structure (18). The single stranded probability profile of the target mRNA sequence 
was incorporated into the prediction of the effective antisense sites. The AGB, AG| AGS, 
and AGDUPLEX are still taken into account. Sfold algorithms also utilizes free energy 
parameters obtained from experiments to calculate the partition function. The statistical 
sampling algorithm in Soligo provides a representative single stranded probability 
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profile based on all possibilities of secondary structures of target mRNAs, whereas the 
Oligowalk algorithm only uses the secondary structures with minimum free energy 
(MFE) or the structures with free energy within certain range of MFE. This difference 
may result in the different prediction results for Lcn2 mRNA seen in Fig. 7 and table 2. 
Based on the results from three different methods, microarray, Oligowalk and 
Soligo, and the predicted Lcn2 mRNA secondary structure by Mfold and Sfold, 7 
antisense oligodeoxynucleotides were selected for further in vivo testing. In table 3 and 
Fig.8 the detailed information and the predicted folding of the related target sequences 
on Lcn2 mRNA are summarized for these 7 oligodeoxynucleotides. The most stable 
secondary structure of Lcn2 mRNA is almost identical when predicted by Mfold and 
Sfold . So in Fig.8, the secondary structure of Lcn2 mRNA predicted by Mfold is 
shown. 
Loop structures in RNAs can promote antisense activity (26) and RNA/RNA 
interaction (27). In Fig. 8, the region A was a hairpin loop structure. In table 3, 
oligodeoxynucleotide 252 received a low AG from both Oligowalk and Soligo prediction. 
Oligodeoxynucleotide 251 showed up in both in the A80 and B80 top 10 list but received 
a higher AG from both Oligowalk and Soligo prediction compared to 
oligodeoxynucleotide 252. Combining the information above, oligodeoxynucleotide 252 
was chosen as one of the seven antisense oligodeoxynucleotides. 
Oligodeoxynucleotide 735 was chosen for similar reasons. The target sequences of 
oligodeoxynucleotide 735 overlapped with the best antisense oligodeoxynucleotide 741 
based on the results of microarray experiments. The target region of 
oligodeoxynucleotide 735 has two loop structures as shown in region D of Fig.8. It 
received low AG values from both the Oligowalk and Sfold predictions. Based on the 
same reasons listed above oligodeoxynucleotide 735 was also selected for in vivo 
testing. As shown in Fig. 4 and 5, oligodeoxynucleotides 501 and 561 had very high 
hybridization signals, second only to the highest signal of oligodeoxynucleotide 741. 
Oligodeoxynucleotide 561 received poor ratings from both the Oligowalk and Soligo 
predictions, as indicated by the high AG value shown in table 3. Oligodeoxynucleotide 
126 
501 received a good rating from the Oligowalk prediction and a poor rating from the 
Soligo prediction as indicated by corresponding AG values shown in table 3. The 
results of these two antisense oligodeoxynucleotides from in vivo testing can provide 
useful information for the evaluating the three methods. So they were both selected. 
The target region of oligodeoxynucleotides 581 and 591 are shown in region C of 
Fig. 8. It is a region rich in loop structures. Oligodeoxynucleotides 561 and 571 both 
had good hybridization signals whereas oligodeoxynucleotide 581 and 591 both had low 
hybridization signals as shown in Fig 4 and 5. Oligodeoxynucleotide 581 and 591 
received good ratings from both the Oligowalk and Soligo predictions as indicated by 
the low AG values shown in table 3. The target sequences of oligodeoxynucleotide 561 
is also located in region C of Fig.8. The structures of the target sequences of 
oligodeoxynucleotides 581 and 591 are similar to the structure of the target sequence 
of oligodeoxynucleotide 561 (Fig. 8C), yet, the results of the analyses of the efficacy of 
oligodeoxynucleotides 581 and 591 for hybridizing with the full-length mRNA from the 
microarray experiment and computational analysis are quite different from the results 
for oligodeoxynucleotide 561. Whereas the microarray showed that the 
oligodeoxynucleotide 561 was a much better antisense ODN than 
oligodeoxynucleotides 581 and 591, the computational analysis indicated that the 
oligodeoxynucleotide 581 and 591 were much better antisense ODNs than 
oligodeoxynucleotides 561. Therefore comparison of these oligonucleotides by in vivo 
testing should provide a basis for the evaluating the three methods. So 
oligodeoxynucleotides 581, 591 and 561 were selected for in vivo testing. The 
oligodeoxynucleotide 741 was also selected for its high hybridization signal in the 
microarray as shown in Figures 4 and 5. 
From these preliminary computational and in vitro studies, seven 
oligodeoxynucleotides (ODNs) shown in table 3 were chosen to be tested in vivo as 
antisense ODNs to target the Lcn2 mRNA of the mouse HC11 cell line. Each of the top 
three microarray-chosen ODNs ( Oligodeoxynucelotides 501, 561 and 741 ) decreased 
the Lcn2 protein level as demonstrated by Western blot analysis. Also, they caused 
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a reduction in the Lcn2 mRNA level as determined by real-time RT-PCR. The other 
four selected Oligodeoxynucelotides 252,581,591 and 735 failed to decrease the level 
of Lcn2 protein or mRNA. 
In a study done by Devireddy et al. (28), two phosphorothioate oligonucleotides 
were used as antisense ODNs to inhibit Lcn2 expression. Antisense ODNs 1 targeting 
11 - 27 nt of Lcn2 mRNA and antisense ODNs 2 targeting 607 - 615 nt of Lcn2 mRNA. 
FI5.12 cell were transfected with 2 pM of each antisense ODNs. Both antisense ODNs 
were found out to reduce the Lcn2 expression level and antisense ODN 1 was shown 
to be particularly effective (28). Antisense ODN 2 (targeting 607-615 nt of Lcn2 mRNA) 
was only 8 nt long. The 20 nt oligodeoxynucleotide 601 was listed as one of the top 
25 antisense ODNs in the ABO microarray results (Fig. 6A ) and the 20 nt 
oligodeoxynucleotide 611 was listed as one of the top 25 antisense ODNs in B80 
microarray results (Fig. 6B). Even though the length of antisense ODNs is different, the 
results from microarray experiments show some agreement with the experiment results 
of antisense ODN 2. The similar agreement about antisense ODN 2 was not found in 
the results of computational analysis (Fig. 7). Antisense ODN 1, is not listed as one of 
the top 25 antisense ODNs identified by our microarray experiments and computational 
analyses. This indicates the strength and accuracy of the tiled microarray experiments 
may need to be further tested. However, we have also not tested the efficacy of ODN 
1 as an antisense oligonucleotide. 
As a second example of testing the effectiveness of microarrays for predicting 
functional antisense oligonucleotides, the Bcl-2 mRNA coding sequence was examined 
for antisense ODNs hybridization using microarray. The microarray results were found 
to be consistent with previous reports of RNA sequence accessible to antisense ODN 
hybridization in vivo. Together, these results show that the in vitro microarray analysis 
predicted appropriate sequences for effective antisense ODNs in vivo with better 
accuracy compared to the prediction from computational analyses. 
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FIGURE LEGENDS 
Figure 1. Design of the Oligodeoxynucleotide Microarray 
( A ) The schematic representative of the design fo a single microarray slide. Each 
slide contained 12 MegaGrids. Each MegaGrid contains 4 subgrids. All 12 MegaGrids 
were the same except the position on the slide. 
( B ) The schematic representative of the design of a single MegaGrid. Each 
MegaGrid contains 4 subgrids. The composition of oligodeoxynucleotides on the 4 
subgrids are the same. But either the printing solution used or the concentration of the 
oligodeoxynucleotides are different. Buffer A was printing solution A. Buffer B was 
printing solution B. The concentration of oligodeoxynucleotides used to print each 
subgrid is shown. For the subgrids where the buffer A and 200 pM 
oligodeoxynucleotides were used, the subgrids were named A80. For the subgrids 
where the buffer A and 150 pM oligodeoxynucleotides were used, the subgrids were 
named A150. For the subgrids where the buffer A and 80 pM oligodeoxynucleotides 
were used, the subgrids were named A80. For the subgrids where the buffer B and 80 
pM oligodeoxynucleotides were used, the subgrids were named B80. Each MegaGrid 
contains four subgrids: A200, A150, A80 and B80. MegaGrid was repeated 12 times 
on each slide. So on one slide there are 12 subgrids of A200, A150, A80 and B80, 
respectively. 
( C ) The schematic representative of the design of a single subgrid. Each subgrid has 
96 spots printed on it. The spots in red identify the positions in which the buffer without 
oligo was printed. The spots in green identify the positions in which each of nine 
oligodeoxynucleotides with random sequences (R1 to 9 in table 1 ) were printed. The 
spots in black are the 84 antisense oligodeoxynucleotides targeting Lcn2 mRNA. 
Figure 2. The SYBR Green II Staining Results 
The microarray slide was stained by SYBR Green II after pre-hybridization. The results 
of whole slides (E) as well as examples of four different subgrids were shown here. A 
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rainbow color scale (F) from blue to red plus white for maximum intensities was used 
by the Scanner used to represent the relative fluorescence intensities. 
(A) An example of a subgrid using buffer A and 200 (JM oligodeoxynucleotides (A200). 
The subgrid was taken from Mega Row 3, MegaColumn 1 of the slide as shown in E. 
(B) An example of a subgrid using buffer A and 80 pM oligodeoxynucleotides (A80). 
The subgrid was taken from MegaRow 3, MegaColumn 2 of the slide as shown in E. 
(C) An example of a subgrid using buffer A and 150 pM oligodeoxynucleotides (A150). 
The subgrid was taken from MegaRow 4, MegaColumn 1 of the slide as shown in E. 
(D) An example of subgrid using buffer B and 80 pM oligodeoxynucleotides (B80). The 
subgrid was taken from MegaRow 4, MegColumn 2 of the slide as shown in E. 
Figure 3. The Hybridization Results 
The hybridization results of whole slides (E) as well as examples of four different 
subgrids are shown. The four subgrids shown here are the same as shown in Fig. 2. 
The same rainbow color scale (F) as in Fig. 2 was used by the Scanner to represent 
the relative fluorescence intensities. 
(A) Subgrid A200 taken from MegaRow 3, MegaColumn 1 of the slide as shown in E. 
(B) Subgrid A80 taken from MegaRow 3, MegaColumn 2 of the slide as shown in E. 
(C) Subgrid A150 taken from MegaRow 4, MegaColumn 1 of the slide as shown in E. 
(D) Subgrid B80 taken from MegaRow 4, MegColumn 2 of the slide as shown in E. 
Figure 4. Summary of the Subgrids A80 Hybridization Results 
The Y axis is the normalized value of fluorescence intensity. The X axis is the 
oligodeoxynucleotides' names listed in the ascending order. Because of the space 
limitation, only each third of the 84 antisense oligodeoxynucleotides are labeled on the 
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X-axis. The total listed of antisense oligodeoxynucleotide's named and in ascending 
order can be found in table 1. The bar for each antisense oligodeoxynucleotide 
represents the normalized value of fluorescence intensity of each oligodeoxynucleotide 
in A80 subgrids on one microarray slide. The normalized value of each 
oligodeoxynucleotide is its average fluorescence intensity divided by the average 
fluorescence intensity of Random Oligo as defined in previous results section. 
Figure 5. Summary of The Subgrids B80 Hybridization Results 
The Y axis is the normalized value of fluorescence intensity. The X axis is the 
oligodeoxynucleotides' names listed in the ascending order. Because of the space 
limitation, only each third antisense oligodeoxynucleotide is labeled on the X-axis. The 
total list of antisense oligodeoxynucleotides named in ascending order can be found 
in table 1. The bar for each antisense oligodeoxynucleotide represents the normalized 
value of fluorescence intensity of each oligodeoxynucleotide in B80 subgrids on one 
microarray slide. The normalized value of each oligodeoxynucleotide is its average 
fluorescence intensity divided by the average fluorescence intensity of Random Oligo 
as defined in previous results section. 
Figure 6. The Top 25 Antisense Oligodeoxynucleotides in A80 and B80 Results 
From A80 and B80 results, the normalized values of fluorescence intensity and names 
of the 25 antisense oligodeoxynucleotides with the highest normalized values among 
the 84 20 nt antisense oligodeoxynucleotides targeting Lcn2 mRNA are listed. The Y 
axis is the normalized value of fluorescence intensity. The X -axis is the name of 
antisense oligodeoxynucleotide indicating the position of 5' end of its targeting 
sequence on Lcn2 mRNA. For example, antisense oligodeoxynucleotide named 81 
indicates that its targeting region on Lcn2 mRNA was from 81 to 100 nt. 
(A) The top 25 antisense oligodeoxynucleotides from A80. 
(B) The top 25 antsiense oligodeoxynucleotides from B80. 
Figure 7. The Top 25 Antisense Oligodeoxynucleotides Predicted by Oligowalk 
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and Soligo 
The - AG values and names of the 25 antisense oligodeoxynucleotides with the lowest 
AG values among the 834 20 nt antisense oligodeoxynucleotides targeting Lcn2 mRNA 
are listed. The Y axis is the -AG value in Kcal/mol. The X -axis is the name of 
antisense oligodeoxynucleotide indicating the position of 5' end of its targeting 
sequence on Lcn2 mRNA. For example, antisense oligodeoxynucleotide named 355 
indicates that its targeting region on Lcn2 mRNA was from 355 to 374nt. 
(A) The top 25 antisense oligodeoxynucleotides predicted by OligoWalk. 
(B) The top 25 antsiense oligodeoxynucleotides predicted by Soligo. 
Figure 8. The Folding by Mfold of Target Sequences of Seven Antisense 
Oloigodeoxynucleotides Selected for In vivo Testing 
The 853nt Lcn2 mRNA folded by Mfold is shown in the middle of figure. The four 
regions on Lcn2 mRNA from which the target sequences of the seven antisense 
oligodeoxynucleotides selected for in vivo testing are circled. The target sequence of 
the antisense oligonucleotide 252 is shown in region A. The target sequence of the 
antisense oligodeoxynucleotide 501 is shown in region B. The target sequences of the 
antisense oligodeoxynucleotides 561, 581 and 591 are shown in region C. The target 
sequences of the antisense oligodeoxynucleotides 735 and 741 are shown in region 
D. All the target sequences are shaded in a light pink color. The overlapping 
sequences are shown in deeper pink color compared to the sequences that have no 
overlap. 
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Tables and Figures 
Table 1. The sequence information of oligodeoxynucleotides used 
84 Antisense Oligodeoxynucleotides targeting Lcn2 mRNA with 10nt overlapping from 5' 
to 3' end. Each oligodeoxynucleotide is 20nt long. The number shown below which 
indicates the position of 5' end of its target sequences on Lcn2 mRNA was used as the 
name of corresponding antisense oligodeoxynucelotide. 
1 11 21 31 41 51 61 71 81 91 101 111 
121 131 141 151 161 171 181 191 201 211 221 231 
241 251 261 271 281 291 301 311 321 331 341 351 
361 371 381 391 401 411 421 431 441 451 461 471 
481 491 501 511 521 531 541 551 561 571 581 591 
601 611 621 631 641 651 661 671 681 691 701 711 
721 731 741 751 761 771 781 791 801 811 821 831 
9 Random Sequences 
Name Sequence Length 
Random Sequence 1 (R1) TCTTTCGGTAAGCCGCATGG 20 nt 
Random Sequence 2 (R2) CCTGGGGGGCTAAGGACGTG 20nt 
Random Sequence 3 (R3) CGTCCGTTTGGAAACGCCTT 20nt 
Random Sequence 4 (R4) TCGTCACAATACAGGGAGGG 20nt 
Random Sequence 5 (R5) CCGGATTTTGCCTCGTATAA 20nt 
Random Sequence 6 (R6) G GAGTG ATCG AAATTG G ACT 20nt 
Random Sequence 7 (R7) AAAAG CACTAATTG G AGTCG 20nt 
Random Sequence 8 (R8) GGACGCATCGATTGAACTGC 20nt 
Random Sequence 9 (R9) GTTCGCGGCCATGTAGTGGT 20nt 
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Table 2. Summary of top 10 oligodeoxynucleotides from three methods. 
Oligodeoxynucleotide 
s 
Microarray OligoWalk Soligo 
A80 B80 
251 y V 
252 y 
253 y 
254 y 
255 y 
256 y 
257 y 
421 V V 
431 V 
461 V V 
478 y 
491 V 
494 V 
499 V 
500 V 
501 V V V 
502 y 
503 V 
504 V 
505 y 
521 y V 
561 V V 
571 V V 
734 y 
735 y 
741 V V 
749 y 
750 y 
751 V V 
798 y 
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Table 3. Oligodeoxynucleotides (ODNs) selected for in vivo testing as the antisense 
ODNs 
Name Antisense Oligonucleotides Target GC A G  (Kcal/mol) 
sequences on 
Lcn2 mRNA 
content (5' to 3') Sfold OligoWalk 
252 GCTATTGTTCTCTTGTAGCT 252-271 40.00% -11.4 -15.8 
501 CAGCT CCTT GGTT CTT CCAT 501-520 50.00% -0.2 -23.9 
561 GT CGTCCTT GAGGCCCAGAG 561-580 65.00% -2.3 -1 
581 GGGACAGAGAAGAT GAT GTT 581-600 45.00% -9.9 -17.7 
591 TTGGTCGGTGGGGACAGAGA 591-610 60.00% -9.9 -18.5 
735 CTTGGTATGGTGGCTGGTGG 735-754 60.00% - 1 1 .6 -16 
741 ATGCTCCTTGGTATGGTGGC 741-760 55.00% -7.4 -14.6 
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CHAPTER 5. DEVELOPMENT OF A MALACHITE GREEN RNA TRAP 
FOR Lcn2 m RNA 
A paper to be submitted to RNA 
Abstract 
In vivo detection and imaging of RNA molecules in living cells will provide critical 
temporal and spatial information about the specific RNA molecule for biological and 
biomedical research and applications. It is well known that changes in the expression 
level of certain genes correlate with the occurrence of certain diseases or with cell 
differentiation. Non-invasive probes that can image the expression of such genes in 
real time would help the early diagnosis of disease and provide an accurate evaluation 
of cell status. 
Here we utilized an in vitro selected malachite green (MG) RNA aptamer to develop 
a MG RNA TRAP probe for the purpose of imaging mRNA in vivo. Thirty two nt, 30nt 
and 28nt MG aptamers were created from the existing 38nt MG RNA aptamer initially 
selected by SELEX. These truncated aptamers were also modified to destabilize the 
stable secondary structure. The Kds of these truncated and modified MG RNA 
aptamers for MG were estimated and the results showed the 32nt, 30nt and 28nt MG 
RNA aptamers still affinities for MG within 1 -fold of the parent aptamer. Selected from 
a previous study (Chapter 4), the 20nt antisense oligonucleotide that targets 741-760 
nt of Lcn2 mRNA was chosen to be used in the MG RNA TRAP. Through rational 
design, a TRAP that has a 32nt modified MG RNA aptamer and a 9nt attenuator was 
found to have up to 20-fold activation upon interaction with 20nt regDNA. 
To facilitate transfer of the TRAP concept to in vivo conditions a yeast selection 
system was created to test the function of selected TRAPs in vivo in which inhibition of 
URA3 expression by an active MG aptamer inserted in its 5'UTR is reflected by slow 
growth in a yeast spot assay. A hammerhead (HH) ribozyme - MG - hepatitis delta 
virus (HDV) - ribozyme expression cassette was also built to produce RNA molecules 
with defined and homogenous 5' ends and 3' ends. To determine if an optimal TRAP 
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could be derived by combinatorial selection, SELEX was carried out using 3 different 
ssDNA pools. The primary results indicated that the key for a successful selection of 
a MG RNA TRAP using SELEX could be an effective negative selection to get rid of the 
sequences that bind MG in the absence of regDNA. In comparison with SELEX, 
rational design was found to be a more effective means of developing a well-regulated 
MG TRAP for detecting the presence of Lcn2 mRNA. 
INTRODUCTION 
In the last ten years, the discovery of small non-coding RNAs (ncRNAs ), such as 
small interfering RNAs (siRNAs), microRNAs (miRNAs) and riboswitches, have 
broadened our understanding of the scope of biological activities of RNA molecules 
(7). Another big surprise came in 1982 when Cech et al. (2, 3) reported the first 
catalytic RNA or ribozyme: the self-splicing intron of the Tetrahymena pre-rRNA. 
Accumulating evidence through many years of research began to fully reveal the 
kingdom of RNAs hiding from the central land. Now we know RNAs not only play the 
role of messenger to convey and interpret the genetic information stored in DNA, but 
also have essential catalytic activity and contribute to the structure of molecular 
complexes that regulate gene expression. The expression levels and stabilities as well 
as the temporal and spatial distributions of specific RNAs in a cell are directly related 
to their functions. It is very important to understand the dynamics and localization of 
RNA molecules in the living cell. It will help us to understand how the RNA molecules 
fulfill their diversified functions. 
Changes in the expression levels of certain genes are correlated with the 
occurrence of certain diseases or with the differentiation states of a cell. For example, 
mammaglobin antigen transcripts were detected in 100% of human breast 
adenocarcinoma cell lines (BrCa) and were absent from normal lymph nodes (4). 
Through microarray analysis, many transcripts were revealed to undergo dramatic 
changes during cancer development and inflammation (5, 6). The rapidly developing 
knowledge of the genome enables a view of gene regulation in the genomic level rather 
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than a single gene at one time. In many cases, the increase or decrease of certain 
mRNAs is the earliest event of certain biological processes, such as apoptosis, tumor 
occurrence and cell differentiation. Real time and non-invasive detection of such 
changes in mRNA levels may provide critical information for the early diagnosis of 
diseases or determination of cell differentiation state or could be used for monitoring 
certain biological events. 
There are many in vitro methods developed to detect and quantify RNA molecules 
using purified DNA or RNA samples obtained from cell lysates. These methods include 
Northern blotting (7), in situ hybridization (8), RT-PCR (9), Nucleic Acid Sequence 
Based Application (NASBA) (10), expressed sequence tags (ESTs) (11), realtime RT-
PCR (12), Serial Analysis of Gene Expression (SAGE) (13), differential display (14), 
and DNA microarray (15). Along with the rapidly advancing knowledge of genomic 
sequences for many organisms, the in vitro methods mentioned above enable the fast, 
accurate and systematic detection and identification of RNA targets in the cell. But 
these in vitro methods can not provide temporal and spatial information about the RNA 
target in the living cell. 
Many efforts have been given to detect and imaging RNA, especially mRNA 
molecule in living cells. For example, MS2-GFP fusion protein containing a nuclear-
localization signal was used to capture the co-expressed Ash1 mRNA carrying an 
insertion of six tandem copies of the stem-loop binding site for bacteriophage MS2 coat 
protein (16). The Ash1 mRNA was visualized through fluorescence of re-localized 
GFP. Using GFP as a reporter, other studies had been done in which the selected 
RNA targets were visualized in individual living cells (17, 18). 
For the system using MS2-GFP fusion protein, even though the mRNA detected 
was produced inside the cell, it is modified from native mRNA. With fluorescence in 
vivo hybridization (FIVH), fluorescence labeled unstructured linear nucleic acid probes 
were used to detect and image the specific RNA in the living cells (19-21). But the 
linear unstructured probes suffer drawbacks such as a high background signal and lack 
of conformational change upon binding to the target. It is also difficult to use linear 
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unstructured probes to detect single base difference compared with using stem-loop 
structured probes such as molecular beacons (22). Peptide linked molecular beacons 
have been used to detect native mRNA in living cells (23, 24). 
Integrating ribozymes/aptamers into the design of molecular beacons, we 
developed the ribozymes/aptamer-based structured nucleic acid probe - targeted 
reversibly attenuated probes (TRAPS) (25, 26). In the aptamer -based TRAPs, an 
aptamer is used as the module to signal the interaction between TRAP and its nucleic 
acid target through the binding of aptamer to its ligand. The study done in the ATP-
DNA TRAP shown that it can be fully activated by the regDNA. Also, the activation of 
the ATP DNA aptamer in the ATP DNA TRAP by a complementary nucleic acid at 
physiological temperatures is sensitive to single-base mismatches (26). Aptamer-
based TRAPs that can be regulated by a specific nucleic sequence such as in an 
mRNA have the potential for being used to image RNA molecules in vivo. Even though 
aptamers are selected in vitro through SELEX (27, 28), many have been applied to both 
extracellular (29-36) and intracellular (37-42) in vivo applications. In most in vivo 
applications, aptamers have been used as antagonists of their target ligand molecules. 
But they could be used in a broad range of other in vivo applications as well. Several 
studies have been done to utilize aptamers to image cells using extracellular targets. 
For example, an [1231 or1251] labeled thrombin aptamer was used to imaging thrombus 
in blood (29) and a ["mTc] labeled neutrophil elastase aptamer was used to imaging 
inflammation in a rat reverse passive arthitus reaction model (43). Aptamers can be 
used to regulate transcription or translation processes. For example, by inserting the 
MG RNA aptamer before the AUG of a cyclin transcript in S. cerevisiae, the translation 
of modified cyclin transcript was regulated by tetramethylrosamine (TMR), a structural 
analog of MG (44). Another example of the MG RNA aptamer and TMR that works in 
vivo was the development of a TMR-dependent transcription activator through in vivo 
selection in S. cerevisiae (45). The transcription rate of an engineered RNA molecule 
containing the MG aptamer increased 10-fold in the presence of TMR. 
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Lcn2 is a member of lipocalin protein fam ily (46). Many members of lipocalin family 
have the function of binding and transporting small hydrophobic molecules (47). Lcn2 
was first identified as a secreted protein regulated by growth factors and later shown 
to be an acute phase protein and involved in the inflammatory response (48, 49). 
Although the in vivo function of Lcn2 is not fully understood, it has been verified that 
Lcn2 has very high expression during tissue involution in uterus and mammary gland 
(50). Lcn2 mRNA was observed to have over~100 fold increase over the average level 
on day 5 of gestation in the mouse mammary gland (50). This dramatic expression 
change in the uterus and mammary gland makes it an ideal target transcript for 
developing an RNA TRAP utilizing the MG RNA aptamer. 
Here we report the development of a MG RNA TRAP targeting Lcn2 mRNA. The 
efficacy of rational design and SELEX are tested in the process. Through rational 
design, a TRAP containing a 32nt mutant MG RNA aptamer and 9nt attenuator was 
shown to be activated up to 20-fold upon interaction with a 20nt regDNA. A yeast 
negative and positive selection system was created to further verify the function of 
produced RNA TRAP molecule in vivo. Our results show the advantages and 
disadvantages of rational design and SELEX, respectively. It provides general 
guidance for the future development of TRAPs that may utilize RNA aptamers other 
than the MG aptamer. 
Materials and Methods 
Materials and Equipments 
Malachite green was from Sigma (St. Louis, MO). Malachite green isothiocyanate 
was from Invitrogen (Carlsbad, CA). EZ-link Biotin-LC-PEO Amine was from Pierce 
(Rockford, IL). [a-32P]CTP was purchased from ICN (Costa Mesa, CA). 
Streptavidin-agarose CL-4B was from Sigma and Pierce. HT-450 Tuffryn membrane 
filters (0.45 m pore size) were from Pall (Ann Arbor, Ml). Imagequant software 
(Amersham-Pharmacia) was used to analyze radioactive bands in gel scans obtained 
using a Typhoon scanner (Amersham-Pharmacia). The concentration of nucleic acid 
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molecules was determined by a NanoDrop ND-100 UV spectrophotometer (NanoDrop 
Technologies, Inc.) Fluorescent spectra were taken on a Gary Eclipse (Varian, 
Australia)fluorescence spectrophotometer with a Xenon pulse lamp. Yeast YPD media 
was purchased from Sigma. The FastStart Taq DNA polymerase was purchased from 
Roche (Indianapolis, IN), superscript III reverse transcriptase was from Invitrogen. 
Micro Bio-Spin P30 Tris columns were from Bio-Rad (Hercules, CA). Yeast extract, 
yeast nitrogen base without amino acids, tryptone peptone and yeast agar were 
purchased from Becton Dickinson and Company (Franklin Lakes, NJ). Uracil dropout 
media supplement was from Qbiogene (Morgan Irvine, CA). TLC plates( Silica gel, 
Polyester, 250uM thickness ) was from VWR (West Chester, PA). 
RNA and DNA molecules 
The names, descriptions and sequence information for DNA and RNA molecules 
in this study are listed in Table 1, 2, 3 4 , 5, 6 and 7. The oligonucleotide with an 
unique oligo number indicates it was purchased from Integrated DNA Technology (IDT) 
(Coralville, IA) or Iowa State University DNA Facility (Ames, IA). The oligonucleotide 
without oligo number was produced by experiments or listed for information. 
Oligonucleotides are listed from 5' end to 3' ends if not particularly annotated. 
Oligonucleotides described as PAGE-purified preparations were purified by 
polyacrylamide gel electrophoresis (PAGE). All other purchased oligonucleotides were 
prepared as standard desalted preparations. All MG RNA TRAPs were synthesized by 
in vitro transcription using the AmpliScribe™ T7-FlashT Transcription Kit from 
EPICENTRE (Madison, Wl) and purified by denaturing (7M Urea) 8% PAGE. The gel-
purified MG RNA TRAPs were quantified by using a NanoDrop ND-100 UV 
spectrophotometer. The double strand (ds) DNA template for in vitro transcription were 
obtained by PCR. The PCR strategy to make ds DNA templates for different TRAPs 
is shown in Fig. 4A. The PCR reactions contained 1 nM template, 1 pM forward primer, 
1 pM reverse primer, 2 mM Mg++ and 200 pM dNTP. The PCR conditions were: 95°C 
4 min pre-denaturation, 95°C 2 min denatu ration, 55°C 2 min annealing, 72°C 1 min 
elongation and 15 cycles. Each PCR reaction ended with a 10min incubation at 72°C. 
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The PCR products were purified using Micro Bio-Spin P30 Tris columns (Bio-Rad, 
Hercules, CA) and used in the in vitro transcription reaction. 
Fluorescence Spectra Measurement 
Fluorescent spectra were taken on a Cary Eclipse fluorescence spectrophotometer 
using a single quartz cuvette or 96 well microplate. Experiments were performed at the 
excitation wavelength of 630nm with 5nm slit and emission scan of 640-800nm with 
5nm slit. PMT voltage was set to high. The fluorescence emission value of each 
spectrum was reported and exported to Microsoft Excel files and drawn appropriately. 
The maximum emission peak of each spectra was selected to use in the data analysis. 
Estimation of Kd's of MG RNA aptamers 
For each MG RNA aptamer, from 0.05 pM to 20 pM, 18 different concentrations of 
RNA samples were tested with MG concentration at 0.2 pM for all samples. All tests 
were done in binding buffer (10mM HEPES, 0.1 M KCI, 5mM MgCI2, pH 7.4 at 23°C). 
The maximum peak value for each spectrum was reported and exported to Microsoft 
Excel files and drawn appropriately. Based on the equation: F=[L]*Fmax / (Kd +[!_]), the 
non-linear least-square regression was used to fit the data and to estimate Kd. For 
each regression, R2 value was also given. The regression analysis was done using 
CoStat (Cohort, Monterey, CA). 
Yeast Strain and Plasmids 
The yeast strain 200897 was from the American Type Culture Collection(ATCC). 
Organism: Saccharomyces cerevisiae. ATCC number: 200897. Genotype: MATalpha 
ade2delta::hisG his3delta200 Ieu2delta0 metl SdeltaO trpdelta63 ura3delta0. The pYX 
vectors are a comprehensive set of yeast/E.coli shuttle vectors for expression in S. 
cerevisiae (pYX021 and pYX043 plasmids are the gifts of Dr. Alan Myers). pYX021 
and pYX043 both are yeast integrative plasmids. A pYES2 plasmid is a yeast 2p 
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plasmid carrying a URA3 marker and a Gal-1 promoter for galactose-inducible gene 
expression in S. cerevisiae (the pYes2 plasmid was a gift from Dr. Daniel Voytas). 
Construction of Yeast Integrative Plasmid 
To obtain a yeast vector by which the MG aptamer is expressed as part of the 
URA3 mRNA, oligonucleotides corresponding to the 40MG0 aptamer sequence were 
chemical synthesized and ligated into pYX043, previously digested with Xho I and 
Sacll. The resulting recombinant plasmid (pYX043MG) was digested with Xho I and 
Sacll to cut off part of pYX043MG including the polyA tail after the MCS, f1 origin and 
the existing Leu2 promoter. The sequence including the polyA tail after the MCS and 
the f1 origin from pYX043 was amplified by PCR (PCR1 ). The resulting PCR1 product 
included Xhol and Xbal cutting sites. A second PCR(PCR2) was carried out to obtain 
a fragment that included the 786 promoter from pYX021. The PCR2 product included 
Xbal and Sacll cutting sites. The PCR1 product was digested with Xhol and Xbal. The 
PCR2 product was digested with Xbal and Sacll. Then the enzyme digested PCR1 and 
PCR2 products were ligated into PYX043MG, previously digested with Xho I and Sacll. 
The resulting recombinant plasmid was called pYX043786. 
To obtain a yeast expression plasmid for a URA3 mRNA containing a 5' MG 
aptamer, PCR was carried out to obtain a fragment including the URA3 coding 
sequence from pYes2. The PCR product was digested with Sacll and BsrGI and 
cloned into the plasmid pYX043786 which had been digested with Sacll and BsrGI. 
The resulting recombinant plasmid (P3) was digested with Eco47lll and Sacll. 
Oligonucleotides corresponding to the 40 M GO aptamer sequence were chemical 
synthesized and ligated into P3, previously digested with Eco47lll and Sacll. The 
resulting recombinant plasmid (P6) has one copy of MG aptamer coding sequence 
inserted into URA3 5'UTR sequence. 
Yeast Transformation and Media 
To obtain yeast with plasmids expressing URA3 with or without the MG aptamer 
in the 5'UTR integrated into the yeast genome, the recombinant plasmids (P3 and P6) 
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was linearized using Eco47lll and transformed into 200897 using the Lazy Bones yeast 
transformation method (51). Transformants resulting from homologous recombination 
were isolated by selection on SD-Uracil plates. SD-Uracil liquid media (per liter): 6.7 
g yeast nitrogen base W/o amino acids, 1.92g Uracil dropout media supplement, 2% 
glucose. YPD liquid media (Per liter) :10 g yeast extract, 20 g tryptone peptone, add 
dH2O, bring volume to 900ml. After autoclaving at 121 °C for 15 min, add 100ml 20% 
Glucose. SD-Uracil plates : 2% yeast agar in SD-Uracil liquid media. 
Yeast Cell Growth and Spot Assay 
Yeast cells were cultured in SD-Uracil liquid media at 30 °C shaker overnight. The 
OD of the overnight culture was determined by absorbency at 600 nm using UV/Visible 
spectrophotometer. Yeast cultures with OD6OO nm absorbing around 0.5 were used 
for spot assays. If overgrown, the cells were diluted with water; 4 to 6 serial dilutions 
were made of each yeast culture and 3-5 pi of each dilution was spotted onto an 
assigned grid on the appropriate plates. The spots were allowed to dry before 
incubating at 30° C for 2 to 3 days. Pictures were taken at the desired time points. 
Construction of 5'HH-MG-3'HDV Ribozyme Constructs 
Oligonucleotides corresponding to 31- 85nt of the modified 85nt wild-type genomic 
hepatitis delta virus (HDV) sequences (HDV0) (52) were chemically synthesized and 
ligated into pcDNA3.1(-), previously digested with Xho I and EcoRI. The resulting 
plasmid was pR1. Oligonucleotides corresponding to a modified 50nt hammerhead 
ribozyme (HH) sequence (HH0) (52), the 40nt MG aptamer (40MG0) and 30nt (1-30)nt 
of the modified 85nt wild-type genomic HDV sequences (HDVO) were ligated into the 
pR1 vector, previously digested with Nhe I and EcoR I. The 30nt (1-30nt) of HDVO 
sequence and 55nt (31 -85nt) of HDVO sequence mentioned above were joined together 
to form the full length HDVO sequence. The resulting plasmid was pR2. 
Oligonucleotides corresponding to HH ribozyme sequences with low Mg2+requirement 
for maximum activity (HH1, 53) were ligated into the pR2 vector, previously digested 
with Nhe I and Sacll. The resulting plasmid was pR3. Oligonucleotides corresponding 
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to a randomized HH ribozyme sequence (HH2) were ligated into pR2 vector, 
previously digested with Nhe I and Sacll. The resulting plasmid was pR4. 
Oligonucleotides corresponding to a mutant (inactive) HDV ribozyme sequence (HDV1) 
were ligated into the pR3 vector, previously digested with Agel I and Kpn I. The 
resulting plasmid was pR5. Oligonucleotides corresponding to the mutant (inactive) 
HDV ribozyme sequence (HDV1 ) were ligated into the pR4 vector, previously digested 
with Agel and Kpnl. The resulting plasmid was pR6. 
RNA Transcription Reaction 
Plasmids were digested with the Hind III restriction enzyme to linearize the DNA 
and provide templates for run-off transcription reaction. After complete enzyme 
digestion, the mixtures were phenol-chloroform extracted, ethanol precipitated and the 
cut plasmids re-suspended in water. 
Transcription from linearized dsDNA templates were performed in 20 pi reaction 
volumes containing 40mM Tris-HCI buffer, 10mM NaCI, 1 mM spermine, 0.05% Tween 
20, 6mM MgCI2, pH7.9 at 23 °C, 40mM dithiothreitol (DTT), 0.08ug/ul templates, 
1,25mM ATP, OTP, UTP and CTP, 1 U/pl Ribonuclease, 1 U/pl T7 RNA polymerase and 
trace amount of [a-32P] CTP (25 pCi/20ul). The transcription reactions were kept at 37 
°C for 3 h. 0.05U/pl DNase I was added to mixture at the end of the transcription 
reaction and the mixture incubated at 37 °C for 15 min to digest dsDNA template. 
Following DNase I digestion, half of each reaction was removed, the MgCI2 
concentration was adjusted to 40mM and the sample was subjected to three rounds of 
thermal cycling (1 min at 72 °C, 5 min at 65 °C and 10 min at 37 °C) to facilitate the 
ribozyme folding into its active structure. The product of each transcription reaction 
was resolved by 8% denaturing polyacrylamide gel electrophoresis. The incorporation 
of [a-32P] CTP in the transcription reaction allowed visualization of the bands with a 
phosphor-imager. 
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Synthesis of Biotinylated MG 
3 mM EZ-link Biotin-LC-PEO Amine and 0.6 mM MG-isothiocyanate were mixed 
in 10ml 100% CH2CI2. The mixture was put in a dark room and incubated on a rotating 
shaker for 1 h at room temperature. After the incubation was completed, the mixture 
was applied to a thin layer chromatography (TLC) plates (Silica gel, Polyester, 250uM 
thickness). After being air dried, the TLC plate was developed for 1 h using a mobile 
phase containing 90% CH2CI2, 10% Methanol. The band containing the biotinylated 
MG was cut out and the MG extracted using N ,N-Dimethylformamide (DMF). The 
silica gel was removed by centrifuge at 16,000 g for 5 min. The biotinylated MG in DMF 
was concentrated under vacuum. The absorbency at 619 nm of purified Biotinylated 
MG was checked using a UV/Vis spectrophotometer and the concentration of 
biotinylated MG was calculated using a standard curve of MG absorbency at 619 nm. 
Coupling of Biotinylated MG with Streptavidin Agarose Beads 
30uM biotinylated MG and 7.5uM streptavidin (25 pM/ml packed agarose) were 
mixed in buffer containing 10 mM HEPES, 0.1M KCI, 5 mM MgCI2 pH 7.4 at 23 °C and 
incubated 4 h in the dark room at room temperature. After incubation, the reaction 
mixture was transferred into an empty Poly-Prep chromatography column and washed 
with buffer containing 0.1 M sodium acetate, 0.1 M acetic acid, 0.1 M KCI, 5mM MgCI2, 
pH 4.5 at 23 °C. The flow-through and wash, which contained un-coupled biotinylated 
MG, were collected and their absorption at 619 nm was determined. The concentration 
of biotinylated MG that passed through the column was determined based on the MG 
standard curve. From this data the coupling efficiency and amount of MG coupled to 
the agarose were calculated. 
Filter Assay 
Single-stranded MG RNA TRAPs (32P labeled during in vitro transcription) or MG 
RNA aptamers (2 - 20 pmoL, 5' labeled with 32P) were incubated in the presence or 
absence of other ssDNAs, as defined in each experiment, at 75°Cfor5 min then cooled 
to room temperature for 10 min. These samples were mixed with 20 pM Biotinylated 
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MG : streptavidin-agarose or other concentration noted in each experiment. Each 
sample was equilibrated at room temperature for 10 min then filtered through an 
HT-450 filter and washed with 5 ml of binding buffer. Fractions were analyzed for32P 
by measuring Cerenkov radiation. The radioactive cpm bound to biotinylated MG was 
divided by the total cpm in the original sample to give the fraction bound. 
In Vitro SELEX 
Three different ssDNA pools were used in three independent TRAP SELEX (S10, 
S15 and S20 as shown in Table 7). All MG TRAPs' RNA pools were synthesized by 
in vitro transcription using the AmpliScribeTM T7-FlashT Transcription Kit from 
EPICENTRE and purified by denaturing (7M Urea) 8% PAGE. The three RNA pools 
were named as the N10, N15 and N20 pools with their names corresponding to the 
length of randomization region in the TRAP RNA. Concentrations of the gel purified 
MG TRAPs'RNA pools were quantified by NanoDrop ND-100 UV spectrophotometer. 
The double strand (ds) DNA templates for in vitro transcription were obtained by PCR 
using purchased ssDNA pools. The PCR reaction contained a 5 nM template, 2 pM 
forward primer, 2 pM reverse primer, 2 mM Mg2+and 200 pM dNTP. The PCR 
conditions were: 95°C 4 min pre-denaturation, 95°C 2 min denaturation, 55°C 2 min 
annealing, 72°C 3 min elongation and 15 cycles. Each PCR reaction ended with 10min 
incubation at 72°C. The PCR products were purified using Micro Bio-Spin P30 Tris, 
columns and used in the in vitro transcription reactions. 
TRAP SELEX was done using filter capture. In each round, 1 or 3 consecutive 
negative selections were done first followed by 1 positive selection. Each round began 
with 5-10 pg TRAP RNA pool. In the negative selections the TRAP RNA pools were 
first incubated for 10 min at room temperature with or without 5 X non-regDNA and 5 
X E.coli tRNA, as defined in each experiment. At the end of incubation, each mixture 
was transferred into a tube that contained biotinylated MG coupled with streptavidin-
agarose. After 10 min incubation, the mixture was filtered through an HT-450 filter and 
washed with 5 ml of binding buffer. The flow-through was collected and ethanol 
precipitated. The precipitated nucleic acids were dissolved in water and applied to the 
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next negative or positive selection. In the positive selections, 5 X regDNA was 
incubated with the TRAP RNA pools. The flow-through from the filter was discarded. 
The filter was washed using water and the bound TRAPs were eluted with water and 
ethanol precipitated. RT-PCR was carried out using the re-dissolved ethanol 
precipitated nucleic acid from the positive selections. 
The reverse transcription (RT) reactions used 10 pM reverse primer (SR1 in Table 
7 ) and superscript™ III reverse transcriptase. The reaction mix was incubated at 55 
°C for 1 hour. 2ul of RT product was used in the subsequent PCR reaction to 
regenerate dsDNA pool. The PCR conditions were the same as those used to amplify 
the original ssDNA pool. After each round a new RNA pool was generated and the pool 
was tested for MG binding using fluorescence spectral measurements. 
RESULTS 
Destabilization of the MG RNA Aptamer and Kd Determinations 
The 38nt MG RNA aptamer has strong stem loop structure (Fig. 1a ,c). Two stems 
flanking the binding pocket provide strong support for its overall stability. It is easy to 
understand that if an aptamer has a very stable structure, it will be difficult to regulate 
its binding activity by an attenuator. A short attenuator will not interrupt the binding and 
by the time the attenuator is long enough to destroy the binding activity it is difficult to 
dislodge and release the inhibition on the aptamer. In order to make the MG RNA 
aptamer less stable and more easily regulated, we synthesized several truncated MG 
RNA aptamers with the length 34nt, 32nt, 30nt and 28nt, respectively. We also 
introduced the modifications into the 32nt MG RNA aptamer. We gave each sequence 
a simple and unique name ( Table 1). Every sequence of the MG RNA aptamer 
variations listed in Table 1 was analyzed by Mfold (54) which provided a predicted 
folding and corresponding AG of each sequence. Four examples of secondary 
structure given by Mfold are shown in Fig. 2A. 
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From Table 1, we can see that by shortening the length of the stem formed by the 
5' and 3' ends, the resulting overall stability (AG) of the MG RNA aptamers was 
reduced. One concern about this destabilizing effort is that although the truncation and 
modifications will make the aptamer less stable, the binding affinity for MG may also 
be reduced or lost. If the affinity of a truncated or modified aptamer for its ligand was 
reduced significantly compared with the wild type (38MG0), it could not be used in the 
TRAPs. Therefore, the dissociation constants (Kds) of selected aptamers were 
estimated using a non-linear least-square regression analysis of the results from 
fluorescence spectral measurements. The fitting curve and experiment data are drawn 
together on Fig. 2B for the two aptamers. The estimated Kd and R2 values of the 
regression analyses for three selected aptamers are listed in Table 2. 
Determine the Target Region of Attenuator on MG RNA aptamer 
Modular rational design is the most widely used method to obtain allosteric nucleic 
acids such as allosteric ribozymes (55-57) and allosteric aptamers (58). The crystal 
structure of the 38nt malachite green aptamer has been solved to a resolution of 2.8 
Â (59). In Fig. 1a (59), the nucleotide bases that are involved in the critical interaction 
with the ligand were labeled in the color other than black. The bulge loop between the 
two stems in the MG aptamer is the binding pocket. The broad side of the bulge loop 
between G24 and U32 of 40MG0 sequence is the obvious target for an attenuator in 
a MG TRAP. To test this possibility, seven 10nt ssDNA oligonucleotides targeting 
different regions of the 40MG0 aptamer were synthesized as shown in Fig.3 B. The 
sequences of all 10nt oligonucleotides were listed in Table 3. Upon binding to the MG 
RNA aptamer, the fluorescence of MG increased more than -2,000 fold (60). Three 
representative fluorescent spectra are shown in Fig. 3A to illustrate the use of 
fluorescence to monitor the binding between MG and MG RNA aptamer. The results 
in Fig. 3C show that oligonucleotide E inhibited about 75% of MG aptamer binding. 
The ratio of the 10nt oligonucleotides to the MG aptamer was 1000:1. Oligonucleotide 
E which targets the bulge loop of the binding pocket had the highest inhibitory effect 
among the seven oligonucleotides tested. 
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Screening for the MG TRAPs allosteric regulated by regDNA 
After determining that the most effective region for targeting the 40MG0 aptamer 
in order to inactivate it was the broad side of the bulge loop where the binding pocket 
is located, 15 MG TRAPs were designed based on different combinations of MG 
aptamer sequences (32MG1, 32MG2, 32MG4, 32MG6, 30MG1 and 28MG0) with 
attenuator lengths of 9nt, 10nt and 11 nt ( Table 4). PCR reactions were carried out 
to amplify the dsDNA needed to produce the MG TRAPs RNA through in vitro 
transcription. The PCR strategy is shown in Fig. 4A. The forward primer was used to 
produce the desired MG RNA aptamer sequence. The reverse primer was used to 
generate an attenuator segment with a defined sequence and length. The MG TRAP 
RNAs were purified by gel purification as described above. In the presence of 2uM 
MG, each MG TRAP RNA alone or with 5X regDNA or 5X non-regDNA were subjected 
to fluorescence spectral measurement. The 32MG0 aptamer was used as the positive 
control and the spectrum of binding buffer (10mM HEPES, 0.1 M KCI, 5mM MgCI2, pH 
7.4 at 23 °C) was subtracted from each sample's spectrum. TRAP 32MG1-9 showed 
the best fold increase in fluorescence in the presence of 5X regDNA compared with 5X 
non-regDNA (Fig. 4B). 
Design of the Yeast In Vivo Selection System 
The MG RNA TRAP was developed in vitro. In order to verify that the MG-TRAP 
functions in vivo, a yeast in vivo selection system was designed. The MG RNA 
aptamer has previously been shown to work in vivo (44, 45). In the in vivo studies 
done so far, TMR was used as the ligand of MG RNA aptamer. As shown in Fig. 1b, 
TMR is a structural analog of MG. It contains an oxygen bridging two of the three 
benzol rings. The affinity of the MG RNA aptamer for TMR is more than ten times 
higher than its affinity for MG (~40nM compared to 800nM) (61). Used in yeast study, 
TMR was shown to go into the yeast cell quickly and has little effect on yeast growth 
at the 1|JM concentration used in the cell media (44, 45). So TMR was chosen to be 
the ligand of choice for the MG RNA aptamer in the yeast study done for this work. The 
strategy, as shown in Fig. 5A, involves the MG RNA aptamer inserted into the 5'UTR 
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of a selected marker gene. A functional TRAP and its target gene are also expressed 
in the yeast cell. In the presence of MG the inserted aptamer prevents translation from 
the mRNA, which is recognized by an appropriate test (for example growth in the select 
marker is required for growth). In the condition of high expression of MG TRAP RNA 
and its target mRNA, the functional TRAP can recognize its target gene and bind to 
TMR. Then the MG RNA aptamer inserted into the 5'UTR of selected marker gene will 
have little chance to bind to TMR and the marker gene will be translated with little 
inhibition or even normally. As shown in Fig. 5B, in the absence of its target RNA, a 
functional TRAP will form a structure that inhibits the MG RNA aptamer portion of the 
TRAP from binding to TMR. Without the competition of the TRAP for binding of TMR, 
the MG RNA aptamer inserted into the 5' UTR of the marker gene will bind to TMR and 
form a structure that is stable enough to inhibit translation of the marker protein by up 
to more than 90% as shown in previous study (44). Through the expression status of 
the marker gene, the function of desired MG TRAP RNA could be tested. To test this 
idea, a series of yeast constructs were made. In Fig. 5C, plasmid P6 which originated 
from pYX043 had URA3 replace Leu2 as the reported gene. One copy of the 40MG0 
aptamer sequence was inserted into 5' UTR of URA3. The 786 promoter from pYX021 
was cloned into pYX043 to drive expression of URA3 gene. 786 promoter is a 
constitutive promoter for the yeast heat shock transcription factor 1(HSF1) gene 
(Saccharomyces Genome database: http://www.yeastgenome.org/). According to 
the pYX vectors manual, the gene under 786 promoter has about 15 copies of 
transcripts per cell if the plasmids are integrated into the genome. Plasmid P3 was also 
prepared with the same sequences as P6 but without the MG aptamer sequence 
inserted into 5' UTR of URA3. 
Inhibition of Yeast Growth Assayed by the Spot Assay 
In the previous study where one copy of MG RNA aptamer was inserted into the 
5'UTR of cyclin transcripts in S. cerevisiae, Grate etal. (44) used 40MG0 sequence 
instead of 38MG0 sequence. Compared to the 38MG0,40MG0 has one more Watson-
Crick base pair inserted into the stem that flanks the aptamer's binding pocket and 
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lacks the a potential AUG start codon in the original 38MG0 aptamer sequence. One 
more base pair also provides more stability needed to inhibit translation. The 40MG0 
sequence was also used in this study and inserted into the 5'UTR of URA3 transcripts. 
Results from the spot assay showed that the growth of yeast cells expressing URA3 
transcripts bearing the 40MG0 sequence in 5'UTR (P6/200897 in Fig. 6) was greatly 
inhibited by the presence of 10 pM (Fig. 6A) and 20 pM TMR (Fig. 6B) in the SD-Uracil 
plates. Yeast cells transformed by plasmid bearing URA3 coding sequence without 
40MG0 coding sequence inserted into 5'UTR (P3/200897 in Fig. 6) did not shown 
growth inhibition. 
5'HH-MG-3'HDV Ribozyme Vector to Generate RNA with Homogenous Ends 
Through rational design, a functional 32MG1-9 TRAP has been shown in this work 
to be regulated by regDNA in vitro. Inhibition of URA3 mRNA translation by a 40MG0 
inserted in the 5'UTR of URA3 gene was also obseived using the spot assay in the 
yeast. In the future, we need to put a TRAP developed in vitro inside the cell and test 
its function in vivo. The MG TRAP is a short RNA molecule and its function will be 
sensitive to sequence variations if present in a larger RNA molecule. Therefore it will 
be desirable to cut the aptamer sequence out of the RNA in which it is first synthesized. 
The strategy used here to generate the desired TRAP RNA molecules is promoter 
independent. The fully processed product from HH-MG-HDV expression cassette as 
shown in Fig. 7A will have defined 5' and 3' ends that does not depend on the 
transcriptional start and termination sites. This will be achieved because the ribozyme 
in the transcripts will cleave the RNA and produce homogenous ends as shown in Fig. 
7B. 
In Fig. 8, the RNA produced from 5 different constructs was analyzed by 8% 
denaturing PAGE. R2 and R3 both had fully functional HH and HDV ribozyme 
sequences. In R3, the 46 nt HH1, which was selected in vitro by others (53) to have 
a very high cleavage rate at low Mg++ concentrations, replaced the 50 nt HHO in R2. 
In R4, a shuffled sequence of HH1 (HH2) replaced HHO in R2 and the HDVO sequence 
was unchanged. In R5, the HDV1 sequence replaced HDVO sequence in R3 and the 
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HH1 sequence was unchanged. In R6, the HDV1 sequence replaced the HDVO 
sequence in R4 and both HH ribozyme and HDV ribozyme were designed to be 
inactivities in R6. On the left side of the gel, RNA was loaded directly from the in vitro 
transcription reaction. The modification introduced in the HDV ribozyme sequence 
diminished the HDV cleavage activity shown as the absence of HDV sequence from 
MG aptamer sequence. The shuffled HHO sequence that replaced HH 1 resulted in loss 
of the HH cleavage activity. The MG sequence was not separated from the HH 
sequence. On the right side of gel, all samples went through 3 rounds of denaturation 
and re-naturation in the presence of 40mM Mg++, which resulted in increased cleavage. 
In Vitro SELEX to Select MG RNA TRAPs 
Rational design is a fast and simple way to achieve functional allosteric nucleotide 
acid molecules. As shown above, after truncation and modification of the 38MG0, the 
32MG1 sequence was found to be well regulated by a 9nt attenuator. The sequence 
space that rational design explores is very small compared to the SELEX process. In 
order to achieve a better MG RNA TRAP in terms of fold of activation by regDNA , in 
vitro SELEX was carried out using filter capture. Biotinylated MG was synthesized and 
purified by thin layer chromatography (TLC) (Fig. 9). The primary results for the 
SELEX assay are summarized in Fig. 10. For the N10 pool, the first round included 
1 negative selection followed by 1 positive selection. The second to fourth rounds 
included 3 consecutive negative selections followed by 1 positive selection per round. 
For N15 and N20 pools, each round included 3 consecutive negative selections 
followed by 1 positive selection. In the first and second rounds of the N10 pool 
selection and first round of N15 pool selection, 5X Non-regDNAand 5 X E. coii tRNA 
were present during the first negative selection. All other negative selections in the 3 
pools did not include non-regDNA and £. coli tRNA. 
Before selection the N10 R0 RNA pool was found to be regulated by regDNA, but 
it also had high binding activity in the absence of regDNA (Fig. 10A). After the first 
round with 1 negative selection, the resulting N10 R1 RNA pool had higher MG binding 
activity than the N10 R0 pool itself. The next round included 3 consecutive negative 
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selections. The fold activation by regDNA was increased from the N10 R1 to the N10 
R2 pool. Compared with the N10R2 pool, the N10R3 pool showed increased 
activation by regDNA. From the N10 R3 pool to the N10R4 pool, there was no 
improvement in the activation. The overall performance of N10 pool showed no 
significant improvement over 4 rounds of SELEX. 
The N15 pool had a longer randomized attenuator region (Fig. 10B). Each round 
of N15 pool selection included 3 consecutive negative selections. In the first round, 5X 
non-regDNA and 5X E. coli tRNA were present during the first negative selection. 
There was no obvious change in the fold of activation from the pool. The second round 
of N15 pool included neither non-regDNA nor £. coli tRNA. The activation was 
reduced a little from the first round. 
The N20 pool went through one round in the absence of non-regDNA and £. coli 
tRNA (Fig. 10B). The activity of pool in the presence of regDNA was increased after 
one round but the resulting pool showed less activation by the regDNA compared to the 
original pool. 
The TRAP SELEX experiments here were not taken through many rounds of 
selection compared with the number of rounds needed to select for an aptamer. 
However, considering the short length of the randomized region, the pool should show 
significant improvement in many fewer rounds than are usually required for selecting 
an aptamer, which is usually 8 to 14 rounds. The lack of improvement observed in 
these preliminary results of in vitro SELEX for selection of an MG TRAP suggested that 
the selection pressure in the negative selection may not have been sufficient. 
DISCUSSION 
The TRAP design integrates the binding property of the aptamer and the stem-loop 
structure of molecular beacons. It is an unique nucleic acid based probe which has 
great potential for in vivo imaging applications. The binding by an active aptamer 
module on a TRAP can transfer the presence of the target nucleic acid molecule into 
166 
the binding event between the aptamer and its ligand. The ligand molecule can be 
labeled with fluorescence, a quantum dot (62) or positron emitting isotopes (63). By 
contrast the signal output of the molecular beacon is limited to the fluorescence 
molecule because its mechanism of action requires a paired quencher and fluorophore. 
Fluorescence is not strong enough to penetrate most tissues and bone. This limits the 
in vivo use of molecular beacons for use in a broader range of imaging applications 
than the cultured cell. The ability of TRAP to utilize quantum dots and positron emitting 
isotopes for the signal output makes it a superior candidate to be developed for 
biological and biomedical applications, especially for in vivo non-invasive molecular 
imaging. For example, the TRAP could be use to enrich the intracellular concentration 
of an 18F-labeled ligand upon interaction with a target mRNA in the body. The 3D real 
time image can be visualized through positron emission tomography (PET), which 
detects 18F. 
Similar to other allosteric nucleic acid molecules utilizing aptamers, such as the 
allosteric chimeric ribozyme-aptamer molecules with ribozyme activities regulated by 
aptamer ligands, successful regulation of the TRAP activity by its effector molecule 
(target nucleic acid molecule) is closely related to the structural stability and binding 
property of aptamer chosen. So far, many effector regulated ribozymes have been 
developed using the ATP aptamer (57, 64-66), theophylline aptamer (65-68) and FMN 
aptamer (55, 66, 67, 69). All three aptamers demonstrate global ligand-induced 
conformational changes. At the same time, efforts to utilize the arginine aptamer (65) 
and chloramphenicol aptamer (66) to develop allosteric ribozymes regulated by the 
aptamer ligands were not successful. The reason was suspected to be that the 
arginine and chloramphenicol aptamers did not possess global or relevant ligand-
induced conformational changes found in ATP, theophylline and FMN aptamers (70). 
The MG aptamer does not demonstrate global, ligand-induced conformational changes. 
The two stems flanking the binding pocket provide stability as well as rigidity (Fig. 1 ). 
In the studies in which the MG aptamer was used to develop allosteric nucleic acid 
molecules, the MG aptamerwas destabilized by truncation (58) or modification of stems 
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(71). This may be the way to make the MG aptamer more flexible so that it can be 
regulated in the case that it does not have ligand-induced conformational changes. 
In the 2.8 Â crystal structure of the malachite green aptamer bound to 
tetramethylrosamine (TMR), the binding pocket was located in the bulge loop flanking 
by two stems (Fig.1 a, from 59 ). One stem is longer and formed by the 5' and 3' ends. 
The other stem is shorter and is located between the hairpin loop and bulge loop. The 
colored residues are involved in binding the ligand. The G8:C28 (orange) base-pair, 
the G24 A31G29:C7 base quadruple (blue) and the perpendicularly stacking A9 and 
A30 adenosines (magenta) are involved in direct base stacking with the ligand. The 
A27 C10:G23 base triplet (cyan) and the A26 U11:A22 base triplet (cyan) provide 
additional stability to the pocket by base stacking and base paring. The U25 (silver in 
Figure 1a) is involved in the U-turn which makes the base triplets and quadruplet 
feasible. The structural information provided by the 3D crystal structure was critical for 
TRAP rational design in determining which modifications and truncations to make. 
As shown in Fig. 2A, the three base pairs shaded in blue in the 38MG0 aptamer 
were truncated to make the 34MG0 and 32MG0 aptamers. Our initial efforts of using 
the 34MG0 and 32MG0 aptamers to design functional TRAPs were not successful. 
The attenuator was either too long so that the TRAP could not be activated by regDNA 
or the attenuator was too short so that the TRAP had high aptamer binding activity in 
the absence of regDNA. We decided to introduce modifications in the base pairs 
shaded in red in Fig. 2A to further destabilize MG aptamer after truncating the stems. 
After the MG aptamer was truncated and modified, the affinity to its ligand could be 
decreased. However, although the overall stability of the MG aptamer was reduced 
after being truncated and modified, the affinity of MG aptamer was not significantly 
decreased compared to the 38MG0 ( Tables 1 and 2). The 32nt MG aptamer had a 
similar affinity to MG with the 38MG0 aptamer. The results also showed the 
adaptability of the structure of 38MG0 aptamer. The two stems can be extensively 
manipulated as long as the binding pocket is untouched. 
168 
To start the MG TRAP design, an experiment was carried out to find the region on 
the MG aptamer with which the attenuator could interact easily. The MG RNA aptamer 
had been selected by in vitro SELEX to be used in the process of chromophore-
assisted laser inactivation (CALI) (72). Babendure etal. (60) discovered that the 
fluorescence of MG increased more than -2,000 fold after being bound by the MG RNA 
aptamer. The fluorescence can be used to measure the binding of the MG aptamer to 
MG. As shown in Fig. 3A, 400 nM MG alone without any RNA (sample 1) and 4 pM 
yeast tRNA plus 400 nM MG (sample 2) did not show any fluorescence peak whereas 
1 pM 40MG0 plus 400 nM MG (sample 3) showed fluorescence with excitation at 630 
nm where the emission spectra collected from 640-800 nm. The maximum emission 
was found at about 650 nm (60). Seven 10nt ssDNA oligonucleotides were used to find 
out which region on the 40MG0 aptamer sequence was a good target for an attenuator 
(Fig. 3B). Oligonucleotide E which targeted 21-30 nt of the 40MG0 aptamer was the 
best inhibitor of the MG aptamer. The region targeted by oligonucleotide E included 
the 3 nt in the stem that is closed by the hairpin and bulge loops and 7 nt into the bulge 
loop. Eight out of 10 nt complementary to oligonucleotide E are involved in the 
interaction with MG (the 40MG0 has one more base GC base pair at the stem form by 
5' and 3' end compared to the 38MG0 shown in Fig.1) . Seven of 10 nt of 
oligonucleotide F also target residues in the bulge loop that are involved in MG binding. 
The small inhibition effect of oligonucleotide F may be because its interaction with MG 
aptamer involves bases in the longer and more stable stem formed by 5' and 3' ends 
compared to the shorter, less stable stem targeted by oligonucleotide E. Also, the 
residues involved in the direct interaction with MG form strong base stack interactions 
with MG. Therefore it may be difficult for oligonucleotides F to intervene. These 
residues are close to the long stable stem. By contrast, the residues participating in 
forming and stabilizing the binding pocket that are targeted by oligonucleotide E do not 
directly interact with the ligand and may therefore more easily to be intervened. So, the 
oligonucleotide E seems to attack from the weaker side of the binding pocket and 
therefore effectively inhibits aptamer activity. The 1000:1 ratio of oligonucleotides to 
aptamer needed in these studies to demonstrate inhibition of the aptamer in trans by 
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oligonucleotide E and others was in part because the intermolecular interaction was far 
weaker than intramolecular interaction. Another reason is that DNA complement was 
used here, which forms a less stable hybrid than an RNA complement. The 
oligonucleotides that targeted regions out of binding pocket did notshow good inhibition 
indicating that the design of attenuator should concentrate on targeting the broad side 
of bulge loop where the binding pocket is located. 
After the broad side of the bulge loop was verified to be the optimal target of the 
attenuator, a series PGR reactions were carried out to produce dsDNA templates for 
15 different MG TRAPs. The template contained the MG aptamer sequence and a 
20nt antisense sequence targeting 741-760 nt of Uterocalin mRNA (Fig. 4A). The 
target region on uterocalin mRNA was selected in a previous study where a tiled 
microarray of 20nt oligonucleotides and antisense experiments was done to find out the 
accessible region on uterocalin mRNA (Chapter 4). The forward primer for producing 
the templates for the 15 TRAPs contained the T7 promoter and the desired MG 
aptamer sequence. The modifications on MG RNA aptamer were introduced through 
PGR reactions using the appropriate primer. The reverse primers with different lengths 
and sequences were used to form the desired attenuator sequences. The templates 
and primers for the PGR reactions are listed in Table 4. The regDNA and non-regDNA 
used in this study are also listed in Table 4. The 15 different MG TRAPs are listed in 
Table 5. The naming scheme, sequence, description and AG values predicted by 
Mfold are also listed in Table 5. The screening experiment of 15 TRAPs was done in 
96 well format. From these studies, two TRAPs, 32MG1-9 and 30MG1-9, had better 
regDNA-dependent activation compared to the other tested TRAPs. The 
32MG1 aptamer had two G:U base pairs compared to two G:C base pair in the 32MG0 
aptamer (red shaded region in Fig. 2A). The 30MG0 aptamer had one G:ll base pairs 
compared to one G:C base pairs in 32MG0 aptamer. The results indicated thatthe G:U 
wobble base pair was a good choice to put into the MG aptamer to replace the G:C 
base pair in order to provide structural flexibility without losing much stability. 
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The 32MG2 (one G:U, one G:C) TRAPs with 9 , 10 or 11 nt attenuator, 32MG4 
(one A:U, one G:U) TRAPs with 9 , 10 or 11 nt attenuator and the 32MG5 (one G:U, 
one A:U) TRAPs with 9 , 10 or 11 nt attenuator did not have good regDNA-dependent 
activation. For these TRAPs, increasing the strength of attenuator may reduce the 
aptamer activity of the TRAP in the absence of regDNA, but it will probably also reduce 
the extent of activation by regDNA as well. Shortening the attenuator may increase the 
extent of activation by regDNA but it will also probably increase the regDNA-
independent activation. The results indicated thatthe MG aptamer sequences in these 
TRAPs may still be too stable to be well regulated. 
The 28MG0-9 TRAP had a good fold increase in aptamer activity when the activity 
in the presence of the regDNA was compared with TRAP alone, but it had much less 
fold increase in aptamer activity when activation by regDNA was compared with 
activation by non-regDNA. The lose of specificity indicates that the 28MG0 aptamer 
was not sufficiently stable. 
In both the 32MG1 TRAPs and 30MG1 TRAPs, increasing the attenuator length 
from 9 nt to 10 nt reduced the fold activation significantly. This indicated that the 
introduced G:U base pair brought the MG aptamer to the edge of being flexible enough 
to be regulated and stable enough to keep the specificity. The two TRAPs, 32MG1-9 
and 30MG1-9, were subjected to the further testing and characterization. 
Even though the TRAP can be designed to be functional in vitro, successful 
functioning in vivo is not guaranteed. To test the TRAPs function in vivo, a yeast 
selection system was developed. As shown in Fig. 5A and 5B, the function of the 
TRAP was reflected by expression of the reporter gene. The success of selection 
mainly relied on two things: first, the MG aptamer inserted into the 5' UTR was 
functional and it only efficiently inhibited the expression of the reporter gene in the 
presence of TMR as shown in Fig. 5B. Second, the active MG aptamer module in the 
TRAP showed to be able to efficiently compete with the inserted MG aptamer for 
binding to TMR and release the inhibition as shown in Fig. 5A. If these two elements 
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were found to work well, this system could be used to test the properties of individual 
TRAPs. 
Two plasmids, P6 and P3, were constructed to test whether the MG aptamer was 
functional when inserted into the 5' UTR and whether it inhibited expression of a 
reporter gene in the presence of TMR. The feature map of plasmid P6 is shown in Fig. 
5C. The plasmid P3, identical to P6 except that it lacked the 40MG0 aptamer 
sequence inserted into 5' UTR of URA3, was used as a negative control. In the yeast 
strain 200897, the URA3 gene was deleted from genome so that it can not grow on SD-
U media. After transformed by P6 or P3, the resulting yeast cell P6/200897 and 
P3/200897 can grow on SD-U media. When 10 pM TMR was presented in the SD-U 
media, the growth of P6/200897 was greatly inhibited compared to the growth on SD-U 
media without TMR (Fig. 6A). The growth of P3/200897 was very similar on both 
media (Fig. 6A). In Fig. 6B, the TMR concentration was increase to 20 pM and a 
similar inhibition of growth of P6/200897 by TMR was observed. Growth of the control 
P3/200897 cells was not inhibited on TMR containing SD-U media compared to the SD-
U media without TMR. This results showed the MG aptamer inserted into 5' UTR of 
URA3 gene was functional and it inhibited translation of URA3 mRNA only in the 
presence of its ligand-TMR. In the previous study done by Grate etal. (44), the MG 
aptamer was inserted immediately before (6 nt upstream) the start codon of CLB2 and 
the expression of CLB2 was inhibited more than 90% based on the data got from 
western blot. The quantitative measurement of inhibition of URA3 was not done. The 
TMR concentration used in the CLB2 study was 1 pM. In these studies we observed 
full inhibition of yeast growth at 10 pM TMR. In these studies, the MG aptamer was 
also inserted 6 nt upstream of the start codon of URA3. The higher concentration of 
TMR required to observe the full inhibition of yeast cell proliferation may be due to leaky 
expression of URA3 at the lower TMR concentrations providing enough orotidine 
5'-monophosphate decarboxylase (encoded by URA3)to support yeast growth at a high 
enough level to escape detection by the spot assay. 
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The 786 promoter of the yeast heat shock transcription factor 1 ( HSF1) is a house 
keeping gene with a low level of expression. Further comparisons of the effects of 
different promoters on inhibition byTMR may reveal a relationship between the strength 
of promoter and the effectiveness of inhibition of yeast growth. If needed, several MG 
aptamer sequences can be inserted into the 5' UTR of URA3 gene, which may provide 
stronger inhibition at similar TMR concentrations. 
One advantage of selecting the URA3 gene as reporter was the ability to carry out 
counter-selection when 5-fluoro-orotic acid (5-FOA) was added into SD media. Yeast 
cells with wild-type URA3 genes convert 5-FOA into the toxic substance 5' fluorouridine 
monophosphate, severely limiting growth of the cells (73). The ability to carry out 
positive and negative selection with one marker suggested that the yeast system could 
be developed into an in vivo TRAP SELEX system. In the negative selections the yeast 
cells expressing TRAPs that have weaker attenuators and inhibit URA3 in the absence 
of target mRNA will be eliminated on SD-U media. In the positive selections, the target 
mRNA was expressed inside the yeast cell and the yeast cell expressing the TRAPs 
that can not inhibit URA3 in the presence of the target mRNA will be eliminated on SD 
media containing 5-FOA. The in vivo TRAP SELEX system is needed to clone TRAP 
RNA pool into yeast cells and the assay needs to be sensitive enough to establish 
sufficient selection pressure. The knowledge gained from testing individual TRAPs can 
facilitate the development of appropriate designs for the in vivo TRAP SELEX system. 
By using P3/200897 as the controls, the growth of yeast cell was not inhibited on 
the SD-U media with 10 pM and 20 pM TMR. So the current experimental set up of the 
spot assay is well suited for the testing the TRAPs and aptamer's activity inside the 
yeast cell. Future experiments will entail expressing the MG RNA aptamer inside the 
yeast to see whether it will release the inhibition by TMR in the P6/200897 yeast cells. 
Also, we need to use PGR to verify the integration sites in the genome. We need to 
verify that the URA3 mRNA is carrying the MG sequence at its 5' UTR as we think they 
were. This could be done using RNase protection assay (74) or with 5' RACE (Rapid 
Amplification of cDNA Ends) (75). All these studies will be part of in vivo testing and 
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development of the MG RNA TRAP. It is likely to be done along with the further in vitro 
optimization of MG RNA TRAP. 
TRAPs as well as aptamers are short nucleic acid molecules and their functions are 
sensitive to sequence variations in the RNAs that contain them. In order to express the 
TRAPs and aptamers inside the yeast cell, one challenge was to generate RNA 
molecules with defined 5' and 3'end. In other studies, the aptamer targeting the HIV-1 
reverse transcriptase (RT) was cloned into an expression vector flanked by two self-
cutting ribozyme. The resulting aptamer had minimum flanking sequence derive from 
cleavage at both ends by the self-cleaving ribozymes. In otherstudies, the 5' ribozyme-
aptamer-3' ribozyme expression cassette was expressed in mammalian cells driven by 
a U6 promoter from an expression vector (38, 76). Successful inhibition of HIV-1 
replication was observed and 50%-80% of the U6-expressed aptamer was shown to 
be located in the cytoplasm. This 5' ribozyme-aptamer-3' ribozyme expression cassette 
can be used to generate aptamer and TRAP in yeast. The 5' and 3' ribozyme used in 
the cited study required base pairing with the cleavage substrate. In TRAP the 5' end 
is defined by the aptamer sequence, which is constant. Therefore we can modify the 
5' ribozyme sequence to base pair with the 5' end of TRAP. But the 3' end of TRAP is 
attenuator sequence that will be varied from TRAP to TRAP during selection. 
Therefore the HDV ribozyme was used as the 3' ribozyme. HDV ribozyme does not 
need to pair with the substrate, which is released after being cut, and can 
accommodate any desired 3' end without sequence adjustment. The HH-target RNA 
-HDV expression cassette was successfully cloned into a plasmid and an RNA with 
homogeneous ends was produced from in vitro transcripts (52). 
The designed HH-aptamer/TRAP-HDV is shown in Fig. 7. The sequences of HH 
and HDV ribozyme used in this study are shown in Table 6. As shown in Fig.8, R2 and 
R3 both had fully functional HH and HDV ribozyme and the 40nt MG aptamer sequence 
was produced by both constructs. In R3, the 46 nt HH1, which was selected in vitro by 
others to have very high cleavage rates at low Mg++ concentrations replaced the 50 nt 
HHO in R2. In R4, a shuffled sequence of HH1 (HH2) replaced HH1 in R3. In the R4 
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reaction lane, the MG, HH and MG-HDV bands are missing, indicating the loss of the 
HH ribozyme activity with replacement of the shuffled HH2 sequence for HHO. In R5, 
the HDV1 replaced HDVO in R3. In the R5 reaction lane, the MG, HDV and HH-MG 
bands are missing reflecting the loss of HDV ribozyme activity. In R6, the HH2 and 
HDV1, mutants of HH1 and HDVO, respectively were used to replace the respective 
active ribozymes. In the R6 reaction lane, the only band seen was the full length HH-
MG-HDV RNA. The results demonstrated the production of a 40nt MG aptamer 
fragment in the R2 and R3 reaction lanes was due to cleavage by the ribozymes. With 
3 rounds of thermal cycles and increasing the [Mg++] from 6 to 40 mM to help the RNA 
to fold correctly, 100% cleavage by the functional ribozymes was seen with R2, R3, R4 
and R5. Inside the cell, the free Mg++ concentration is about 0.2 to 1 mM (77). This 
concentration is much lower than the 40mM in which full ribozyme activity was 
observed. But the successful use of ribozymes inside the cell in previous studies and 
the fact that the ribozyme was naturally fully functional inside the cell made the HH-
aptamer/TRAP -HDV expression cassette a practical method to express aptamer and 
TRAP inside yeast cells. 
Short RNA molecules, such as ribozymes, aptamers, small hairpin RNAs (shRNAs) 
and antisense oligonucleotides, have been expressed inside cells to explore their 
biological or biomedical functions. Inside eukaryote cells, RNA polymerase II 
transcribes protein-encoding genes. RNA polymerase I synthesizes rRNAs and RNA 
polymerase III synthesizes 5s rRNA, tRNA, 7SL RNA, U6 snRNA and many other small 
nuclear RNAs (snRNAs). mRNA made by RNA polymerase II goes through post-
transcriptional modification such as 5' and 3' end modification and has a 5' cap and 
polyA tail. The transcripts of RNA polymerase I and III do not have 5' caps and 3' end 
polyA tails. It has been shown that in yeast Saccharomyces cerevisiae, the transcripts 
of RNA polymerase I and III can be polyadenylated if the 3' end of the transcript has 
been generated independently by a hammerhead ribozyme (78). In another study in 
yeast Saccharomyces cerevisiae, transcripts synthesized in vivo by the bacteriophage 
T7 RNA polymerase were found not to be capped. However, the 3' end 
polyadenylation that occurred was sufficient for such non-capped transcripts to be 
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exported from the nucleus (79). This group replaced the mRNA cleavage and 
polyadenylation signals with a self-cleaving hammerhead ribozyme element. The 
resulting RNA was unadenylated. Even though a significant fraction of this RNA 
reached the cytoplasm, the unadenylated transcripts were accumulated near their site 
of synthesis in nucleus. Insertion of a stretch of DNA-encoded adenosine residues 
immediately upstream of the ribozyme element (a synthetic A tail) relieved the nuclear 
accumulat ion (80) .  
If the HH-Aptamer/TRAP-HDV expression cassette (Fig. 7) were used in yeast 
Saccharomyces cerevisiae driven by highly expressed pol II promoter such as the Gal 
1 promoter, the resulting aptamer and TRAP will have no 5' cap and 3' poly A tail after 
cleavage by ribozyme at the both ends. In view of the evidence about the 
polyadenylation and nuclear export of transcripts in yeast Saccharomyces cerevisiae 
mentioned above, it is expected that inserting a stretch of DNA-encoded adenosine 
residues is inserted immediately upstream of the HDV ribozyme element (a synthetic 
A tail) will allow the HH-aptamer/TRAP-HDV transcripts to be efficiently be exported 
to the cytoplasm after self-cleavage to form the aptamer/TRAP. Cytoplasmic 
localization of the TRAP is desired because this is where the target mRNA is located. 
Even though rational design can produce a TRAP that is specifically allosteric 
regulated by regDNA as shown in Fig. 4B, the number of sequences screened by this 
approach was limited to a small fraction of all possible sequence combinations. The 
in vitro SELEX process has been used to generate allosteric ribozymes, such as the 
allosteric ribozyme ligase (64) and the hammerhead ribozyme (81). In order to produce 
a MG TRAP with better sensitivity and specificity, TRAP selex was carried out using 
three TRAP RNA pools as shown in Table 7. Filter capture was selected to be the 
partition method used in TRAP selex. Biotinylated MG was coupled to streptavidin 
agarose beads to capture the bound RNA. The chemical reaction to make biotinylated 
MG is shown in Fig. 9C. The initial effort in which MG-isothiocyanate (Fig. 9A) was 
mixed with biotin-amine (Fig.9B) in aqueous solution was not successful. After the 
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coupling reaction was moved to a non-polarorganic solvent (100% CH2CI2), it produced 
the desired compound: biotinylated MG (Fig. 9D). 
From the results in Fig. 10A, after 4 rounds of SELEX, the performance of the N10 
RNA pool in terms of regDNA-dependent activation was not increased significantly. 
Similar results were seen in the N15 and N20 pools (Fig. 10B). One major difference 
in TRAP SELEX compared with SELEX for aptamers is that every sequence in the RNA 
pool used in the TRAP SELEX contains a full aptamer module. The key of SELEX for 
aptamers is to preserve and amplify the sequences with binding ability. The key of 
SELEX for the TRAP is to get rid of the sequences with unwanted binding ability. 
Because every TRAP possesses an aptamer module, it will exhibit its binding activity 
if the attenuator is weak. In other words, the key for success of TRAP SELEX will be 
to only keep the TRAPs that exhibit their aptamer activities when they are wanted, for 
example, in the presence of regDNA or target mRNA. So, the conditions for negative 
selection need to be well set up so that the TRAPs with aptamer activity in the absence 
of regDNA are removed efficiently. If the negative selection is not powerful enough to 
remove the unwanted TRAPs, such as TRAPs with weak attenuators, they will exhibit 
very good aptamer activity in the presence of regDNA in positive selection and be 
amplified and enriched in the subsequent RT-PCR step. Due to the heterogeneous 
folding of RNA molecules, it was very difficult to efficiently remove the TRAPs with 
weak attenuators in the negative selections. Based on this consideration, three 
consecutive negative selections were carried out in each round. The results showed 
that the repeat of a low pressure negative selection did not provide enough selection 
pressure needed to promote the effective evolution of a TRAP RNA pool. 
The need for high pressure negative selection is a common requirement for the 
selection of allosteric nucleic acids. For example, in the selection of an ATP-dependent 
DNA enzyme, in the first three rounds, the negative selection was first set up to 
proceed for 21 hour and followed by 1 hour positive selection (82). These investigators 
ran into the same problem that the effector-independent activity began to accumulate. 
The solution was to proceed with the negative selection for 19 days! This increase in 
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stringency in round 4 resulted in a more-than-30-fold increase in effector-dependent 
activation. 
In the selection of effector-dependent ribozymes or deoxyribozymes, the longer 
incubation time in the negative selection will allow more molecules with effector-
independent enzyme activity to exhibit its enzyme activity resulting in cutting itself or 
ligated to a substrate. The shorter or longer molecule can then be efficiently remove 
from the pool by PAGE. But aptamer binding activity will not result in physically 
changing of the TRAP molecules. So simply increasing the incubation time in the 
negative selection will not work for TRAP SELEX. 
The design of N20 pool was an effort to get around the problem of inadequate 
negative selection in SELEX. By randomizing the 10nt sequence of 32MG0 aptamer 
on TRAP, it reduced the regDNA-independent aptamer activity of N20 pool to a low 
level (Fig 10 B). The 10nt sequence was 9 to 18 nt of aptamer and it included the 
hairpin loop and part of following stem. None of the 10 nt involved in the binding with 
ligand as shown in Fig. 1. The designed N20 pool had two 10nt randomized regions 
on each TRAP and it had the best regDNA-dependent activation among the three pools 
before selection. After one round, the increase in activity regulated by regDNA 
decreased showing that the negative selection may have caused a similar problem for 
selection from the N20 pool as for selection from the previous N10 and N15 pools. 
Another solution for selecting a well-regulated MG TRAP by SELEX could be to 
utilize the ability of a 630 nm laser to activate MG catalyzed cleavage of MG aptamer 
(72). After MG is bound by MG aptamer, it will release an active OH- radical with very 
short half-life if a 630 nm laser was given. The released OH- radical cleaves the 
38MG0 aptamer between the U25 and A26. Negative selections of TRAP SELEX could 
include a laser treatment to cleave the TRAPs with regDNA-independent aptamer 
activity and to remove them from the pool by PAGE. By applying repeated treatments 
by laser in the presence of MG and increasing the incubation time with each repeated 
laser treatment, an efficient negative selection in TRAP SELEX may be achieved. 
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Including the aptamer module on the TRAP brings the ligand-capture and 
enrichment abilities to the TRAP which is the basis for signal output. At the same time, 
integrating the aptamer into the stem-loop structured probes adds another functional 
module than the stem structure itself, which is in molecular beacon. The interaction 
between aptamer and attenuator on the TRAP not only holds the antisense sequence 
to prevent non-specific interactions similarto the function of stem structure in molecular 
beacons, but also prevents the binding of aptamer to its ligand. Upon release of this 
interaction, the formation of aptamer : ligand complex will provide the extra driving 
force, which is absent in the molecular beacons, to promote the TRAP to fully open and 
recognize its target nucleic acid molecule. At the same time, the ability of the aptamer 
to form a stable complex with its ligand upon dissociation from the attenuator indicates 
that inhibition of aptamer needs to be strong enough to prevent the TRAP from being 
activated in the absence of target molecule. 
As shown in Fig 11 A, the (AG° + AG° ) represents the free energy given by 
aptamer folding and binding for its ligand. This indicates the stability of aptamer as well 
as the affinity of aptamer to its ligand. AG° indicates how stable the TRAP was in the 
absence of target mRNA. In the presence of target mRNA, the initial interaction 
between closed TRAP and mRNA will mostly likely involve a small number of base 
pairing interactions followed by the extension of base pairing from the initial core to 20 
bp like a closed zipper. Once the TRAP is fully interacting with target mRNA, it is very 
stable as illustrated in Fig.4B and 4C ( AG° ). If the difference between AG° and (AG° 
+ AG2) is too small, the TRAP could be opened by non-target molecules and lose its 
specificity. If the difference is to big, then it could not be efficiently opened by target 
mRNA and could lose its sensitivity. So the difference between AG° and (AG° +AG° ) 
are thermodynamic parameters related to a successful TRAP design. Using 32MG1-9 
as an example, if Kd of 32MG1 is set to 500 nM, then the approximate AG^ value can 
be calculated (AG° = - RTIn(1/Kd)) which is about - 8.9 Kcal/mol. The AG° predicted 
by Mfold was about -7.3 kcal/mol (Table 1). The AG° of 32MG1-9 was about -28.5 
kcal/mol predicted by Mfold (Table 5). The difference between AG° and (AG°+AG°) 
was about -12 kcal/mol. But examining the 32 MG aptamer's AG° value in Table 1 
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and 32 MG TRAP'S AG° value in Table 5, assuming that the Kd for different 32MG 
aptamers do not vary much as shown in Table 2, the difference between AG° and 
(AG° + AG°) for different 32MG TRAPs are very similar. So this value alone may not 
be enough to explain the difference between the TRAPs. 
Unlike the cartoon representative shown in Fig. 10B, in reality the 20nt antisense 
sequence was not un-paired in the TRAP structure. Folding of the 32MG1-9 predicted 
by Mfold showed that, among the 20nt in the antisense sequences, 13nt participated 
in 8 base pairs, 6 Walson-Crick base pairs and 2 G:U wobble pairs. There were three 
G:C base pairings between antisense sequence and aptamer sequence and 5 base 
pairs within antisense sequence itself. The strong interaction between antisense and 
aptamer clearly helped to establish the low regDNA-independent activation of the 
32MG1-9 TRAP. How the antisense sequence participates in the overall folding of 
TRAP is directly related to the overall stability of TRAP and interaction of the TRAP 
with target molecules. This may also be an important factor in determining the TRAP'S 
sensitivity and specificity. 
So far, there is not enough data from functional TRAPs to be summarized into a 
simple sequence of steps and thermodynamic parameters for general TRAP design. 
In the future, the further characterization and optimization of MG TRAPs selected from 
rational design and SELEX may provide useful information for this purpose. 
Computational design of oligonucleotide-sensing allosteric ribozyme utilized several 
sequence and thermodynamic parameters to filter off the unqualified sequences (83). 
The parameters derived from the MG TRAP development could be used in the future 
to realize the systematic computational design of TRAP for any selected aptamer and 
antisense sequences. 
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FIGURE LEGENDS 
Figure 1. The structure information of the MG aptamer and its ligand (59). 
(a) Secondary structure schematic of the aptamer. (b) Chemical structure of malachite 
green (MG) and tetramethylrosamine (TMR). The aptamer was selected to bind MG 
and the structure was solved with TMR as the ligand. (c) Front and back schematic 
views of the tertiary structure. Color coding for both the secondary and tertiary 
structure schematics is as follows: TMR, red; the canonical G8:C28 base-pair, orange; 
U25, the uridine involved in the U-tum, silver; the A26 U11 :A22 and A27 C10:G23 base 
triples, cyan; the G24 A31 G29:C7 base quadruple, blue; the perpendicularly stacking 
A9 and A30 adenosines, magenta; bound strontium ions, green. (Reprinted from 
Journal of Molecular Biology , 301, Christopher Baugh, Dilara Grate and Charles 
Wilson, 2.8 Â crystal structure of the malachite green aptamer, 117-128, Copyright 
(2000), with permission from Elsevier). 
Figure 2. Folding of selected MG RNA aptamers and Kd estimation. 
A. The folding of four selected MG RNA aptamers predicted by Mfold. In the folding 
of the 38MG0 aptamer, the three base pairs shaded in blue were the ones that were 
deleted to get different aptamer sequences. The two base pairs shaded in red were 
the ones that were both modified and deleted to get different aptamer sequences. 
B. The Kd estimation results of the 38MG0 and 32 MG0 aptamers. The MG 
concentration was set at 0.2 uM in all experiments. The RNA concentration is shown 
on the X-axis. The Y-axis is the fluorescence intensity measured using a single quartz 
cuvette. The filled red triangle is the experimental data of 38MG0 aptamer binding to 
MG. The red line is the curve fit of the experimental data from the 38MG0 aptamer 
binding to MG using non-linear least square regression analysis. The filled green 
rectangle was the experimental data of 32MG0 aptamer. The green line was the curve 
fit of the experimental data from the 32MG0 aptamer binding to MG using non-linear 
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least square regression. The Kd and R2 values shown in red and green are the values 
for the 38MG0 and 32MG0 aptamers, respectively. 
Figure 3. Interaction of 10nt oligonucleotides with 40MG0 aptamer. 
A. Representative fluorescence spectra of three samples. For all samples, the buffer 
used was binding buffer (10 mM HERES, 0.1 M KCI, 5 mM MgCI2 pH 7.4 at 23 °C ) and 
the MG concentration was 400 nM. For sample (1), there was no RNA added. For 
sample (2), 4 pM Yeast tRNA was added. For sample (3), 1 pM 40MG0 aptamer was 
added. In the spectrum of sample (3), the maximum peak was labeled. 
B. A cartoon representation of seven 10nt oligonucleotides targeting different regions 
of the 40MG0 aptamer. The seven oligonucleotides were named as A, B, C, D, E, F 
and G. The neighboring 10nt oligonucleotides have a 5nt overlap in the target 
sequence. 
C. Inhibition of the 40MG0 aptamer binding to MG by 10nt oligonucleotides. For all 
samples, the buffer used was binding buffer (10 mM HERES, pH 7.4, 0.1 M KCI, 5 mM 
MgCI2) and the MG concentration was 400 nM. Annotations on the figure: No RNA: no 
RNA included; Yeast tRNA: 4uM Yeast tRNA include; (A/B/C/D/E/F/G) + Aptamer: 1 mM 
oligonucleotides (A/B/C/D/E/F/G) and 1 uM 40MG0 aptamer included. The fluorescence 
peak value of each sample was normalized using the fluorescence peak value of 1 uM 
40MG0 aptamer binding with 400nM MG in binding buffer. The Y axis represented the 
percentage of aptamer activity. 
Figure 4. Screening of 15 different MG TRAPs. 
A. A cartoon representative of the PGR strategy used to generate dsDNA templates 
for MF TRAPs. The blue line represents the forward primer, which includes the T7 
promoter sequence. The red line represents the reverse primer, which includes 
different lengths of attenuators to produce different TRAPs. The red dot on one of 
forward primer indicates that a modification was introduced through PCR. The green 
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line represents the aptamer sequence on the template. The black line represents the 
20nt antisense sequence targeting 741-760 nt of uterocalin mRNA. 
B. The screen of 15 different TRAPs through fluorescence measurements. For all 
samples, the buffer used was binding buffer (10 mM HEPES,, 0.1 M KCI, 5 mM MgCI2 
pH 7.4 at 23 °C) and the MG concentration was 2 pM. The RNA concentration in each 
sample was 0.5 pM.The fluorescence peak value of each sample was normalized using 
the fluorescence peak value of 0.5 pM 32MG0 aptamer binding with 2 pM MG in 
binding buffer. The Y axis represents the percentage of aptamer activity. The binding 
buffer was used as the background control and its spectrum was subtracted from the 
spectrum of all samples. The concentration of regDNA and non-regDNA was 2.5 pM 
each. Each TRAP had three samples: TRAP alone, TRAP plus 5 X regDNA and TRAP 
plus 5 X non-regDNA. The two numbers shown above each set of three samples is the 
fold increase in fluorescence intensity of TRAP plus 5X regDNA compared to TRAP 
alone and TRAP plus 5 X non-regDNA respectively. 
Figure 5. Design of Yeast Selection and P6 plasmid. 
A. A cartoon representative of how a functional MG TRAP should work inside a yeast 
cell. The big circle represented a yeast cell. Inside it, the black line with polyA 
represented the mRNA of the reporter gene in which the sequence encoding the MG 
aptamer was inserted in the 5' UTR before the translation start site. The thick black line 
represents the open reading frame on the mRNA.The blue line represents the inserted 
40MG0 aptamer sequence. The two overlapping ellipses filled with black represents 
the ribosome. The ellipse with 40S represented the 40S subunit of ribosome. The 
targeted reversibly attenuated probe (TRAP) is represented by blue, green and red line 
linked together. The blue line represents the MG RNA aptamer sequence. The green 
line represents the 20nt antisense sequence in the TRAP. The red line represents the 
attenuator sequence. The pink line represents the target mRNA. The polygon filled 
with red represents TMR. 
B. The annotation of this figure is same as for A. 
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C. The plasmid map of P6. 786 and Gall were the promoter sequences. URA3 and 
Amp were the coding sequences. 40 nt MG aptamer represents the sequence 
encoding the 40MG0 aptamer. Eco 47111 was used to linearize P6 for transformation 
and integration. 
Figure 6. Spot Assay. 
A. The yeast strain 200897 was transformed by Eco 47111 linearized P3 and P6, 
respectively. The resultant yeast cells were P3/200897 and P6/200897. Beginning 
with a yeast suspension absorbing 0.5 OD at 600 nm, serial 10 X dilutions were put on 
the two kinds of media: SD-U and SD-U containing 10 uM TMR. Every dilution was 
repeated once on each plate. Every yeast suspension was spotted on two different 
plates in each media. The picture were taken approximately 3 days after spotting. 
B. The yeast cells used were same as in A, P3/200897 and P6/200897. Beginning 
with a suspension absorbing 0.5 OD at 600 nm, the series 10 X dilution was put on the 
two kinds of media: SD-U and SD-U containing 20 uM TMR. Every dilution was 
repeated three times on one plate. Every yeast cell was spotted twice on one plate in 
each media. The picture were taken approximately 3 days after spotting. 
Figure 7. Design of HH-MG-HDV expression cassette. 
A. The linear structure of the HH-MG-HDV expression cassette. The HH ribozyme was 
placed at the 5' end. The target sequence, MG aptamer or TRAP sequence was 
placed in the middle. The HDV ribozyme was placed in the 3' end. 
B. The detailed structure and product information from the HH-MG-HDV expression 
cassette (52). R2 contained HH0, 40MG0 and HDV0 sequences. R3 contained HH1, 
40MG0 and HDV0 sequences. R4 contained HH2,40MG0 and HDV0 sequences. R5 
contained HH1,40MG0and HDV1 sequences. R6 contained HH2,40MG0 and HDV1 
sequences (Ribozyme sequences are listed in Table 6). The rectangular areas 
indicate the included sequences in corresponding constructs. The arrow indicates a 
ribozyme cleavage site. Six fully and partially cleaved products are listed. The shaded 
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P1 stem in the HDV ribozyme are the positions in which restriction enzyme cutting sites 
can be introduced to facilitate cloning. 
Figure 8. The cleavage of HH-MG-HDV RNA. 
Half of the products from in vitro transcription reactions (6 mM MgCI2) of five different 
constructs (R2, R3, R4, R5 and R6) were run on a 8% 8 M Urea polyacrylamide gel. 
The other halves of the products were subjected to the three rounds of thermal cycling 
(1 min at 72 °C, 5 min at 65 °C and 10 min at 37 °C) in the presence of 40 mM MgCI2 
followed by PAGE on the same gel. The bands were labeled with corresponding 
sequence elements included. 
Figure 9. Biotinylated MG Synthesis. 
A. The structure of malachite green isothiocyanate. 
B. The structure of EZ-link biotin-LC-PEO amine (Biotin-amine). 
C. The reaction scheme represented the coupling reaction between malachite green 
isothiocyanate and EZ-link biotin-LC-PEO amine. 
0 The TLC results of malachite green (MG) isothiocyanate and biotinylated MG ( MG-
biotin). 
Figure 10. Summary of the Results of Fluorescence Measurements from TRAP 
SELEX. 
A. The fluorescence measurements of the N10 RNA pool during the process of 4 
rounds of SELEX. Forall samples, the buffer used was binding buffer (10 mM HEPES, 
0.1 M KCI, 5 mM MgCI2 , pH 7.4 at 23 °C). The RNA concentration and MG 
concentration in each sample were 0.5 pM and 2 pM or 1 pM and 4 pM, respectively. 
The fluorescence peak value of each sample was normalized using the fluorescence 
peak value of the same concentration of the 32MG0 aptamer and MG in binding buffer. 
The Y axis represents the percentage of aptamer activity. The concentration of 
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regDNA and non-regDNA was five times that of the RNA pool concentration. Each pool 
had three samples: pool alone, pool plus 5 X regDNA and pool plus 5 X non-regDNA. 
The two numbers shown above each set of three samples was the fold increase in 
fluorescence intensity of the pool plus 5X regDNA compared to the pool alone and the 
pool plus 5 X non-regDNA respectively. RO represents the pool before any selection. 
R1 represents the pool that went through 1 round with defined negative and positive 
selections. The same naming scheme was used for R2 , R3, R4, etc. 
B. Fluorescence measurements of the N15 RNA pool during the process of 2 rounds 
of SELEX and N20 pool during the process of 1 round of SELEX. The annotation was 
same as with A. 
Figure 11. Thermodynamics Related to TRAP Design. 
A. The curve line represents denatured MG aptamer in the random coil. AG° and AG° 
is the change of free energy upon folding. AG° is the change of free energy when the 
folded aptamer binds to its ligand, which was represented by the red-filled polygon. 
B. The targeted reversibly attenuated probe (TRAP) is represented by blue, green and 
red lines linked together. The blue line represents the MG RNA aptamer sequence. 
The green line represents the 20nt antisense sequence in the TRAP. The red line 
represents the attenuator sequence. The pink line represents the target mRNA. The 
polygon filled with red represents TMR. The curved line represents the denatured 
TRAP in a random coil. AG° is the change of free energy upon folding. AG° is the 
change of free energy when the folded TRAP binds to ligand and the effector (regDNA 
or target mRNA). The circle with a dashed line represents the folded aptamer binding 
to the ligand with the (AG° +AG°) as a contribution to the overall free energy AG°. 
C. The thermodynamics related to TRAP design. The line with two arrows represents 
the energy gap between the closed TRAP and aptamer : ligand complex. 
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Tables and Figures 
Table 1 : Sequences of MG RNA Aptamers used. 
Name1 Description Length AG° (Kcal/ 
mol) 
Synthetic 
Oligo2 
40MG0 
The MG RNA aptamer inserted into 5'UTR in Yeast 
study. (44) 
40nt -21.41 None 
GGAUCCGCGA CUGGGGAGAC CCAGGUAACG AAUCGGAUCC 
38MG0 
The MG RNA aptamer comes out of SELEX, structure 
with TMR determined. (59, 72) 
38nt -17.9 Oligo258 
GGAUCCCGAC UGGCGAGAGC CAGGUAACGA AUGGAUCC 
34MG0 
Truncated from 38MG0: U4C5 and G34A35 34nt -13.3 Oligo1374 
GGACCGAC UGGCGAGAGC CAGGUAACGA AUGUCC 
32MG0 
Truncated from 34MG0: A3 and U32 
32nt -12.8; 
-12.2 
Oligo1375 
GGCCGACUGG CGAGAGCCAG GUAACGAAUG CC 
32MG1 
From 32MG0: C17C^gto U17U^3. GgC18to GgU 18, G^C^y 
to G10U17 
32nt -7.3 0ligo1410 
GGCCGACUGG CGAGAGUUAG GUAACGAAUG CC 
32MG2 
From 32MG0: C18 to U18. G9C18to GgU18 32nt -9.8 None 
GGCCGACUGG CGAGAGCUAG GUAACGAAUG CC 
32MG3 
From 32MGO^ Gg to Ag, C^8 to U^8. GgC^gto AgU-]8 32nt -10.1 None 
GGCCGACUAG CGAGAGCUAG GUAACGAAUG CC 
32MG4 
From 32MG0: G9 to A9, C17 to U17,C18 to U18. GgC18to 
AgU18,G10C17tO G10U17 
32nt -7.7 None 
GGCCGACUAG CGAGAGUUAG GUAACGAAUG CC 
32MG5 
From 32MG0: G^Q to A^Q, C^7 to U^7,C^8 to U^8. GgC^8to 
G9U18,G10C17to A10U17 
32nt -7.8 None 
GGCCGACUGA CGAGAGUUAG GUAACGAAUG CC 
32MG6 
From 32MG0: Gg to A9 G10 to A10, C17 to U17,C18 to U18. 
GgC^8to AgU18,G10C17to A10U17 
32nt -7.7 None 
GGCCGACUAA CGAGAGUUAG GUAACGAAUG CC 
30MG0 
Truncated from 32MG0: G9 and C18 30nt -8.8 None 
GGCCGACUGG GAGAGCAGGU AACGAAUGCC 
30MG1 
From 30MG0: C16 to U16. G9C16 to GgU16 30nt -6.8 Oligo1421 
GGCCGACUGG GAGAGUAGGU AACGAAUGCC 
Truncated from 30MG0: Gg and C16 28nt -5.7 Oligo1422 
2oMuU 
GGCCGACUGG AGAGAGGUAA CGAAUGCC 
1 Zero (0) after MG in the name indicates there is no mutation. It is either the original sequences from other studies 
or the truncated ones. 
2 None indicates there was no corresponding RNA oligonucleotides purchased from IDT. The Oligonucleotide 
number was the name given when it was purchased from IDT. 
197 
Table 2: Kd estimation of three synthetic MG RNA aptamers 
Name Sequence Kd R2 
38MG0 GGAUCCCGACUGGCGAGAGCCAGGUAACGAAUGGAUCC 563 nM 0.955 
34MG0 GGACCGACUGGCGAGAGCCAGGUAACGAAUGUCC 991 nM 0.958 
32MG0 GGCCGACUGGCGAGAGCCAGGUAACGAAUGCC 725 nM 0.951 
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Table 3: Sequences of 10nt ssDNA oligonucleotides 
Name Description Length Oligo 
Number1 
A 
Complementary from 1 to 10 nt of 40MG0 10nt Oligo993 
TCGCGGATCC 
B 
Complementary from 6 to 15 nt of 40MG0 10nt Oligo994 
CCCAGTCGCG 
C 
Complementary from 11 to 20 nt of 40MG0 10nt Oligo995 
GTCTCCCCAG 
D 
Complementary from 16 to 25 nt of 40MG0 10nt Oligo996 
CCTGGGTCTC 
E 
Complementary from 21 to 30 nt of 40MG0 10nt Oligo997 
CGTTACCTGG 
F 
Complementary from 26 to 35 nt of 40MG0 10nt Oligo998 
CGATTCGTTA 
G 
Complementary from 30 to 40 nt of 40MG0 10nt Oligo999 
GGATCCGATT 
1 The Oligo number was the name given when it was purchased. 
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Table 4: Sequences of ssDNA oligonucleotides used in the TRAP rational Design. 
Name Description Length Oligo Number1 
regDNA 
Sequence of Uterocalin cDNA 741-760nt 20nt Oligo1399 
GCCACCATACCAAGGAGCAT 
non-regDNA 
Mixture of four 19nt Random ssDNA pools (25% each 
pool) 
20nt Qligo1401/2/3/4 
NNNNNNNNNNNNNNNNNNN (A/T/G/C) 
T1 
PGR template for 32MG TRAPs (PAGE3) 47nt Oligol 411 
ACTGGCGAGAGTTAGGTAACGAATGCCATGCTCCTTGGTATGGTGGC 
T2 
PGR template for 30MG TRAPs 45nt Oligo1423 
ACTGCGAGAGTAGGTAACGAATGCCATGCTCCTTGGTATGGTGGC 
T3 
PGR template for 28MG TRAPs 43nt Oligo1425 
ACTCGAGAGAGGTAACGAATGCCATGCTCCTTGGTATGGTGGC 
F1 
Forward Primer for 32MG1 TRAPs 45nt Oligo1412 
TTCTAATACGACTCACTATAGGCCGACTGGCGAG AGTTAGGTAAC 
F2 
Forward Primer for 32MG2 TRAPs 45nt Oligo1414 
TTCTAATACGACTCACTATAGGCCGACTGGCGAGAGCTAGGTAAC 
F3 
Forward Primer for 32MG3 TRAPs 45nt Oligo1415 
TTCTAATACGACTCACTATAGGCCGACTAGCGAGAGCTAGGTAAC 
F4 
Forward Primer for 32MG4 TRAPs 45nt 01 igol 416 
TTCTAATACGACTCACTAT AGGCC G ACTAGCG AG AGTTAGGTAAC 
F5 
Forward Primer for 32MG5 TRAPs 45nt Oligo1417 
TTCT AATACG AC TCACTAT AG G CC G ACTGACG AG AGTTAGGTAAC 
F6 
Forward Primer for 32MG6 TRAPs 45nt Oligo1418 
TTCT AATACGAC TCACTAT AGGCC G ACTAAC GAG AGTTAGGTAAC 
F 7 
Forward Primer for 30MG1 TRAPs 43nt Oligo1424 
TTCTAATACGACTCACTATAGGCCGACTGCGAGAGTAGGTAAC 
F8 
Forward Primer for 28MG0 TRAPs 41 nt Oligo1426 
TTCT AATACG AC TCACTAT AGGCC G ACTC G AG AG AGGTAAC 
Fi1 
Reverse Primer Provides 9nt attenuator sequence 33nt Oligo1413 
TTTT GTAACGAATGCCACCATACCAAGGAGCAT 
R2 
Reverse Primer Provides 10nt attenuator sequence 34nt Oligol 419 
TTTT GGT AACGAATG CCACCAT ACCAAGGAGCAT 
R3 
Reverse Primer Provides 11 nt attenuator sequence 35nt 0ligo1420 
TTTTAGGTAACGAATGCCACCATACCAAGGAGCAT 
1 The Oligo number was the name given when it was purchased. 
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Table 5: Sequences of Designed MG TRAPs1 and Predicted AG value. 
Name2 Description Length AG (Kacl/mol) 
32MG1-9 
MG TRAP bearing 32MG1 aptamer and 9nt attenuator sequence 
65nt -28.5 GGCCGACUGG CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGCAUUCGUUACAAAA 
32MG1-10 
MG TRAP bearing 32MG1 aptamer and 10nt attenuator sequence 
66nt -29.6 GGCCGACUGG CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACC AAAA 
32MG1-11 
MG TRAP bearing 32MG1 aptamer and 11 nt attenuator sequence 
67nt -32.5 GGCCGACUGG CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGCAUUCGUUACCUAAAA 
32MG2-10 
MG TRAP bearing 32MG2 aptamer and 10nt attenuator sequence 
66nt -30.5 GGCCGACUGG CGAGAGCUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACC AAAA 
32MG2-11 
MG TRAP bearing 32MG2 aptamer and 11 nt attenuator sequence 
67nt -31.5 GGCCGACUGG CGAGAGCUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCUAAAA 
32MG3-10 
MG TRAP bearing 32MG3 aptamer and 10nt attenuator sequence 
66nt -30.8 GGCCGACUAG CGAGAGCUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCAAAA 
32MG3-11 
MG TRAP bearing 32MG3 aptamer and 11 nt attenuator sequence 
67nt -30.8 GGCCGACUAG CGAGAGCUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGCAUUCGUUACCUAAAA 
32MG4-10 
MG TRAP bearing 32MG4 aptamer and 10nt attenuator sequence 
66nt -28.4 GGCCGACUAG CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGCAUUCGUUACCAAAA 
32MG4-11 
MG TRAP bearing 32MG4 aptamer and 11 nt attenuator sequence 
67nt -29.3 GGCCGACUAG CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCU AAAA 
32MG5-10 
MG TRAP bearing 32MG5 aptamer and 10nt attenuator sequence 
66nt -28.5 GGCCGACUGA CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCAAAA 
32MG5-11 
MG TRAP bearing 32MG5 aptamer and 11 nt attenuator sequence 
67nt -28.6 GGCCGACUGA CGAGAGUUAG GUAACGAAUG CC 
ALJGCUCCUUGGUAUGGUGGC AUUCGUUACCU AAAA 
32MG6-10 
MG TRAP bearing 32MG6 aptamer and 10nt attenuator sequence 
66nt -28.4 GGCCGACUAA CGAGAGUUAG GUAACGAAUG CC 
ALJGCUCCUUGGUAUGGUGGC AUUCGUUACC AAAA 
201 
32MG6-11 
MG TRAP bearing 32MG6 aptamer and 11 nt attenuator sequence 
67nt -28.6 GGCCGACUAA CGAGAGUUAG GUAACGAAUG CC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCU AAAA 
30MG1-9 
MG TRAP bearing 30MG1 aptamer and 9nt attenuator sequence 
63nt -28 GGCCGACUGG GAGAGUAGGU AACGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUAC AAAA 
30MG1-10 
MG TRAP bearing 30MG1 aptamer and 10nt attenuator sequence 
64nt -27.5 GGCCGACUGG GAGAGUAGGU AACGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACC AAAA 
30MG1-11 
MG TRAP bearing 30MG1 aptamer and 11 nt attenuator sequence 
65nt -28 GGCCGACUGG GAGAGUAGGU AACGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCU AAAA 
28MG0-9 
MG TRAP bearing 28MG0 aptamer and 9nt attenuator sequence 
61 nt -26.9 GGCCGACUGG AGAGAGGUAA CGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUAC AAAA 
28MG1-10 
MG TRAP bearing 28MG0 aptamer and 10nt attenuator sequence 
62nt -26.4 GGCCGACUGG AGAGAGGUAA CGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACC AAAA 
28MG1-11 
MG TRAP bearing 28MG0 aptamer and 11 nt attenuator sequence 
c
 
CO CO 
-26.5 GGCCGACUGG AGAGAGGUAA CGAAUGCC 
AUGCUCCUUGGUAUGGUGGC AUUCGUUACCU AAAA 
c
 
CO CO 
1 The underlined sequence indicates the attenuator sequence. The sequence in bold is the regions with 
which the attenuators designed to interact. 
2 The name of MG TRAP was made of two parts. The first part was the aptamer sequence used in TRAP. 
The number after the dashed line indicated the length of attenuator of that TRAP. 
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Table 6: Sequences of HH ribozyme and HDV ribozyme 
Name Description Length 
HHO 
Hammerhead ribozyme sequence (52) 50nt 
UCGCGGAUCCCUGAUGAGUCCGUGAGGACGAAACGGUACCCGGUACCGUC 
HH1 
Hammerhead ribozyme sequence with low Mg2+ requirement From 
HHO: (U19C20CGUGAGG27A28) to HH1(C19U20UUU23G24) (53) 
46nt 
UCGCGGAUCCCUGAUGAGCUUUUGCGAAACGGUCCGCGGGACCGUC 
HH2 
Shuffled Hammerhead ribozyme (HH1 ) sequence 46nt 
UCUAUGGAGUCCUCACUCCGAUGCGGGGGAAUUCCGCGGGACCGUC 
HDVO 
HDV Ribozyme sequence (52) 85nt 
GGCCGGCAUGGUCCCAGCCUCCUCGCUGGCGCCGGCUGGGCAACACCGGU 
AGGGGACCGUCCCCUACCUGGUGGCGAAUGGGACC 
HDV1 
Mutated HDV Ribozyme sequence (mutation introduced :75C to A, 
78A to G) 
85nt 
GGCCGGCAUGGUCCCAGCCUCCUCGCUGGCGCCGGCUGGGCAACACCGGU 
AGGGGACCGUCCCCUACCUGGUGGAGAGUGGGACC 
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Table 7: Sequences of ssDNA Oligonucleotides AND MG RNA TRAP pools used in the 
TRAP SELEX1 
Name Description Length Oligo 
Number2 
S10 
ssDNA pool with 10nt randomized attenuator sequence 
(PAGE3) 
96nt Oligo1398 
ACTATAGGCCGACTGGCGAGAGCCAGGTAACGAATGCC 
ATGCTCCTTG GTATG GTGGCNNNNNNNNN N AAC AAAAAAAAAAAAAAAAC AAAAA 
AAA 
N10 RNA 
pool 
TRAP RNA pool with 10nt attenuator sequence randomized 90nt None 
GGCCGACUGGCGAGAGCCAGGUAACGAAUGCCAUGCUCCUUGGUAUGGUGGC 
NNNNNNNNNN AAC A AAAA AAA AAA A AAA AC AAAA AAA 
S15 
ssDNA pool with 15nt randomized attenuator sequence 
(PAGE3) 
101 nt 0ligo1405 
ACTATAGGCCGACTGGCGAGAGCCAGGTAACGAATGCC 
ATGCTCCTTG GTATG GTGGGNNNNNNNNNNNNN N N AAC AAAAAAAAAAAAAAAAC 
AAAAAAAA 
N15 RNA 
pool 
TRAP RNA pool with 15nt attenuator sequence randomized 95nt None 
GGCCGACUGGCGAGAGCCAGGUAACGAAUGCCAUGCUCCUUGGUAUGGUGGC 
NNNNNNNNNNNNNNN AAC AAAAAAAAAAAAAAAAC AAAAAAAA 
S20 
ssDNA pool with 10nt randomized attenuator and 10nt 
randomized 32MG0 aptamer sequenc (PAGE ) 
102nt 0ligo1408 
GGAAAAAAAAAAGGCCGACTNNNNNNNNNNAGGTAACGAATGCC 
ATGCTCCTTG GTATG GTGGCNNNNNNNNNN A A C A A A A A A A A A A A A A A A AC A A A A A 
AAA 
N20 RNA 
pool 
TRAP RNA pool with 10nt MG aptamer sequence and 10nt 
attenuator sequence randomized 
102nt None 
GGAAAAAAAAAAGGCCGACUNNNNNNNNNNAGGUAACGAAUGCC 
AUGCU CCU UGGU AUG GUGGCNNNNNNNNNN AAC AAAAAAAAAAAAAAAAC AAAA 
AAAA 
SF1 
Forward Primer for the S10 and S15 ssDNA pool 35nt Oligo1396 
TTCTAATACGACTCACTATAGGCCGACTGGCGAGA 
SF2 
Forward Primer for the S20 ssDNA pool 40nt 0ligo1409 
TTCTAATACG ACTC ACTATAG G AAAAAAAAAAGGCCG ACT 
SR1 
Reverse Primer for the S10, S15 and 520 ssDNA pools 28nt Oligo1397 
TTTTTTTTGTTTTTTTTTTTTTTTTGTT 
1 RegDNA and non-regDNA used in TRAP Selex were listed in Table 4. 
2 The Oligo number was the name assigned when it was synthesized. 
3 PAGE indicates the oligo was purchased as the PAGE purified preparations. 
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CHAPTER 6. GENERAL CONCLUSION 
THE TRAP DESIGN IS PRACTICAL 
The development of functional ATP DNA TRAPs and MG RNA TRAPs showed that 
the idea of TRAP is workable. Both the ATP DNA TRAP and MG RNA TRAP were 
shown to have regDNA-dependent aptamer activity. The 9att-cmRas 15-ATP DNA 
TRAP has the ability to distinguish single nucleotide mismatches. The 32MG1-9 MG 
RNA TRAP demonstrates a 20-fold increase in aptamer activity upon hybridizing with 
regDNA. In both cases, target mRNA-dependent activation has not yet been realized. 
But the data so far shows that the basic principles of TRAP design are practical. 
Further optimization and selection should result in the generation of a TRAP with target 
mRNA-dependent aptamer activity in vitro and in vivo. 
COOPERATIVE INTERACTIONS AMONG THE THREE ELEMENTS OF THE 
TRAP DESIGN ARE CRITICAL FOR ITS FUNCTION 
The three elements of the TRAP design are the aptamer, intervening sequence and 
attenuator sequence. Each element was introduced into the TRAP design to perform 
specific tasks. The aptamer has the ability to bind to its ligand. The intervening 
sequence was designed to interact with the target nucleic acid molecule. The 
attenuator is responsible for preventing the aptamer from binding to its ligand in the 
absence of the ligand. In the TRAP, the three elements interact extensively. Not only 
does the attenuator base pair with the aptamer by design, but also the intervening 
sequence has base pair interactions with aptamer and with itself due to elements of 
complementary sequence. Therefore the question of how to design the TRAP so that 
the interactions among three elements prompt the desired performance of each 
element was the key for success of TRAP design. 
Base pairing within the intervening sequence is important and too low or too high 
a percentage of base pairing in the intervening sequence may damage the overall 
performance of TRAP. When the base pairing percentage is very low, the length of 
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attenuator needed to inhibit the aptamer may be too long such that effective activation 
of the TRAP by the regDNA is decreased. If the base pairing percentage is very high, 
it may inhibit the interaction between the intervening sequence and target nucleic acid 
molecule. Therefore optimal TRAP activity depends on the balance of the intensity of 
interaction between the three elements and within themselves. Quantitative values 
such as the percentage of base pairing of the intervening sequence, the AG difference 
between aptamer: ligand complex and TRAP will provide guidance for achieving the 
correct a balance so that the three elements will cooperate with each other. 
THE INTERACTION BETWEEN TRAP AND ITS TARGET MRNA IS BOTH 
SEQUENTIAL AND STRUCTURALLY CONFINED 
Using computational analysis and microarray experiments, the region of the Lcn2 
mRNA to be targeted by the intervening sequence of the TRAP was selected. Our 
results showed that the 32MG1-9 TRAP had regDNA-dependent aptamer activity but 
it failed to recognize its target Lcn2 mRNA under the same conditions under which 
regDNA was recognized. In the computational analysis and microarray experiments, 
the 20nt long antisense oligonucleotide and was not part of folded stem-loop structure 
involving other sequences. This difference is likely to be critical and suggests that the 
failure of the 32MG12-9 TRAP to recognize Lcn2 mRNA may be because the 
intervening sequence has a strong interaction with the aptamer and in self base 
pairings. Similarly the target sequence in the mRNA may participate in intramolecular 
folding. The interaction between these two sequences may not be strong enough to 
provide the force for releasing the inhibition of aptamer by attenuator sequence. 
THE TRAP HAS A UNIQUE POTENTIAL TO BE DEVELOPED INTO A PROBE 
FOR IN VIVO IMAGING OF NUCLEIC ACID MOLECULES 
Aptamers have been used widely for in vivo applications (12, 14-16, 18). 
Riboswitches were recently discovered as natural aptamers that regulate transcription 
and translation in the bacteria and eukaryotes (259, 290). This evidence shows that 
aptamers can perform their functions inside the cell. 
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The TRAP utilizes an aptamer for signal output. There is a broad range of ligand 
options for the aptamer in the TRAP. The freedom in ligand selection and the power 
of SELEX to generate aptamers that recognize the desired ligand made the TRAP a 
good candidate as a nucleic acid probe for in vivo gene imaging. We showed that, in 
vitro, a functional MG RNA TRAP responded with a 20-fold increase in fluorescence 
in the present of regDNA. A similar principle can be applied for in vivo applications. 
If RNA TRAPs are expressed in cells or delivered into cells, the presence of the target 
mRNA could be visualized by the increase of fluorescence or radioactive signal. 
Besides the binding ability of aptamer to its ligand, the signal output of the TRAP 
design can also utilize the catalytic activity of the ribozyme. For example, a ribozyme 
that will catalyze a chemical reaction upon binding to its ligand could be selected in vitro 
by SELEX. Allosteric ribozymes (aptazymes) with ribozyme activity regulated by small 
effector molecules have been developed (160, 291). The effector molecules for 
aptazymes included peptides (291), FMN, ATP and theophylline (128). In the 
aptazymes developed so far, the ribozyme either performed a phosphodiester cleavage 
reaction or had ligase activity. In both case, nucleic acids were the substrates for the 
ribozyme. Recently, a Diels-Alderase ribozyme catalyzing true intermolecular 
interaction was selected through SELEX by in vitro compartmentalization (292). The 
selected Diels-Alderase ribozyme catalyzed the cycloaddition reaction between dienes 
and dienophiles in solution. Such an enzyme-like ribozyme could be used to design a 
TRAP that reports the presence of target nucleic acid molecule by an enzyme catalyzed 
chemical reaction. If an appropriate enzyme catalyzed chemical reaction were applied, 
it could increase the signal output of the TRAP significantly. 
DESIGNING A FUNCTIONAL TRAP CAN BE ACHIEVED EFFICIENTLY AND 
SYSTEMATICALLY 
Because the way the TRAP recognizes its target nucleic acid molecule is through 
base pairing, the TRAP needs to be designed and optimized for each specific target 
sequence. Through rational design, we developed functional ATP DNA TRAPs and 
MG RNA TRAPs targeting regDNA designed from sequences of human 61L Ras gene 
218 
and the mouse Lcn2 gene, respectively. In each case, every TRAP was experimentally 
selected from a number of TRAPs with different sequences. Even though the rational 
design was simple and accomplished relatively rapidly, the process was low-throughput 
and still took significant time and effort. The SELEX procedure increased the number 
of sequences screened and therefore had greater potential to generate a functional 
TRAP compared to rational design. However, in this study the use of SELEX was not 
successful for improving the TRAP. Another approach to developing a functional TRAP 
with high efficiency would be the use of a high throughput assay such as microarray. 
For example, different TRAPs could be linked to a solid surface to form an 
oligonucleotide array. Functional TRAPs could be selected after the array was 
hybridized with target nucleic acids and fluorescence labeled ligands under defined 
conditions. 
Computational design combined with experimental validation of the TRAP is 
another high-throughput method that might be used for efficiently and systematically 
developing a TRAP to recognize any desired target nucleic acid. By analyzing the 
experimentally selected functional TRAPs, the sequential and thermodynamic 
parameters needed for practical computational design could be deduced. We can 
expect that the development of computational and experimental high throughput 
methods will great improved the efficiency of TRAP design. 
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